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CHAPTER I    
           General Introduction
 
       Adaptive and innate immune responses are orchestrated by the dynamic interaction 
between cell-surface molecules expressed on various types of leukocytes and cellular 
effectors. In addition to the uniquely specific interactions between TCR/CD3 and their 
cognitive MHC/peptide complexes and between cell surface immunoglobulin (BCR) and 
antigens, adaptive immune responses utilize a number of co-stimulatory molecules to 
support the interactions that are based on the variable elements of TCR and BCR. During 
the last few decades a considerable number of co-stimulatory molecules, which function 
to strengthen the adhesion of the immune cells to other cells, have been reported. 
Engagement of these co-stimulatory molecules by their ligands also triggers specific 
intracellular signaling networks, which regulate functions, such as activation, 
differentiation, apoptosis, proliferation, and acquisition of effector function and/or 
tolerance induction (1, 192).  
 
      The best-characterized T cell co-stimulatory pathways involve B7/CD28 and 
B7/CTLA-4. B7/CD28 provides signals that augment and sustain T-cells activation in 
context of TCR/CD3 signaling, while B7/CTLA-4 functions as inhibitory signal which 
reduces immune responses and induces tolerance (2, 3). The co-stimulatory molecules of 
the SLAM family (SLAM, CD84, Ly108, CD48) and their adaptors have been shown to 
perform important functions in adaptive immune responses (Figure 1) (5-7). The role of 
the homophilic cell surface receptor SLAM (SLAMF1/CD150) and its association with 
the adapter SAP (SLAM Associated Protein) during T cell activation have been studied 
in more detail than the other members of the SLAM-receptor-family. Furthermore, 
SLAM-family receptors, which are expressed on the surface of most hematopoietic cells, 
also function in innate immune responses and in adhesions between hematopoietic cells 
(5-7).   
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Figure 1. The T cell Immune Synapse: MHC---TCR/CD3 and the SLAM family co-stimulatory molecules. 
Receptors of the SLAM family are widely expressed in hematopoietic cells. Receptor–ligand interactions occur 
between members of the SLAM family in a homotypic fashion, except for 2B4 that binds to CD48.  The binding to 
their ligands induces the phosphorylation of their cytoplasmic tails and the subsequent binding of SLAM-associated 
protein (SAP) and EAT2 through a tyrosine-containing motif (ITSM). SAP is widely expressed by T cells and EAT2 is 
expressed by antigen-presenting cells (APCs). These two molecules can recruit and activate several SRC kinases, 
including FYN, that will modulate cell activation mediated by signals generated through the T-cell receptor (TCR) and 
co-stimulatory proteins such as CD28. Signals mediated by the SLAM receptors can also affect the function of APCs. 
SLAM receptors recruit different SH2-domain-containing proteins giving rise to different signals that determine 
distinct and, in some cases, opposite biological outcomes.  
 
1. The TCR/CD3 Complex. 
 
      The T cell antigen receptor (TCR) is a multimeric complex consisting of eight 
polypeptides: the Ag-binding clonotypic heterodimer TCR-�� or TCR-�� and the 
invariant CD3 dimers CD3-�� and CD3-��, and CD3-�� dimers, which are non-
covalently bound to each other and to the TCRs (Figure 2) (8-10). TCRs deliver signals 
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that are crucial for distinct stages of T cell development in the thymus, as well as during 
the activation and the final stages of differentiation of mature T cells.  
 
Figure 2. Components of TCR and CD3 complex. 
The TCR complex of MHC-restricted T cells consists of TCR-�� heterodimer, CD3-��, CD3-��, and CD3-��  sigaling 
dimmers, in which TCR�� noncovalently linked to the CD3 proteins. One possible stoichiometic combination is 
shown. The associations of these proteins are mediated by charged residues in their transmembrane region. Potential 
charges in the transmembrane regions are also depicted ( +  -  ).  
 
1.1 Variable T cell receptors 
      During thymocyte development, two T cell lineages develop, which can be 
distinguished by the expression of two different types of antigen receptors: �� and �� 
TCRs. Most T cells express ��TCRs, comprised of disulfide-bonded � and � chains, 
while a small subset of T cells express ��TCRs composed of disulfide-bonded � and � 
chains. TCR-�, -�, -�, and, -� are membrane glycoproteins belonging to the 
immunoglobulin superfamily, which contain an extracellular domain, consisting of a 
variable (V) and a constant (C) region. The junction between the V and C regions is 
encoded by the joining (J) segment gene, and, in case of the TCR-� chain, also a diversity 
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(D) segment gene is included. Furthermore, additional diversity is generated by the 
inclusion of N and P nucleotides during V (D) J recombination (11, 12). The V regions of 
the TCR-� and -� chains are highly diverse, and are responsible for MHC-peptide 
recognition. The constant regions of the TCR extracellular domains are anchored in the 
plasma membrane by a helical transmembrane region (13-15). The highly conserved 
charged residues in the transmembrane regions are of importance for TCR/CD3 complex 
assembly (16). The TCR-� and -� chains are similar to the TCR-� and -� chains (17). V 
and C regions are found to have weak but significant homologies to Ig domains. The C� 
and C� sequences have a lower degree of homology to the members of Ig superfamily 
than to the C� and C� constant regions. Relatively little is known about antigen 
recognition by �� TCRs (18, 19). 
 
      Whilst the short cytoplasmic tails of the TCR-�, -� , -�, and -� polypeptide chains are 
incapable of initiating signal transduction themselves, the associated CD3-�, -� , -� and -� 
chains are specialized in transducing signals upon antigen recognition by �� and �� 
TCRs. CD3-�, -� and -� belong to immunoglobulin superfamily, as their extracellular 
region contains one immunoglobulin-like domain (10, 20, 21). In contrast to the TCR-� 
and TCR-� chains, there is no variability or polymorphism in the CD3 chains. CD3-� 
does not belong to the immunoglobulin superfamily, as it has a very short extracellular 
domain (23). The transmembrane regions of all four CD3 polypeptide chains contain a 
negatively charged amino acid residue. The CD3-�,-�, and -� have long cytoplasmic tails 
which comprise a conserved sequence referred to as immune receptor tyrosine-based 
activation motif (ITAM) (22, 182).The long cytoplasmic tail of CD3-� contains three 
ITAM motifs, and is therefore thought to be the most dominant component of the signal 
transduction events initiated by the TCR/CD3 Complex (193-195). 
 
     Although the components of the TCR/CD3 complex were defined many years ago, no 
consensus has been reached about the precise composition and stoichiometry of 
TCR/CD3 complex, i.e. are one or two ��TCR receptor pairs present in the TCR 
complex (24-28,186). Using a novel method to isolate intact protein complexes, Call et al 
find that the TCR/CD3 complex contains only a single ��TCR heterodimer together with 
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one copy of each of the CD3-��, CD3-��, and CD3-�� dimmers (29). However, using 
non-denaturizing gel electrophoresis, Alarcon et al observed two ��TCR pairs to be 
associated with the CD3 dimers (26-28,185). The TCR-� and TCR-� constant Ig and 
transmembrane regions couple TCR-� and TCR-� to the CD3 dimers (26, 29, 31, 184, 
185). Assembly of the TCR/CD3 complex takes place within the endoplasmic reticulum 
and efficient transport to the cell surface is only possible if the complete TCR/CD3 
complex, containing �������� chains has assembled (32). The generation of a 
heterotrimeric complex containing CD3-� and -� and TCR-� involves interaction 
between critical glutamic acid residues in the transmembrane regions of CD3-� and -� 
with the conserved lysine residues in the transmembrane domain of TCR-� (191, 196). 
The generation of the TCR-�/CD3-�� heterotrimer follows TCR-�/CD3-�� formation and 
involves the aspartic acid and glutamic acid residues in the CD3-� and -�, respectively, 
which interact with the conserved lysine in the TCR-� transmembrane domain (196). 
Non-assembled partial complexes are rapidly degraded within the cell (33). The 
ectodomains CD3-� and CD3-� also contribute to the specific interaction involved in 
TCR assembly.  
      Preassembled CD3-� dimers are the final subunit to assemble with the complex (25, 
29, 34). NMR studies revealed that several polar features in the CD3-� transmembrane 
region are important for its dimerization as well as for its interaction with the TCR (34). 
The aspartic acids at position 6(D6) in the transmembrane region of the CD3-� chains are 
located at the dimer interface and form a single structural unit. This arrangement is 
stabilized by hydrogen bonds between the D6 carboxyl group of one strand and the D6 
backbone amide of the opposite strand. Interestingly, there is direct experimental 
evidence for water molecule(s) in the vicinity of D6, suggesting that structural water 
molecule(s) may stabilize this unusual arrangement. Two lateral hydrogen bonds formed 
between the threonine at position 12 and the tyrosine at position 17 of the CD3-� chain 
(T12-Y17) represent a second polar feature that is important for ��-dimer formation. The 
structure thus establishes a general framework for understanding the assembly of the 
signaling modules with the TCR. 
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1.2 The CD3-�, -�, -� and -� genes. 
      The genes coding for the invariable CD3-�, CD3-�, and CD3-� polypeptides are 
mapped to band q23 on human chromsome11(117.69 -117.72Mb) and to mouse 
chromosome 9 (44.77-44.82Mb) (Figure 3) (36, 187-189). It is likely that the 
glycosylated CD3-� and CD3-� chains arose through gene duplication because they have 
extensive sequence similarity both at protein and nucleic acid levels and are located only 
1.4 kb in mouse (1.6 kb in humans) from one another, which are organized in a head-to-
head configuration (35-38). The CD3-� gene is split into five exons and the CD3-� gene 
contains 7 exons. Exon-intron boundaries are located at homologous positions in the two 
genes with the exception that the CD3-� gene contains an additional 24 bp coding exon 
(exon 2) and a separate 3’ untranslated exon. The murine CD3-� gene consists of eight 
exons, two of which are unusually small, encoding 6 and 5 amino acids of the N terminus 
of the protein(39), whereas human CD3-� gene contains nine exons in which three such 
miniexons exist , encoding 7, 6, and 5 amino acids, respectively(40).The overall 
homology between CD3-� and the CD3-�/CD3-� gene pair is relatively low, being 
confined to areas around the Cys-residues in the extracellular domains of the chains 
(189). Upon comparison of the genomic sequences the short stretch of high homology 
located directly N-terminal of the transmembrane segment (41, 42) was found to coincide 
with the presence of a conserved boundary. The observations strongly suggest that all 
genes in the CD3 gene cluster are derived from a common ancestral gene. 
      The gene encoding the CD3-� is located on chromosome 1q22-1q25 in the human 
(43) and on chromosome 1 (167.72mb-167.80mb) in the mouse (44, 45). The CD3� gene 
spans 31 kilobases and  is split into eight exons  The mouse and human CD3-� share 
significant homologies both at the nucleotide and amino acid level, but show limited 
sequence similarity to CD3-�, CD-� , and CD3-�. Unlike the other CD3 proteins, CD3-� 
lacks the extracellular Ig-like domains, having only a very short ectodomain of nine 
amino acids and has a long cytoplasmic tail (43-45) 
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       Since the genes encoding the subunits of the CD3 complex (CD3-�, CD3-�, and 
CD3-�) are tightly clustered in a stretch of 50 kb of DNA in human or 40kb of DNA in 
mouse, this tight clustering might suggest that the CD3 genes are controlled by a single 
cis-acting element. Experiments with transgenic mice, however, showed that at least the 
CD3-� and CD3-� genes carry a complete and independent set of regulatory elements 
(46, 47). CD3-� gene expression appears to be controlled by a downstream T 
lymphocyte-specific enhancer element. Van de Wetering et al. (48) identified a T cell-
specific transcription factor, which they called TCF1 (T-cell factor 1), which showed -
two independent germline mutations, binding domain or species conserved domain, in 
TCF 1 were generated by targeted disruption. The mutant mouse strains exhibit a specific 
block in the proliferation of DN thymocytes and their maturation to the DP stage of 
thymocyte development, suggesting that TCF1 controls an essential step in thymocyte 
differentiation (49). Ikaros, the founding member of a family of Krüppel-like zinc finger 
transcription factors related to Drosophila melanogaster protein Hunchback (50-52), was 
identified by its ability to bind to the enhancer of CD3-� (53). In vitro, Ikaros stimulates 
Figure 3.  Genomic organization of murine CD3 gene cluster. 
Sketch representing the murine CD3 cluster organization. Murine CD3-�, -�, and -� genes  are mapped to 
chromosome 9 where CD3 gene cluster spans 40 kb. Approximated sizes of the CD3 genes and the intervening 
sequences are given. The direction of transcription is showed by arrows. Note that the sketch does not represent 
the exact size.   
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expression of reporter genes under the control of multimerized Ikaros-binding sites (190), 
where the core consensus binding site is 5'-GGGA-3' (51). In vivo, Ikaros is predicted to 
regulate the expression of genes whose products determine lymphoid-cell fate and 
function (54). These Ikaros mutant mice have  a severe defect in  T, B, and NK cell 
development  and their earliest defined progenitors, whereas the deletion of Ikaros have 
no effect on the development  of  other hematopoietic lineages (55). The observation, 
thus, suggests that Ikaros defines the earliest transcriptional checkpoint in lymphoid 
lineage commitment. 
 
1.3 The TCR/CD3 complex is requisite for thymocyte development.  
      ��- and ��-T cell development in the mouse is characterized by a series of 
developmental stages, which have been defined on the basis of the expression of 
temporally regulated cell-surface proteins. The earliest thymocytes express neither CD4 
nor CD8 and are termed double negative (DN) T cells. Depending on CD44, c-Kit, and 
CD25 expression, the DN thymocytes are further separated into four DN subsets 
according to the following maturation sequence: DN1 (CD44+cKit+CD25-), DN2 
(CD44+cKit+CD25+), DN3 (CD44
-
cKit
-
CD25+), and DN4 (CD44
-
cKit
-
CD25
-
) (Figure 
4) (56-57). The initial progenitors which enter the thymus express high levels of c-Kit 
and CD44 and no CD25. Concomitant with TCR-� chain gene rearrangements, c-Kit and 
CD44 levels go down and CD25 is expressed transiently. The rearrangement of the TCR-
� chain is not always successful because two-thirds of all genes assembled by VDJ 
recombination will be out-of-frame. During TCR-� rearrangement, both TCR-� and 
TCR-� rearrangements occur, which lead to expression of TCR-�� on a distinct set of T 
cells. While the molecular mechanisms that regulate rearrangement of TCR genes are not 
well understood, there is a strong correlation between transcription of a gene segment and 
its rearrangement.  
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 Successful rearrangement of TCR-� variable regions leads to the assembly of a surrogate 
receptor complex termed the pre-TCR, consisting of the TCR-�, the invariant pre-TCR 
(pT�) chain and CD3 (58). TCR-� expression in combination with pT� results in a 
process called � selection, characterized by survival, extensive proliferation, 
differentiation, allelic exclusion at the other TCR-� locus, and initiation of TCR-� 
germline transcription, which promote maturation of CD4
-
/CD8
-
 double negative (DN) 
thymocytes to the CD4+/CD8+ double positive (DP) thymocytes (59). Subsequently, DN4 
cells start rearrangement of the TCR-� locus. If a productive TCR-� gene rearrangement 
occurs, the TCR-� chain can pair with TCR-� chain to replace pT� chain. As a result, 
functional TCR-�/� heterodimer is expressed and lead to the formation of CD4+/CD8+ 
double positive (DP) TCR-�/� cell (60, 61). The precise mechanisms by ensuring the 
sequential expression of pre-TCR and TCR are not fully understood, but the most 
obvious possibility is that the structural differences between pT� and TCR-� allows 
TCR-� chains to compete favorably for pairing with TCR-� chain (62). If the 
Figure 4. Schematic diagram of thymocyte development.
CD4-CD8-double negative (DN) thymocytes progress through 4 stages: DN1, DN2, DN3, and DN4. The highly immature 
progenitors, comprising about 1-2% of thymocytes, reside within CD4-CD8- DN population. The pre-TCR controls 
transition from the CD44-CD25+DN compartment. TCR-� gene rearrangements are completed at the CD44-CD25+ stage. 
TCR signals result either in single positive (SP) thymocytes or in negative selection. The block points in thymocyte 
development are indicted by null mutations of genes encoding: RAG1/RAG2, TCR-� chain, pre-T-cell receptor �-chain, 
CD3-�, CD3-�, CD3-�/�, TCR-� chain, CD3-�, and CD3-�.
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rearrangement of TCR genes fails to generate a productive TCR-� chain, then the cells 
will die unless they have the potential to develop into �� T cells. It is of interest to note 
that RAG-1 and RAG-2 mRNA expression is actively regulated during T cell 
development in the thymus. The high expression of RAG-1 and RAG-2 is detected during 
two periods. The first occurs at the double positive thymocyte stage corresponding to the 
appearance of TCR-�, -�, and -� transcripts, and the second occurs at the double positive 
thymocyte stage when full-length TCR-� transcripts appear. Between these two waves 
RAG-1 and RAG-2 expression is downregulated (65). 
 
      Thymocytes bearing TCR-�� chains are subjected to either positive or negative 
selection based on the strength of TCR signaling. Thymocytes expressing TCR with 
intermediate affinity for MHC/peptide complexes migrate deeper into the medulla and 
are subsequently exported to the periphery (63-64).  The majority (~97%) of the double 
positive thymocytes will disappear due to death by neglect because they fail to recognize 
any of the available MHC molecules and consequently do not receive a survival signal. In 
contrast, DP thyomyctes with high-affinity TCRs for self-MHC/self-peptide ligands will 
receive strong signaling leading to rapid apopotic death (negative selection). Only few 
cells expressing TCRs recognizing self-ligands with apparently low avidity receive 
intermediate intracellular signaling and initiate a multi-step process known as positive 
selection (197, 198). Positive selection results in further differentiation into single 
positive stages. Conventionally, thymocytes expressing a TCR interacting with MHC 
class II molecule differentiate to the CD4+ lineage and thymocyte with TCRs interacting 
with MHC class I molecules differentiate to the CD8 lineage. 
 
      Direct evidence of critical roles for pre-TCR and TCR signaling in thymocyte 
development was provided in mutant murine models. In spontaneous mutant SCID 
(Severe Combined Immuno-Deficient) mice, the development of T and B lineage-
committed cells was shown to arrest in the early stages because of their inability to 
effectively recombine antigen receptor gene. The lymphocyte deficiency in SCID mice 
appears to result from a defect in gene encoding for DNA-dependent protein kinase 
(DNA-PKcs) (66). Because V (D) J recombination does not occur, the humoral and 
cellular immune systems fail to mature (67, 68). Similarly, inactivation of recombination 
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activating gene (RAG)-1 or RAG-2 by gene targeting results in the inability of 
lymphocytes to initiate V(D)J recombination during development, leading to the arrest of 
lymphocyte differentiation at a very early stage.  T-cell differentiation is blocked at the 
DN3 (CD44
-
cKit
-
CD25+) stage in the thymus and B-cell differentiation is blocked at the 
B220+CD43+ pro-B cell stage in the bone marrow (69, 70) . Furthermore, introduction of 
functional TCR or Ig transgenes into the RAG-deficient mice can restore T- or B-
lymphocyte differentiation (71, 72). As expected, a similar phenotype in the thymocytes 
was observed in mice with a mutation in TCR-� locus or pT� gene (73, 74). Those data 
strongly support that the productive TCR-� chain or pre-TCR complexes regulate 
development of thymocytes from the DN to the DP stage and the signaling initiated from 
TCR-a/� promote the maturation of DP thymocytes to the CD4+ or CD8+ stage. 
      Ample biochemical studies have shown that the CD3 proteins are important for 
assembly and efficient surface expression of TCRs as well as signal transduction (75-77). 
In prothymocytes, CD3 proteins associate with pT�/TCR-� to form the pre-TCR/CD3 
complex (78). Studies of T cell mutants have demonstrated that a complete CD3 complex 
is required for efficient assembly and expression of the TCR heterodimer. TCRs lacking 
CD3-�, -�, -�, or -� can reach the cell surface, albeit 10-100 fold less efficiently than 
wild-type receptors, because of a certain degree of redundancy in their assemble potential 
(25, 79). Moreover, individual CD3-�, CD3-�, CD3-�, or CD3-�-deficient mice exhibit 
various degrees of developmental arrest in thymocytes, which further demonstrates a 
clear role for these CD3 complex proteins in T cell maturation (80-84). 
 
2 The SLAM Family of hematopoietic cell surface receptors, 
      The SLAM family in the mouse is comprised of nine cell-surface receptors: CD150 
(SLAM), CD48, CD229, CD84, CD244 (2B4), NTB-A (ly108), CD319 (CRACC), 
SLAMF8 (BLAME), and SLAM 9 (SF2001) (Table 1, Figure 5). The cytoplasmic tails 
of six of these SLAM family members carry one or more copies of a unique Intracellular 
Tyrosine-based Signaling Motif(ITSM)(T-I/V-Y-x-x-V/I), which has a high affinity for 
the single SH2-domain signaling molecules SAP (SH2D1A) and/or EAT-2A (SH2D1B) 
or EAT-2B (SH2D1C), respectively. Sequence analyses show that the SLAM family 
genes share sequence homologies and are located in  close proximity in a 260 kb 
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fragment on both mouse (173.2Mb till 173.6Mb) and human (1q23 173.2Mb till 
173.6Mb) genomes ( 85-87) (Figure 5). The human and mouse genes encoding SLAM8 
and SLAM9 as well as the human adapter EAT2 are located in close proximity to the 
“core” SLAM-locus (Figure 5). Based on their sequence similarities and gene 
localization, SLAM-family genes are thought to have arisen via successive duplications 
of a common ancestral gene (88). 
 
 
TABLE 1  SLAM family receptors.
Abbreviations: Ab: antibody; B: B-cells; baso: basophils; CD8: CD8+ T-cells; DC: dendritic cells; eo: eosinophils; 
Fc: Fc fusion protein; ��: ��T-cells; glyco: glycosylation; H: human;  HSC: hematopoietic stem cells; IFN: 
interferon; IL: interleukin; ITSMs: Immunoreceptor tyrosine-based binding motif that bind SAP or EAT-2; 
M:mouse; ; M�: macrophages; mast; mast cells; Mo: monocytes; MHP: multipotent hematopoietic progenitors; N-
Glyco: N-Glycosylation; neutro: neutrophils; ND: Not determined; NK: natural killer cells; NO: nitric oxide; plat: 
platelets; ROS: reactive oxygen species; T:T-cells. 
 
      Whereas eight SLAM molecules are type I transmembrane glycoproteins that contain 
a cytoplasmic tail, CD48 is anchored in the plasma membrane via a glycosyl-
12
phosphatidyliositol (GPI) (89-90). Most of the SLAM family ectodomains are comprised 
of an N-terminal V-set Ig domain lacking the canonical disulfide bond, and a C-terminal 
C2-set Ig domain, characterized by similar patterns of conserved cysteines. The exception 
is CD229, which consists of a tandem repeat of two V-C2 set domains (91). Although the 
extracellular domains of CD2 and CD58 share some of these characteristics (88, 92), the 
homology between these two leukocyte receptors and members of the CD150 family is 
low (less than a 15% identity) (93). 
 
Figure 5.  Genomic Organization of the Human and Mouse SLAM locus. 
The genes encoding members of the signaling lymphocytic activation molecule (SLAM) family are located on human 
chromosome 1q23 and mouse chromosome 1 H2. Seven genes belonging to the SLAM family are clustered in a 
genomic segment of approximately 400 kb, in both humans and mice. The arrangement of the SLAM-gene family is 
identical in both genomes. The only difference is the orientation; the genes that in humans are closer to the centromere 
are situated in mice closer to the telomere. Three other genes that belong to the SLAM family (SLAMF8 and SLAMF9) 
are located in the same chromosome region, but outside of the SLAM locus. Human EAT2 and mouse Eat2a and Eat2b 
are also located close to the SLAM locus.  
Filled boxes represent blocks of sequence containing a complete set of exons of a gene. Black arrows denote the 
transcriptional direction of genes 
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      Through their extracellular domains, almost all the SLAM immunoreceptors are 
involved in homotypic self-association. SLAM, CD84, NTB-A. CD319, and CD229 
participate in homophilic interactions (94-100), whilst CD244 (2B4) is a receptor for 
CD48 (Figure 6) (101, 102, 199). 
      The structure of NTB-A (SLAMF6) shows that opposing molecules engage with their 
N-terminal IgV domains resulting in an orthogonal association of two NTB-A molecules 
(103). The �-sheets at the interface contain multiple residues, which contribute to the 
stability of the interaction resulting in a Kd of ~2uM, considerably higher than that 
published for SLAM(~200uM) (95), yet lower than that CD84 (104). As the case with 
CD84, the orthogonal association of two NTB-A molecules enable these complexes to 
localize to the immunological synapse (103, 104). The data obtained in these studies also 
show that the SLAM-family homophilic affinities span at least three orders of magnitude 
and suggest that differences in the affinities may contribute to the distinct signaling 
behavior exhibited by the individual family members. 
      The cytoplamic domains of SLAM, CD229, CD84, CD244, NTB-A and CD319 
contain both multiple ITSM motifs (105, 106) and non-ITSM phospho-tyrosine residues. 
Thus, SAP/EAT2-dependent and –independent recruitment of intracellular molecules 
leads to the inhibitory and stimulatory signals, which ensue upon engagement of these 
receptors (86, 87). Integration of signaling networks determine the outcome of several 
effector functions depending on the cell type and state of activation 
 
2.1 SLAM associates with the adapters SAP (SH2D1A) and EAT2 
       SAP (SH2D1A), which is mutated in most XLP patients (107-109), encodes a small 
cytoplasmic protein that is composed almost exclusively of a Src homology 2 ( SH2 ) 
domain and is primarily expressed in T lymphocytes and NK cells (107, 111, 112). 
However, SAP mRNA has also been detected in human memory B cells and tumor cell 
lines that are phenotypically related to memory B cells (109, 110, 113-115). It has been 
found that mutations of the SAP gene result in three major XLP disease phenotypes: 
Fulminant Infectious Mononucleosis (FIM), malignant B cell lymphoma and dys-
gammaglobulinema. Moreover, additional studies identified several classes of SH2D1A 
mutants in XLP patients (107, 116, 117). In the genetic analyses, they can be grouped 
into four major mutations: A) Micro/macro-deletion   DNA deletion ranges from small 
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number of nucleotides to several megabase pairs, which result in complete loss of 
SH2D1A protein or truncated SH2D1A protein:  B) Splice-site mutation  the mutations 
are found at either the 5’ donor splice site or the 3’ acceptor splice site, which leading to 
exon skipping or intron retention truncated SH2D1A proteins;  C) Nonsense mutation   
stop codons are introduced in the coding region of SH2D1A  due to single nucleotide 
change,  resulting in premature chain termination. These nonsense transcripts are either 
unstable or degraded by nonsense-mediated decay; D) Missense mutation  Missense 
mutation seems to be the most prevalent mutation causing XLP.  
      Consequently, signaling through SLAM receptors can be altered either through 
reducing the half-life of SAP, by impairing the binding to the receptors or by disabling to 
activate signal transduction downstream of the SLAM-SAP complex (105, 117). 
Missense mutations that disrupt the binding of SAP to SLAM-family receptors interfere 
(a) with the N-terminal interaction (e.g., T53I), (b) binding in the pY pocket (e.g., R32T, 
C42W), or (c) interactions with th Y+3 amino acid in the hydrophobic cleft (E67D, T68) 
(117, 199). Interestingly, the mutant T53I binds to the phosphorylated SLAM, but fails to 
bind to CD244 and CD229 (117). A number of the misssense mutations that decrease the 
half-life of SAP are conserved amino acids in SAP isolated from humans, mice, and other 
species: for example, Y7C, S28R, Q99P, P101L, V102G, Y54C, F87S, and I84T (117, 
200).However, mutations Y54C and F87S also affect SAP binding to some, but not all 
the SLAM-family receptors, suggesting that the requirement of SAP binding might differ 
between receptors. No genotype or phenotype correlation has been observed in XLP 
patients, suggesting an influence of other genetic and environmental factors (203). 
      SH2 domains are typically found in multidomain signaling enzymes or in adapter 
proteins, where they mediate protein-protein interactions and regulate associated catalytic 
subunits. The notion that SAP could function as an adapter, coupling protein-tyrosine-
kinases to the SLAM family receptors is based on the finding that Fyn-mediated 
phosphorylation of the receptors increased markedly with SAP (107, 201). More direct 
experiments with cell lines transfacted with SLAM demonstrated that SAP facilitates the 
selective recruitment and activation of the tyrosine kinase Fyn T (an isoform of the Src 
kinases Fyn expressed in T cells) (201, 202). Later experiments demonstrated that SAP 
recruits Fyn to SLAM in normal mouse T cells (119, 120). In vitro biochemical studies 
and structural analyses unveiled the remarkable mechanism of interaction between the 
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SH2 domain of SAP and the SH3 domain of Fyn that directly couples Fyn to SLAM 
receptor (119, 204). The structure of the ternary SLAM-SAP-FynSH3 complex also 
reveals that SAP binding to Fyn domain does not involve canonical SH3 or SH2 
interactions. Instead, at the point of interaction, the positively charged SAP surface 
interacts with negatively charged Fyn SH3 surface at a dissociation constant of 3.45µM 
for the entire complex. On the SAP SH2-domain, R78 appears to be particularly critical 
for the interaction, as it forms dual salt-bridge hydrogen bonds with D100 in Fyn, and its 
guanidinium moiety stacks with side-chain of W119 in the Fyn SH3 domain. Indeed, the 
R78 mutation of SAP almost abolishes the interaction with Fyn (119, 120). This SAP 
surface, which interacts with Fyn, does not overlap with the SLAM Y281 
phosphopeptide-binding groove of the SH2 domain of SAP. SAP mutant unable to bind 
to the SLAM cytoplasmic tail still bind to Fyn. Similarly, mutations of key residues of 
Fyn reduces in vitro binding to wild-type SAP. Consequently, the SH2 domain of SAP is 
able to bind simultaneously to SLAM and Fyn (119, 120). Importantly, superposition of 
the SAP-FynSH3 complex on the SH3 domain of auto-inhibited Src shows that SAP 
binding is mutually exclusive with the auto-inhibitory interaction. In vitro experiments 
indicate that SAP can activate the inactive form of Fyn (204, 205).  SAP may also 
directly bind to Lck, as suggested by the results from in vitro results and yeast two-hybrid 
analyses (204). Whether SAP also recruits Lck to the tails of the SLAM-family receptors 
awaits further clarification. However, the finding that SLAM phosphorylation is reduced, 
but not eliminated in Fyn-/- T cells suggests that other Src kinases may be involved in 
SLAM phosphorylation (204). 
      The generation and characterization of SAP-deficient mice give us some idea of the 
varying functions of this molecule and its role in mediating the immune dysregulation 
that results in XLP. Since it acts directly downstream of the SLAM family, it also sheds 
light on some of the overall in vivo functions that they participate in. SAP plays an 
important role in Th2 T cell response and T-dependent humoral immunity. When 
challenged with pathogens like LCMV, Toxoplasma Gondii or L. Major, SAP-deficient 
mice have an inappropriate immune response, with increased IFN-� production and T cell 
activation, impaired IL-4 cytokine production, and hypogammaglobulinemia (121, 122), 
similar to the features observed in XLP patients, many of which are also present in 
SLAM-deficient mice (123, 124). 
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       SLAM-deficient mice have indeed shown that this molecule, in fact, positively 
regulates the production of IL-4 by CD4+ T cells, while negatively regulating the 
production of IFN-� by both CD4+ and CD8+ T cells (123). Stimulation with anti-CD3 
and anti-CD28 results in lower IL-4 production, and slightly higher IFN-� production, in 
SLAM-deficient T cell, than wild-type. With polarizing conditions however, with IL-4 
being exogenously supplied, normal levels of IL-4 are secreted. This defect in IL-4 
production is also evident with stimulation of antigen-specific TCR-transgenic T cells 
with APCs and peptide, although normal levels are secreted upon secondary stimulation 
(123). More importantly, a Th2 response deficit is observed in Ly108- and Ly-9-deficient 
mice (125, 126). These observations strongly suggest that SLAM family members have 
complex, overlapping patterns of function, at least in the regulation of Th2 responses. 
      Not surprisingly, given its importance in the signaling of SLAM family receptors 
through SAP, as revealed from the SLAM knock-out mice, the ability of SAP to bind the 
Src kinase FynT is critical in the induction of the Th2 pathway in CD4+ T cells (124, 
127). SAP-deficiency leads to a defect in recruitment of PKC and BCL-10, and this in 
turn leads to impairment in the phosphorylation and ubiquitin-degradation of I�B�, 
which is important in activation of the p50 components of the NF�B complex. The 
resultant defective transcription of GATA-3(127), the master regulator of Th2 
differentiation (128), is responsible for the impairment in IL-4 production (Figure 9). By 
contrast, SAP-deficient cells have normal levels of T-bet, the Th1 regulator (12).
      EAT-2(EWS/FLI1 activated transcript 2) was originally cloned from EWS/FLI1 
transformed NIH3T3 cells (129). Subsequently, two related EAT-2 genes, EAT-
2A(SH2D1b) and its duplication form, EAT-2B(SH2D1c, ERT), were identified in 
mouse and rat (130, 131). EAT-2A and EAT-2B have the same genomic organization, 
which is also shared with the SH2D1A gene. Both EAT-2 genes show high levels of 
sequence similarity between their coding regions and even in the flanking intronic 
sequences. Similarly to the SH2D1A gene, EAT-2A and EAT-2B consist of four exons 
spanning approximately 6.5 kb and 20kb, respectively. The distance between the genes is 
26 kb on chromosome. EAT-2A and EAT-2B are mapped to the long arm of the mouse 
chromosome 1, which are very close to SLAM family locus (Figure 5). Thus, as EAT-2B 
presents significantly structural and sequence identity with EAT-2A, this demonstrates 
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that EAT-2B may be a functional homolog of EAT-2A.  However, it is of note that a 
similar gene duplication event is not detectable in human (118).  The sequence alignment 
shows that the first, second and fourth exons are highly conserved between human and 
mouse, while their exon 3 is slightly less conserved. Intriguingly, the coding sequences of 
the SH2 domains of human and mouse share sequence homologies with all other SH2 
domain, including SH2D1A, SHIP, Grb2, and Lck (107, 118). 
       The expression pattern of EAT-2 is different from that of SH2D1A. EAT-2A is 
detectable in the NK cells, macrophages, dendritic cells, CD8+ T cells, and B cells, while 
EAT-2B is tested for positive in the NK cells and CD8+ T cells (118, 130, 131). 
Moreover, the quantitative analysis of the combined expression of EAT-2A and EAT-2B 
shows that EAT-2 also is present in the mast cells. Interestingly, the EAT-2 expression is 
reduced dramatically upon activation of CD8+ cell, CD11b+ cells, macrophages and B 
cells (130). Despite of the fact that EAT-2A/B and SH2D1A are very similar in both the 
gene organization and protein structures, the main difference between EAT-2A/B and 
SH2D1A is that EAT-2A/B have two tyrosine-based motifs in their C-terminal tails, 
instead of an arginine 78-based motif in the SH2-domain that medicates binding of 
SH2D1A to FynT (85, 131). Studies of the function of NK cells derived from EAT-2A-/- 
and EAT-2B-/- (129Sv) mice indicate that EAT-2A and EAT-2B may have an inhibitory 
function in these cells (131).The replacement of these tyrosines with phenylalanine in the 
EAT-2A transgenic mice abrogates their natural killing, which indicates that the 
phosphorylated tyrosines of EAT-2A/B may contribute to their inhibitory effect in NK 
cells (131). Our recent studies provide insights into the functions of EAT-2A and EAT-
2B in macrophages and DCs using EAT-2A, EAT-2B or EAT-2A/B-deficient mice. DCs 
and macrophages from EAT-2A and EAT-2A/B-deficient mice showed decreased 
secretion of IL-10 and modulated productions of other cytokines such as IL-12 and IL-6 
in the response to stimulation through a variety of TLR receptors, suggesting EAT-2A 
and EAT-2B function as an adapter in non-SAP expressing cell types (Wang and 
Terhorst unpublished data). 
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2.2 The role of SLAM in T cell signaling. 
      The importance of SLAM/CD150 in signaling in T-lymphocytes is derived from the 
observation that SLAM, in the cytoplasm, is constitutively associated with SAP, a unique 
SH2-domain adapter (107, 108, 109). SLAM was initially defined as a cell surface 
molecule that mediated CD28-independent proliferation of T cells and IFN-� production 
(93, 132, 133, 134). Human and mouse SLAM are type I transmembrane glycoproteins 
which are self-ligands (95, 132). Mouse and human SLAM genes consist of seven exons 
corresponding to the signal peptide, the Ig-like V domain, the Ig-like C2 domain, the 
transmembrance region, and three cytoplasmic regions (93, 132, 133). The complete 
mouse SLAM gene is highly homologous to its human orthologue in terms of nucleotide 
sequences (80% homology) and intron/exon organization (10). Different SLAM isoforms 
have been detected in activated T and B cells, including two membrane-bound forms that 
differ in their cytoplasmic tails, a secreted form that lacks that transmembrane region, and 
a cytoplasmic form lacking the leader peptide (132, 94, 135).  
      In mice the largest amount of SLAM mRNA was expressed in the thymus, lesser 
amounts were present in lymph nodes and spleen, but it was barely detectable in the other 
mouse tissues (93). Other studies on the expression of SLAM reveal that it is expressed in 
all thymocytes, in which the highest levels are found in DP thymocytes. The single 
positive T cells and B cells in the spleen show a low level of SLAM expression, but its 
expression is dramatically up-regulated after stimulation (93, 133). In humans, SLAM is 
constitutively expressed on CD45ROhigh memory T cells, immature thymocytes, and B 
cells. Similar to its expression in mouse, human SLAM is rapidly up-regulated upon the 
activation of the peripheral T and B cells (93, 94, 132, 134).  
      The first evidence that SLAM-related receptors regulate immune cells was the finding 
that anti-SLAM antibody-mediated TCR-independent proliferation and INF-� production 
of previously activated CD4+ T cells (132). Similar results were obtained when 
stimulating Ly108 in activated murine CD4+ T cells with a cross-reactive anti-NTB-A 
antibody. However, one important issue arising form these experiments was whether the 
antibodies and fusion proteins mimicked or blocked the effects of physiological 
engagement of SLAM receptors. Supporting the notion that the SLAM antibodies were 
blocking, instead of ligating their receptors, was first provided by experiments with BI-
141 cells transfected with mouse SLAM. These experiments showed that SLAM 
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signaling was able to selectively inhibit IFN-� production (201). The generation of 
SLAM deficient mice further supported this hypothesis, since a slight increase in IFN-� 
secretion was observed in activated CD4+ T cells from SLAM deficient mice (123). The 
most surprising finding was that the severe defect in Th2 differentiation was observed in 
SLAM-deficient mice. 
2.3 Function of SLAM on macrophages, dendritic cells and platelets 
      Accumulating data have been shown that SLAM is not only expressed on T cells and 
B cells, but also detected on other hematopoietic cells (136-140).  Because SAP is only 
expressed in T-, NKT and NK cells, SLAM signal transduction in non-T and non-NK 
cells is influenced by the adapter EAT-2. Although the level of SLAM expression is 
relatively low on resting macrophages, its expression appears to be rapidly up-regulated 
in response to LPS and IFN-� (137). The importance of SLAM for macrophage function 
becomes much clearer when analyzed in the SLAM-deficient mice (123). Macrophages 
from SLAM knockout mice exhibit a severe defect in the production of IL-12, TNF-� 
and nitric oxide upon stimulation by LPS and by IFN-�. In agreement with the deficit, 
C57BL/6 SLAM-deficient mice exhibit heightened susceptibility to infection with L.
major. Recent studies in the Terhorst lab further demonstrate that SLAM-deficient 
macrophages are defective in their ability to kill Gram-negative bacteria because SLAM-
deficient macrophages produce low amounts of superoxide in response to phagocytosis of 
bacteria (Terhorst unpublished data). Thus, those observations strongly show that SLAM 
controls innate and adaptive immune responses. 
      SLAM expression is strongly up-regulated in dendritic cells by triggering CD40 as 
well as TLR receptors (138, 139). Engagement of SLAM with specific antibodies 
enhances IL-12 and IL-8 production, but not IL-10 secretion by CD40L-activated human 
dendritic cells (139). In contrast to the positive effect of anti-SLAM antibodies on 
cytokine production, it appears, however, that negative signaling is initiated by 
SLAM/SLAM interaction on the surface of dendritic cells, as IL-6, TNF-�, and IL-12 
productions are strongly inhibited by SLAM and CD40L co-expressing L929 cells. In 
line with this finding, the co-engagement with SLAM and CD40 on DCs impairs the 
ability of dendritic cells to induce differentiation of native T lymphocytes into Th1 cells 
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(140). The data clearly indicate that SLAM expression on DCs or other cells regulates 
DC function. It is now unclear whether EAT-2 is involved in SLAM/SLAM interaction-
induced signaling in DCs. Studies of SLAM/EAT2-induced signaling in DCs are 
currently under way using EAT2-deficient mice in Terhorst’s lab. 
      SLAM-family receptor/ligand pairs not only regulate innate and adaptive immune 
responses, they also modulate non-immune responses, such as platelet aggregation.  A 
platelet aggregate is a dynamic entity, capable of directing its own growth and stability 
via the activation of signaling cascades that lead to the expression and secretion of 
various secondary agonists. SLAM and CD84 have been identified as receptors that are 
engaged when platelets aggregate (141).While CD84 was shown to be important for 
platelet simulation, SLAM was found to contribute to stabilization of platelet aggregates 
in vitro and thrombus formation in vivo. Like in lymphocytes, these functions seem to be 
dependent on receptor phosphorylation, since both CD84 and SLAM are phosphorylated 
upon plated aggregation (141). Interestingly, CD84 phosphorylation was not dependent 
on signals from the integrin, as the receptor also becomes phosphorylated after 
crosslinking with antibodies or when engaged through homotypic interactions. Unlike 
lymphocytes, however, SAP seemed to be dispensable for SLAM phosphorylation, since 
the similar level of SLAM phosphorylation was detected in SAP deficient platelets. 
Although EAT-2 was also shown to be expressed in platelets, no binding of EAT-2 and 
SLAM could be detected in murine platelets (141). However, it could still be speculated 
that EAT-2 mediates SLAM phosphorylation in the absence of SAP (141). Analysis of 
the triple deficient mice (SAP/EAT-2A/EAT-2B) mice clarify whether the SAP-related 
adaptors are involved in SLAM function in platelets. This is the first demonstration that 
signaling of adhesion molecules other than �3 integrin, activated by proximity during 
aggregation, further stabilizes platelet-platelet interactions during thrombosis 
 
2.4 The role of SLAM family receptors in NKT cell development  
      Natural Killer T (NKT) cells are a group of unconventional T lymphocytes that co-
express both a TCR and NK-cell associated receptors (142, 143). The CD1d-restricted 
TCR is able to recognize glycolipids presented by a variety of cell types and rapidly 
trigger both IFN-� and IL-4 production. Although they appear to arise from common T-
cell precursors, as well as normal TCR rearrangement, selection of NKT cells depends on 
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thymocyte-thymocyte interaction. Invariant NKT (iNKT) cells are positively selected by 
the self-ligand iGb3 presented by CD1d on double positive thymocytes (144, 145). After 
this selection step, NKT cell precursors rapidly up-regulate first CD44 and subsequently 
NK1.1. Recent studies have established a crucial role for SAP and Fyn in iNKT 
development, as NKT cells were absent in both SAP and Fyn deficient mice (146-149), 
as well as SAP deficient XLP patients (146-148). The development arrest of NKT cells 
found in SAP
-/-
 mice is similar to that found in CD1d
-/-
 mice, with an incomplete block 
occurring at a slightly later stage than that found in Fyn deficient mice (142, 148). This 
suggested that SAP might regulate signaling pathways during NKT selection, partly 
through Fyn dependent signaling. 
      Receptors of the SLAM family were put forward as possible candidates to mediate 
NTK development, not only because their signaling is mediated by SAP and Fyn, but also 
because of their homotypic interactions (150). Recently, studies using congenic mice 
derived from C57/6 and NOD strains, identified SLAM (slamf1) as a possible candidate 
for the control of NKT cell number (151). FACS analyses of thymocytes demonstrated 
that both Ly108 and SLAM were expressed on DP thymocytes as well as immature NKT 
cells establishing that homophilic interaction of these receptors was possible at a crucial 
step in selection. The involvement of SLAM and Ly108 on NKT development was 
further assessed by the use of intricate adoptive transfer experiments allowing for their 
simultaneously removal from function (142). As a modest reduction of NKT numbers 
was found in Ly108
-/-
 or  SLAM
-/-
 mice, and because other experiments suggested an 
overlap in function between SLAM and Ly108 (123, 125), bone marrow chimeras were 
generated to investigate the role of SLAM and Ly108 on NKT cell development (142). 
As predicted, this ‘functional double mutant’ (i.e. Ly108
-/-
/SLAM
-/-
) mouse was severely 
impaired in its NKT cell development. Together these data demonstrate a complementary 
role of SLAM and Ly108 in the positive selection of NKT cells, mediated through their 
homophilic interactions between thymocytes. Importantly, early development of NKT 
cells prior to the SAP-dependent stage proceeded normally in these bone marrow 
chimeras (142). It is important to note that while the effects seen on SAP deficient mice 
are dramatic, the reduction of NKT cells in Fyn or in SLAM/Ly108 double mutant 
chimeras is not complete, suggesting a possible role of other Src kinases (like Lck) or 
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SLAM family members (such as CD84 and Ly9)(142). Although the precise signaling 
mechanism by which SLAM/Ly108-SAP-Fyn control NKT cell development remain to 
be elucidated, PKC� and possible NK-�B might be involved (150, 152, 153). It is 
conceivable then, that phenotypes observed in XLP patients and SAP-/- mice might also 
be explained, in part, by an absence of NKT cells. 
 
2.5 SLAM family gene isoforms and polymorphisms, and their role in genetic 
predisposition for Systemic Lupus Erythematosis. 
      Several studies reveal that the polymorphisms and alternative isoform usage 
contribute to the role of the human and mouse SLAM-family genes in susceptibility for 
Systemic Lupus Erythematosis(SLE) as they are part of epistatic pathogenic networks 
with other genes(154). Genome-wide linkage scans of families with multiple members 
affected with SLE have consistently demonstrated the presence of a susceptibility locus 
on chromosome 1q23, which includes the SLAM-family genes (155-160). In mice, the 
region syntenic to human 1q23 has been implicated in three different models of 
spontaneous lupus: the (NZB x NZW) F2 interacross, the NZM/Aeg2410 New Zealand 
mice, and the BXSB mice (161-163). 
      Using congenic mouse strains derived from NZM2410 (New Zealand black 
(NZBxNew Zealand white), three susceptibility loci for the development of SLE, Sle1, 
Sle2, and Sle3, have been identified by genome-wide linkage studies (164).  When the 
three lupus susceptible regions are expressed on a C57BL/6 background, the congenic 
strain develops severe systemic autoimmunity and fully penetrant, fetal 
glomerulonephritis. However, the studies of congenic mice bearing Sle1, Sle2, or Sle3 
regions have also shown that individual B6.Sle congenic strains express component 
phenotypes relevant to autoimmunity. The fine mapping analysis of the location of Sle1 
further demonstrates that four loci, termed Sle1a, Sle1b, Sle1c, and Sle1d, exist in the 
congenic interval (165) (Figure 7). Although each locus of Sle1 can independently cause 
a loss of tolerance to chromatin, the Sle1b locus is the most potent susceptibility locus 
capable of mediating a breach in tolerance to nuclear antigens and is associated with a 
high penetrance to antichromatin autoantibodies and a significant gender disparity (166). 
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Figure 6.  Variability in coding regions of SLAMs 
SLAM family of cell surface receptors. The SLAM family of surface receptors comprises six members. A typical 
receptor consists of an Ig V- and C2-like domain. The cytoplasmic domains of 2B4 (CD244), SLAM (CD150), CD84, 
Ly9 (CD229), and NTB-A contain ITSMs that mediate recruitment of SAP, as well as other SH2 domain–containing 
proteins such as EAT-2. Although CRACC (CS-1) also contains this motif, SAP does not associate with CRACC. All 
the SLAM family receptors other than 2B4 are self-ligands. 2B4 interacts with CD48. The two major haplotypes exist 
in different mouse strains. The coding region of CD244 and CD229 differ the most between the two major haplotypes. 
Less variation is found in the ectodomains of CD319 and CD48 and none in the mouse SLAM, CD84 and Ly108 
ectodomains. In addition, alternative splice forms have been detected for most of the SLAM-family receptors, which 
affect the structure of the cytoplasmic tail and consequently signal transduction event. 
 
      Sle1b has been defined as an approximately 0.9 Mb segment (0.4 cM) that includes 
the SLAM family locus (166). Although this locus contains 24 expressed genes, 19 of 
which are expressed in spleen, it is believed that seven genes of SLAM family receptors 
(CD244, CD224, CD319, CD48, CD150, Ly108, and CD84) potentially present strong 
functional candidates for pathogenesis of SLE in the Sle1b interval, as these functionally 
related genes are widely expressed in T cells, NK cells and antigen-presenting cells and 
function as co-stimulatory molecules (5, 6, 7). These findings strongly suggest that 
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NZM2410-based variants of the SLAM family receptor genes on an otherwise C57BL/6 
background contribute to the pathogenesis of SLE in the Sle1b interval. This notion is 
supported by studies with congenic stains derived from crosses between 129 and 
C57BL/6 mice, which develop spontaneous autoimmunity. By creating a C57BL/6 
congenic strain carrying a 129-derived chromosome 1 segment, Bygrave et al. found that 
this 129 interval was sufficient to mediate the loss of tolerance to nuclear antigens (167). 
To further dissect the contribution to autoimmunity of this 129 interval, the authors 
generated six subcongenic stains carrying fractions of the original 129 region and 
analyzed their serological and cellular phenotypes. At 1 year of age a congenic strain 
carrying a 129 interval between the microsatellites D1Mit 105 (80 cM) and D1 Mit115 
(99.7 cM) (B6.129 chr ab) (Figure7) had high levels of autoantibodies. Thus, the 
NZM2410-derived NZW segments Sle1b and the 129-derived 129 chr 1b segment when 
recombined on the C57BL/6 genomic background are sufficient to induce loss of 
tolerance to nuclear antigens. The NZW and 129 segment each contains the SLAM genes 
of the same haplotype. The studies in the structural and functional polymorphisms 
between the SLE-resistant B6 and SLE susceptibility B6.Sle1b intervals reveal that 
extensive polymorphisms exist in SLAM family genes (166), as do the productive 
sequence polymorphisms between C57BL/6 and 129Sv haplotypes in SLAM family 
members (Figure 6). Most notably, many of these structural mutations occur in the 
functional domains of SLAM family genes and consequently, some of those mutations 
may result in quantitative alterations of SLAM family genes that contribute to SLE 
susceptibility in B6.Sle1b region. Furthermore, the variation in the expression of CD48, 
Ly108, CD84, and CD319 was detected, rather than non-SLAM family genes in spleen B 
cells and T cells between B6 and B6.Sle1b.  Mohan, Wakeland and colleagues postulate 
that amongst the SLAM family members Ly108 in the context of C56BL/6 background 
may be the strongest candidate to be causally correlated with B6.Sle1b phenotype. They 
find that the long isoform of murine Ly108, i.e. Ly108-1 is upregulated, whilst the short 
isoform (Ly108-2) is down-regulated in B6.Sle1b mice compared to C57BL/6 (166). 
Supporting this hypothesis, transfection of Ly108-2 was able to sensitize the immature B 
cell line WEHI-231 to undergo apoptosis, suggesting that Ly108 could regulate the 
stringency with which self-reactive B cells are censored during early development (168). 
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2.6 SLAM, CD48 and CD244 are differentially expressed on hematopoietic 
progenitor cells 
      Hematopoietic stem cells (HSCs) are known as cells which individually are capable 
of both self-renewal and multilineage differentiation, yielding greatly expanded numbers 
of lymphocytes, myeloid cells, and erythrocytes (169). However, it is difficult for 
researchers to efficiently distinguish the long-term from the short-term cells when they 
are removed from the bloodstream or bone marrow. The central problem of the assays 
used to identify long-term stem cells and short-term progenitor cells is that they are 
difficult, expensive, and time-consuming. Classically, Thy-1lowc-Kit+Sca1+lineage- or 
CD34-/lowc-Kit+Sca1+lineage
-
 cells are believed to be the surface makers of mouse HSCs 
that reconstitute myeloid and B- and T-lymphoid lineages over the long-term, but most 
studies have shown only 20% of the cells that are enriched from young bone marrow by 
Figure 7.  Genetic map of the SLAM family genes and EAT2A and EAT2B gene in the Sle1 locus 
Sle loci in mouse Chromosome 1. The upper portion shows the genomic map of mouse chromosome 1 and the position 
of the SLAM receptors and the EAT-2 loci. Filled boxes represent blocks of sequence containing a complete set of gene 
exons. The lower portion shows the three defined regions that compose the Sle1 locus (Sle1a, Sle1b and Sle1c), as well 
as genomic markers and neighboring genes. Sle1a maps to an approximately 1-cM interval between the genomic 
markers D1Mit15 and D1Mit353, Sle1b is located in an interval of about the same size between D1Mit148 and 
D1Mit149, and Sle1c maps to the extreme telomeric end of chromosome 1, specifically to an approximate 2-cM interval 
between  D1Mit274 and D1Mit155. The Eat-2 and SLAM receptor loci map to the Sle1a and Sle1b region, respectively. 
Genomic markers and their positions in chromosome 1 are noted in the map.  
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the complex combinations of markers have a long-term bone marrow reconstitution 
ability (170-172). A potential role for SLAM, CD244 and CD48 in the first steps of 
hematopoietic stem cell differentiation was revealed by the work of the Morrison 
laboratory (136). SLAM, CD244 and CD48 could be used for purification of HSCs, 
either by themselves or in combination with other HSC markers after observing large-
scale gene expression profiling from purified HSCs, transiently reconstituting multipotent 
progenitors (MPPs), and non-reconstituted CD45+ bone marrow cells. (136, 173) (Figure 
8).   Impressively, quantitative (real-time) RT-PCR shows SLAM is upregulated 4 to 17 
fold more in HSCs compared with MPPs or CD45+ bone marrow cells. Although only 
6.6% of bone marrow cells express SLAM, the surface expression of SLAM is detected 
in 46% of long-term reconstituted HSC populations (Thy-1lowc-Kit+Sca1+lineage
-
). 
However, only 0.9% of the MPP population (Thy-1lowMac-1lowSca1+lineage
-
 
CD4lowB220
-
) are SLAM positive. By contrast, CD244 positive cells are contained in the 
transiently reconstituting MPPs, rather than HSCs. CD48 is expressed highly in CD45+ 
progenitors, not in HSCs or MPPs. Further studies in the competitive reconstitution 
assays demonstrate that CD150+ cells have long-term reconstitution activity, while 
recipients of CD150
- or CD244+cells display transient multilineage reconstitution, and 
CD48+ cells were always reconstituted by B cells. Most interesting, using simple 
combination of SLAM+ and CD48
- (also called SLAM code) it is possible to enrich HSCs 
as much as 21%, which is similar to that obtained with Thy-1lowc-Kit+Sca1+lineage
-
. 
Combining both the two sets of identified HSCs markers can further enhance HSC purity 
by 47% (173). These observations suggest that SLAM, CD244, or CD48 each represents 
a different stage in hematopoiesis development, and SLAM code can be used to simplify 
and improve HSCs isolation. In contrast to the antibody studies, the transfer of enriched 
stem cell preparations derived from SLAM-, CD244-, or CD48-deficient mice was 
inconclusive (136), suggesting a compensatory role of other genes, possibly belonging to 
the SLAM-family. 
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Figure 8.  Differential expression of SLAM family receptors distinguish Hematopoietic and progenitor stem cell. 
The SLAM family receptors SLAM, CD244 and CD48 are differentially expressed on hematopoietic stem cells in a 
way that correlates with progenitor maturity in the bone marrow. Self-renewal potential decreases as SLAM+ long term 
reconstituting-hematopoietic stem cells (LT-HSC) differentiate first into CD244+ multipotent progenitor (MPP) and 
then into CD48+ oligolineage-restricted progenitors (OP). This selective expression of SLAM family members permits 
a simplified method of isolation of distinct stem cell progenitor subsets and allows for visualization of these cell types 
in their natural environment. These progenitors further mature into IL-7R+ common lymphoid progenitors(CLP)and 
IL7R- common myeloid progenitor(CMP) cells which give rise to NK cell or T and B cells precursors in the case of 
CLPs, or granulocyte/monocyte progenitors (GMP) or megakaryocyte/erythrocyte progenitors (MEP) in the case of 
CMPs. These progenitors eventually give rise to all mature immune cells in the periphery. The adaptors (SAP, EAT2A 
or EAT2B) that have been identified in each cell type are listed. 
 
2.7 SLAM as a co-receptor for measles virus 
      Measles virus is a member of the Morbillivirus genus in the Paramyxoviridae family. 
It was first isolated from primary human kidney cells inoculated with the blood and throat 
washing of a child with measles (174). Human CD46, a complement receptor molecule, 
was identified as the cellular target of measles virus (175, 176). Interestingly, only certain 
strains such as Edmonston and Halle were able to infect CD46+ cells, whereas B cell 
isolated strains did not (177), suggesting the presence of another receptor for those stains. 
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Further experiments showed that expression of SLAM in those CD46+ resistant stains 
rendered them vulnerable to infection and replication (178). In other set of experiments it 
was demonstrated that the V domain of human SLAM is important for the binding with 
the measles virus Hemaglutinin protein and is required to allow measles virus entry into 
the host cell (179).  
      The generation of transgenic mice expressing human SLAM under the mouse Lck or 
CD11c promoter provided useful insight into measles virus pathogenesis (180,181). 
Expression of human SLAM on mouse T and dendritic cells rendered them susceptible to 
measles virus infection, leading to a decrease in T proliferation and inhibition of dendritic 
cell maturation. After infection, dendritic cells also showed an enhanced susceptibility to 
apoptosis and a decrease in their ability to activate T cells (181). It has been proposed 
that the mechanisms for MV-induced immunosuppression might stem from changes in 
the signaling cascade initiated by SLAM. Indeed, recent studies have shown that measles 
virus binding to SLAM suppresses LPS-mediated IL-12 secretion, implying that measles 
virus binding to SLAM disrupts its signaling and, consequently, cell activation (181). 
 
Conclusion and outline of the thesis 
      TCR/CD3 signaling is central to the initiation of antigen-specific T cell responses to 
pathogens and vaccines, as well as transplanted tissues, tumors, and autoantigens. These 
naturally occurring or targeted TCR/CD3-deficient animal models aid our understanding 
of earliest events in T cell signaling for T cell development. Although more and more 
connecting studies can be added to the puzzle of early T cell development, many 
questions remain unresolved. Targeting of a marker gene, that can give rise to an easily 
identifiable cell surface proteins should therefore allow the generation of a mouse strain 
in which T-lineage-committed precursor cells can be readily identified. 
      The accumulated observations have clearly shown that SLAM family and SAP-
related adapter play important roles in innate and adaptive immune responses. SAP was 
identified as the gene mutated in XLP and its protein crystal structure solved. More 
importantly, SAP enables SLAM family receptors to transducer tyrosine phosphorylation 
signals through its ability to recruit FynT. These findings reveal the mechanisms by 
which the Th2 response is impaired in XLP patients as well as mice deficient in SLAM, 
ly108, and Ly9. Furthermore, the SLAM family members are the strongest candidates for 
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mediating the Sleb phenotype, and may in fact play a fundamental role in autoimmunity 
in general, in multiple mouse models.  Finally, it is worth exploring EAT-2A and EAT-
2B-mediated functions in SAP-lacking dendritic cells and macrophages, as EAT-2A and 
EAT-2B appear to function as negative regulators, which is distinct from SAP in NK cell.  
      Therefore, the goal of this thesis was to analyzing the roles of the components of the 
CD3 complex in T cell development and functions of costimulatory molecule SLAM 
(signaling lymphocytic activation molecule) in T cell activation and antigen presenting 
cells by using targeted gene disruption and transgenic technology to generate new mouse 
models. In Chapter 2 to 5, the series of CD3 gene targeting and transgenic mice were 
used to dissect the roles of CD3 in assembly of TCR/CD3 complex and early T cell 
development. In Chapter 6, we cloned and characterized the mouse SLAM gene. In 
Chapter 7 and 8,   we generated SLAM-deficient mice by gene targeting technology and 
studying immune regulatory functions of SLAM in vitro or in vivo. In particularly, 
Leishmania major and AHR animal models are used to examine Th1/Th2 responses and 
macrophage functions in vivo.  Results will be discussed in the discussion section. 
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Figure 9: SLAM and Fyn interactions with  SAP 
SAP (signaling lymphocytic activation molecule (SLAM)-associated protein) couples SLAM family receptors to 
FYNT. A schematic representation of the two distinct binding surfaces in the SAP SRC homology 2 (SH2) domain that 
allow simultaneous binding of SAP to SLAM-related receptors and to the FYNT SH3 domain is shown. The FYNT-
binding site of SAP is centered on arginine 78 (R78). This mechanism is crucial for tyrosine phosphorylation of 
SLAM-related receptors and recruitment of downstream effectors.  
SAP-mediated signal transduction. (a) SAP associates with the ITSM in the cytoplasmic domain of SLAM. This 
interaction is mediated by tyrosine 281 (Y281) in SLAM and arginine 32 (R32) in SAP. Furthermore, arginine 78 
(R78) of SAP binds the SH3 domain of Fyn and recruits Fyn to the SLAM/SAP complex. Fyn then phosphorylates 
tyrosine residues in the cytoplasmic domain of SLAM. These tyrosine-phosphorylated residues act as docking sites for 
SHIP (SH2 domain–containing inositol phosphatase), which becomes phosphorylated and binds the adaptor proteins 
Dok1 and Dok2. Tyrosine-phosphorylated Dok proteins bind the SH2 domain of RasGAP. This pathway suppresses 
production of IFN-�. (b) SAP also contributes to signaling through the TCR by regulating activation of PKC-�, Bcl-10, 
and NF-�B. The outcome of this pathway is increased expression of the transcription factor GATA-3 and optimal 
production of IL-4 by anti-CD3-stimulated CD4+ T cells. 
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Summary
CD3
 
� and CD3
 
� are two highly related components of the T cell receptor (TCR)ñ CD3 com-
plex which is essential for the assembly and signal transduction of the T cell receptor on mature
T cells. In gene knockout mice deficient in either CD3
 
� or CD3
 
�, early thymic development
mediated by pre-TCR was either undisturbed or severely blocked, respectively, and small
numbers of TCR-
 
��
 
� T cells were detected in the periphery of both mice. 
 
�� T cell develop-
ment was either normal in CD3
 
�
 
�/
 
� mice or partially blocked in CD3
 
�
 
�/
 
� mice. To examine
the collective role of CD3
 
� and CD3
 
� in the assembly and function of pre-TCR and in the
development of 
 
�� T cells, we generated a mouse strain with a disruption in both CD3
 
� and
CD3
 
� genes (CD3
 
��
 
�/
 
�). In contrast to mice deficient in either CD3
 
� or CD3
 
� chains, early
thymic development mediated by pre-TCR is completely blocked, and TCR-
 
��
 
� or TCR-
 
��
 
� T cells were absent in the CD3
 
��
 
�/
 
� mice. Taken together, these studies demonstrated
that CD3
 
� and CD3
 
� play an essential, yet partially overlapping, role in the development of
both
 
�� and 
 
�� T cell lineages.
Key words: CD3
 
� ï  CD3
 
� ï  T cell receptorñ CD3 complex ï  T cell development ï  knockout 
mouse
During thymocyte development, the genes coding forTCR-
 
� and -
 
�, pre-TCR-
 
� (pT
 
�), and the associ-
ated CD3 proteins (CD3
 
�,
 
�,
 
�, and 
 
�) are expressed in a
temporal order (1). The pre-TCRñ CD3 complex, consist-
ing of pT
 
�, TCR-
 
�, and CD3 proteins, plays a major role
in early thymocyte development and in the transition from
CD4
 
�CD8
 
� (double negative, DN) to CD4
 
�CD8
 
� (dou-
ble positive, DP) cells, as targeted mutations in pT
 
�,
TCR-
 
�, RAG, and CD3 genes all result in an arrest of T
cell development at the DN CD44
 
�CD25
 
� check point
(2, 3). Subsequently, TCR-
 
� replaces pT
 
� and the result-
ing TCRñ CD3 complex mediates signal transduction cas-
cades leading to further T cell development (2). Compared
with
 
�� T cell development, 
 
�� T cell development is less
defined (4, 5). The majority of thymic 
 
�� T cells do not
express CD4 or CD8 antigens (6), and pT
 
� and TCR-
 
�
are not involved the development of 
 
�� T cells (7, 8).
However, CD3 proteins are required for the development
of this lineage (2).
Ample biochemical studies have shown that the CD3
proteins are important for assembly and efficient surface ex-
pression of TCR (9). In each TCRñCD 3 complex, there
are two copies of CD3
 
� and CD3
 
�, yet only one copy of
the highly homologous CD3
 
� and CD3
 
� (10ñ1 2). CD3
 
�
forms heterodimers with CD3
 
� and CD3
 
�, and can also
exist as a CD3
 
�� homodimer, whereas CD3
 
� exists as a
CD3
 
�� homodimer (11, 13, 14). TCRs lacking CD3
 
�,
 
�,
 
�, or 
 
� can reach the cell surface, albeit 10ñ 100-fold less ef-
ficiently than wild-type receptors, because of a certain de-
gree of redundancy in their assembly potential (15, 16). In
immature thymocytes, the CD3 proteins are expressed (17ñ
19), before the expression of pT
 
� and TCR-
 
� (1). Thus,
CD3 proteins can be a part of the pre-TCRñ CD3 complex
or part of a clonotype-independent CD3 (CIC) complex
(20). In these complexes, CD3
 
�� dimers are consistently
detected (20, 21), and some studies indicated the presence
of a small quantity of CD3
 
�� dimers (18ñ2 1). This led to
the notion that CD3
 
� may be preferentially required over
CD3
 
� in the assembly of pre-TCR complexes (22).
Recent studies on mutant mice deficient in either the
CD3
 
� or CD3
 
� gene in part support this notion. Whereas
transition from DN to DP 
 
�� thymocytes appears to be
normal in CD3
 
�
 
�/
 
� mice (23), 
 
�� T cell development in
CD3
 
�
 
�/
 
� mice is blocked at the DN CD44
 
�CD25
 
� check
point (24). However, the blockade in T cell development inThe first two authors contributed equally to this work.
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CD3��/� mice is incomplete, as small numbers of DP thy-
mocytes were found and TCR-��� T cells were detected
in the periphery (24). Moreover, in either mutant a consid-
erable number of �� T cells is present (23, 24). Therefore, it
is likely that CD3� and CD3� play an essential, yet to some
extent redundant, role in early development of T cells.
To examine the issue of partial overlap in function be-
tween CD3� and CD3�, a mouse strain with a disruption
in both the CD3� and CD3� genes (CD3���/�) would be
useful. A CD3���/� mouse, however, could not be gener-
ated by breeding the CD3��/� and CD3��/� mice, be-
cause the genes coding for CD3�, �, and � are located in a
single gene cluster and a mere 1.4-kb intergenic sequence
separates the first exons of CD3� and CD3� genes (25).
Therefore, we generated CD3���/� mice by deleting the
promoters and exons 1 of both genes.
Materials and Methods
Generation of CD3���/� Mice. The targeting construct was
generated by standard methods. In brief, a genomic DNA clone
containing a 15.5-kb fragment of CD3�� genes was isolated from
a 129/sv mouse genomic DNA library (provided by Dr. Manley
Huang, GenPharm Int., Mountain View, CA) and subcloned into
pBluescriptSK� (Stratagene, La Jolla, CA). A 2.8-kb SalI-XhoI
DNA fragment containing the PGK-TKr gene was isolated from
pPGK-TK (provided by Dr. Manley Huang), and ligated to the
XhoI site of pPGK-hygromyciner (hygr) (a gift of Dr. Richard
Mortensen). A 1.9-kb XbaI-XbaI intronic fragment between exon
1 and 2 of CD3� was obtained by XbaI digestion of the 15.5-kb
CD3�� genomic DNA fragment. And a 3-kb intronic fragment
between exon 1 and 2 of CD3� was obtained by first subcloning a
5-kb EcoRI-XbaI fragment into SK� followed by a HindIII cut,
so that a HindIII site from the polylinker region of the plasmid was
transferred to one end of the 3-kb fragment. The 1.9-kb XbaI-
XbaI fragment and the 3-kb HindIII-HindIII fragment were
inserted into the 5� and 3� sites of the PGK-Hygr gene. In the
resulting construct, a 3.1-kb DNA fragment containing the 1.4-kb
intergenic DNA fragment between the CD3� and CD3� genes
and exons 1 of both genes were replaced by the 2.8-kb PGK-Hygr
cassette. 10 �g of purified targeting molecules were electroporated
into 107 J-1 ES cells. ES cells were positively selected by hygro-
mycin-B at 200 �g/ml and negatively selected by FIAU at 0.2
�M. 355 clones were selected and examined by Southern blots for
homologous recombination using a 0.8-kb (StuI-XbaI) 5� probe
located outside of the construct. Eight clones were identified as tar-
geted clones, which were confirmed by another Southern analysis
with a hygr probe. Four of the targeted clones were injected into
the blastocysts of either C57BL/6 or BALB/C origin, and 90ñ
100% fur color chimerism was observed in 45 founder mice. Test
breeding of the chimeras indicated that all of the males (n � 28
from 3 embryonic stem [ES] clones) transmitted the ES cell
genome. Four males were mated to C57BL/6 females to generate
heterozygous mice, and homozygous CD3���/� lines were ob-
tained by sibling breeding. Identical results were obtained from
homozygous CD3���/� lines of different ES clones.
Flow Cytometric Analysis. Single cell suspensions of thymo-
cytes, LN cells, spleen cells, PBL, and small intestine intraepithe-
lial lymphocytes (iIEL) were prepared as described (26, 27).
Three-color staining of the cells was performed as previously re-
ported elsewhere (28).
RNA Analysis. Northern blot analysis was performed as de-
scribed (29).
Results
Generation of CD3���/� Mice. To generate mice defi-
cient in both CD3� and CD3� gene expression, a 3.1-kb
DNA fragment containing the promoters (25) and exons 1
of the CD3� and CD3� genes was replaced by a PGK-
Hygr cassette (Fig. 1 A). The PGK-hygr cassette was cho-
sen here over the PGK-neor cassette to prevent a possible
suppressive effect of the PGK-neor on neighboring gene
expression (30, 31). Homozygous mice carrying this muta-
tion in the CD3� and � genes were generated (Fig. 1 B).
Northern blot analysis demonstrated that the expression of
both CD3� and CD3� mRNA was absent in the CD3���/�
thymocytes (Fig. 2). Moreover, no aberrant expression of
the truncated CD3� or � mRNAs were ever detected in
Northern blotting of thymocytes from more than 20
CD3���/� mice. However, the expression of the neigh-
boring CD3� gene and the nonlinked CD3� was normal
(Fig. 2), and pT� expression was detected (data not
shown).
�� T Cell Development in the CD3���/� Mice. Total cel-
lularity of the thymi of CD3���/� mice was 2ñ 5% of
that in wild-type or heterozygous littermates (Fig. 3 A).
Flow cytometric analysis of the thymocytes showed that
these cells are DN, with the majority of them being
CD44�CD25�c-Kit�Sca-1�, identical to the thymocytes
found in RAG�/� mice (Fig. 3 B). Northern blot analyses
of the thymocytes of CD3���/� mice did not detect the
mRNA for rearranged TCR-� and TCR-� genes, whereas
only the 1.0-kb germline C� mRNA was detectable (Fig.
Figure 1. Disruption of CD3�� genes. (A) Diagram of the CD3�� tar-
geting vector for homologous recombination. Exons 1ñ 5 of the CD3�
gene and exon 1 of the CD3� gene are numbered. Arrows indicate the
transcriptional orientations of the CD3�� genes. The 0.8-kb probe was
used for screening the ES cell clones and for Southern analysis of tail
DNA. (B) Southern blot analysis of tail DNA.
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2). Consistent with these analyses, no mature ��� T cells
were detected in the LN, the spleen, or the gut of the
CD3���/� mice (Figs. 3 C and 4 C, Table 1). B cell devel-
opment appeared unaffected (Table 1). Taken together, ��
T cell development in CD3���/� mice is blocked at the
same DN CD44�CD25� check point as RAG�/� mice
(32, 33).
�� T Cell Development in CD3���/� Mice. Next, �� T
cell development in CD3���/� mice was examined. As
shown in Fig. 4, A and B, �� T cells were absent in the
thymus and periphery of CD3���/� mice. Since ��T cells
normally account for only a very small fraction of thy-
mocytes and peripheral T cells, we assessed ��T cell devel-
opment in the small intestine, where �� T cells represent
a major population of the iIEL in wild-type mice. In
CD3���/� mice, �� T cells were again nondetectable in
the intestine (Fig. 4 C). However, normal number of
CD8���B220�CD32�NK1.1� cells, representing T cell
progenitors in the gut (27) could be detected in the gut of
CD3���/� mice (Fig. 4, Cñ E, Table 1, and data not
shown). Therefore, these analyses indicate that deficiency
in CD3� and � completely blocked ��T cell development
beyond the CD8��� stage.
Discussion
We report here that in the CD3���/� double mutant
mice, intrathymic development is completely arrested at
the DN CD44�CD25� prothymocyte stage, a central
check point at which pre-TCR begins to mediate further
thymocyte differentiation into the DP stage. This observa-
tion indicates that the function of pre-TCR is completely
abrogated in CD3���/� mice. In contrast, in recently re-
ported CD3��/� mice, thymic development is undisturbed
up to the DP stage (23), whereas the transition from DN to
DP stages was severely but not completely blocked in
CD3��/� mice (24). The phenotypes of CD3��/� and
CD3��/� mice are consistent with the biochemical evi-
dence that CD3� is preferentially required over CD3� in
prothymocytes for the assembly of the pre-TCRñ CD3
complex (22). However, the present data revealed that
CD3� also participated in vivo in the assembly and func-
tion of the pre-TCRñ CD3 complex. Moreover, small
numbers of TCR-��� T cells were detected in the periph-
ery of CD3��/� and CD3��/� mice, but were absent in
CD3���/� mice. These observations are consistent with
the biological evidence that in mature T cells, the TCRñ
CD3 complex lacking either CD3� or � could sometimes
be detected on the cell surface at reduced levels. However,
no surface expression of the TCRñ CD3 complex could be
detected in cells lacking both CD3� and � (15, 16). Taken
together, CD3� and CD3� collectively play an essential,
yet partially overlapping, role in the assembly and function
of the pre-TCR. It is most likely that in the absence of
Figure 2. TCRñ CD3 expression
in the CD3���/� mice. Northern
blotting of thymocytes from wt,
RAG�/� and CD3���/� mice for
the expression of CD3�, �, �, �, and
TCR-� and -�. The respective
probes are indicated on the left, and
the sizes on the right. Two mice of
each type were analyzed in this blot.
Figure 3. T cell deficiency in the CD3���/� mice. (A) Thymic cellu-
larity of the mutant mice. Each symbol represents the total number of
thymocytes from a mouse. The ages of the mice are indicated. For each
age group, the average number of thymocytes from mutant mice was
compared with that of wild-type (including CD3���/�) littermates or
age-matched, wild-type mice (28). (B) Flow cytometric analysis of thy-
mocytes from CD3���/�, RAG-2�/� and wild-type mice for surface ex-
pression of CD4, CD8, CD44, CD25, Sca-1, and c-Kit. (C) Flow cyto-
metric analysis of peripheral lymph node cells for surface expression of
CD4 and CD8.
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CD3� and CD3�, pre-TCR cannot be expressed on the
surface of prothymocytes.
In addition to the structural requirement, CD3� and
CD3� may regulate pre-TCR function through the signal-
ing capacity of the immunoreceptor tyrosine-based activa-
tion motifs (ITAMs) presented in their cytoplasmic do-
mains (34). It is known that not every ITAM plays a
distinct role in pre-TCR function. For instance, pre-TCR
function is competent in mutant mice deficient in the
CD3� cytoplasmic domain (35). Moreover, the defect in
pre-TCR function in CD3��/� (24), CD3��/� (36), or
RAG�/� (19, 27, 37) mice can be overcome by anti-
CD3�-mediated cross-linking. However, the same anti-
CD3� treatment in vivo in CD3���/� mice failed to re-
lieve the block at the DN check point (data not shown).
Since the anti-CD3� antibody used in all of these studies,
namely 2C11 (or 500A2), binds CD3� efficiently when ei-
ther CD3� or CD3� is presented but poorly when both
CD3� and CD3� are missing (38; data not shown), the lack
of thymocyte differentiation upon 2C11 treatment of
CD3���/� mice might be explained by the following non-
exclusive possibilities: (a) pre-TCR could not be expressed
on the surface of CD3���/� prothymocytes; (b) the ineffi-
cient binding of 2C11 to CD3� on the surface of CD3���/�
prothymocytes results in a weak signal that is below the
threshold level for further thymic development; and (c) the
cytoplasmic domains of CD3� and CD3� collectively play
an essential role in pre-TCR function. The last possibility,
nevertheless, is less likely because it has been shown that
under artificial circumstances, either CD3� or CD3� cyto-
plasmic domain alone can independently generate signals
for thymocyte development to the DP stage (39). Thus, the
ultimate assessment of the physiological role of the cyto-
plasmic domains of CD3� and CD3� awaits the generation
of mutant mice in which the cytoplasmic domains of
CD3� and CD3� are deleted.
An important observation of this study was that ��T cell
development was completely blocked in the CD3���/�
mice. In comparison, �� T cell development was partially
blocked in the CD3��/� mice and was undisturbed in
CD3��/� mice (23, 24). Thus, this study demonstrated that
CD3� also plays a role in regulating the development of the
��T cell lineage, and CD3� and CD3� collectively are es-
sential for �� T cell development. Like their regulation of
�� T cell development, CD3� and CD3� may regulate ��
T cell development by their structural contribution and/or
signaling capacity. Nevertheless, the function of CD3� or
CD3� for �� T cells may not be a duplication of their re-
spective roles for �� T cells. For instance, although surface
expression of TCR-�� is severely reduced (8ñ 10-fold) in
CD3��/� mice, their TCR-�� expression is only mildly
Figure 4. Flow cytometric analysis of the �� T cell compartment in
CD3���/� mice. (A) Thymocytes were stained with anti-TCR-��-
biotinylated (detected with RED-670), anti-CD3-PE, and anti-CD4/
CD8-FITC. (Left) Profile of CD4/CD8 expression. (Right) Profile of
TCR-�� and CD3 expression in the analytically gated DN cells. (B)
Lymph node cells were similarly analyzed as in A, except that a mixture of
FITC-conjugated antibodies, i.e., anti-CD4, -CD8, ñ TCR-��, -B220,
-Mac-3, and Gr-1 (collectively termed Lin), was used. (C) Expression of
TCR-�� and TCR-�� in iIEL. (D) iIEL were stained with anti-CD8�,
anti-CD8�, and anti-CD32. (Left) Profile of CD8�/CD8� expression.
(Right) Profile of CD32 expression in the analytically gated CD8��� cells.
The CD8�� cells were all CD8��� and were predominantly CD32�. (E)
iIEL were stained with anti-CD8�, anti-B220, and anti-CD32, and the
profile of CD8�/B220 expression in the analytically gated CD32� cells is
shown.
Table 1. T Cell and B Cell Compositions in CD3���/� Mice
Tissue Cell CD3���/� Wild type
Thymus Cellularity (% of wt) 2.5 � 1.1 100 � 21
LN TCR-��� 0 73 � 9
B220�CD19� 84 � 2 19 � 4
Spleen TCR-��� 0 35 � 3
B220�CD19� 67 � 6 47 � 10
iIEL TCR-��� 0 41 � 5
TCR-��� 0 50 � 6
CD8-��* 64 � 5 66 � 10
A total of 9ñ 14 mice of each type were analyzed in five independent
experiments, and data are pooled and shown as mean � SD. Thymic
cellularity was determined as shown in Fig. 3 A. Data for the peripheral
lymphoid tissues and iIEL were obtained by cytometric analyses, and
represent the percent of cells positive for the indicated marker in the
whole lymphocyte population.
*CD8�� iIEL are CD8���CD32�B220�NK1.1� T cell precursors in
CD3���/� mice (Fig. 4; 27). In wild-type mice, CD8�� iIEL consist
of both CD8��� and CD8��� cells, and are mostly TCR-���CD3�
(27).
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(less than twofold) reduced (23). On the other hand, severe
reduction of both TCR-�� and TCR-�� expression in
CD3��/� mice indicated a pivotal role of CD3� in the as-
sembly of TCR-��ñ CD3 and TCR-��ñ CD3 complexes
(24). Taken together, it is likely that the complete block in
�� T cell development in CD3���/� mice was a result of
the incomplete TCR-��ñ CD3 complex not being ex-
pressed on cell surface in the absence of CD3� and CD3�.
It remains to be investigated whether the cytoplasmic do-
mains of CD3� and CD3� also have distinct functions in
the development of �� T cells.
In conclusion, in the CD3���/� mice, early thymic de-
velopment mediated by pre-TCR was completely blocked,
and TCR-��� and TCR-��� T cells were absent. These
observations are different from those made on either
CD3��/� or CD3��/� mice, in which pre-TCR function
was either undisturbed or incompletely blocked, as TCR-
��� and TCR-��� T cells were detected in the periphery.
Taken together, these studies demonstrated that CD3� and
CD3� play an essential, yet partially overlapping, role in
the development of both �� and �� T cell lineages.
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Overlapping functions of human CD3� and mouse CD3� in ��T-cell
development revealed in a humanized CD3�-deﬁcient mouse
Edgar Ferna´ndez-Malave´, Ninghai Wang, Manuel Pulgar, Wolfgang W. A. Schamel, Balbino Alarco´n, and Cox Terhorst
Humans lacking the CD3� subunit of the
pre-TCR and TCR complexes exhibit a mild
�� T lymphopenia, but have normal T cells.
By contrast, CD3�-deﬁcientmice are almost
devoid of mature �� T cells due to an early
block of intrathymic development at the
CD4�CD8�double-negative (DN)stage.This
suggests that in humans but not in mice,
the highly related CD3� chain replaces
CD3� during �� T-cell development. To
determine whether human CD3� (hCD3�)
functions in a similarmanner in themouse
in the absence of CD3�, we introduced an
hCD3� transgene in mice that were deﬁ-
cient for both CD3� and CD3�, in which
thymocyte development is completely ar-
rested at the DN stage. Expression of
hCD3� efﬁciently supported pre-TCR–
mediated progression from the DN to the
CD4�CD8� double-positive (DP) stage.
However, ��TCR-mediated positive and
negative thymocyte selection was less
efﬁcient than in wild-type mice, which
correlated with a marked attenuation of
TCR-mediated signaling. Of note, murine
CD3�-deﬁcient TCR complexes that had
incorporated hCD3� displayed abnormali-
ties in structural stability resembling
those of T cells from CD3�-deﬁcient hu-
mans. Taken together, these data demon-
strate that CD3� and CD3� play a different
role in humans and mice in pre-TCR and
TCR function during �� T-cell develop-
ment. (Blood. 2006;108:3420-3427)
© 2006 by TheAmerican Society of Hematology
Introduction
The pre–T-cell receptor (TCR) and the ��TCR are multimeric
protein complexes expressed on the surface of developing T cells at
different stages of their ontogeny in the thymus. The pre-TCR
complex consists of a disulﬁde-linked heterodimer of an invariant
pre-T� (pT�) and a variable TCR� chain noncovalently associated
with the CD3�, �, �, and � polypeptides.1 The TCR contains an
identical subunit composition but with a variable TCR� chain in
lieu of pT�. Within the pre-TCR and TCR, the CD3 subunits are
assembled as ��, ��, and �� dimers, with all but CD3�� being
structurally related.2 Functionally the CD3 proteins play a role in
the assembly, surface transport, and signal capacity of the pre-TCR
and TCR complexes.3,4
During thymocyte development, the pre-TCR and ��TCR
control discrete developmental checkpoints through which T-cell
precursors have to pass to mature successfully.5,6 Signals initiated
at the pre-TCR trigger progression from a CD44�CD25�
CD4�CD8� double-negative (DN) to a CD4�CD8� double-
positive (DP) differentiation stage, through CD44�CD25� DN
intermediates. Thus, only cells with a productive TCR� gene
rearrangement undergo this transition (a checkpoint termed �
selection). Subsequently, signals emanating from the TCR deter-
mine the positive (survival and differentiation) and negative (clonal
deletion) selection of immature DP thymocytes, processes that
shape the repertoire of mature CD4�CD8� and CD4�CD8�
single-positive (SP) T cells that exit from the thymus and populate
the peripheral lymphoid organs. The position of the CD3 proteins at
the initiation of the pre-TCR and TCR-mediated signaling cascade
implies a critical role of these molecules in alternate signal
transduction during thymic selection.
The overall structure and functioning of the pre-TCR and
TCR complexes in mice and humans are quite similar. Despite
this similarity, ablation of the highly related CD3� and CD3�
subunits has markedly different effects in mice and humans. In
mice made deﬁcient for CD3�, thymocyte development is
completely blocked at the DP stage due to defective TCR
expression and function,7,8 but pre-TCR function is normal. On
the other hand, CD3�-deﬁcient humans exhibit an earlier
developmental block at the pre-TCR–controlled checkpoint.9,10
Loss of CD3� in the mouse results in a severe block at the
DN-to-DP transition, indicating that pre-TCR signaling is
defective.11 In particular, the majority of CD3�-deﬁcient thymo-
cytes cannot pass the CD44�CD25� DN checkpoint. In contrast,
CD3�-deﬁcient humans show only slightly reduced numbers of
peripheral T cells, which display decreased TCR surface expres-
sion, and functional defects that lead to immunodeﬁciency with
a variable spectrum of clinical signs.12 Since CD3�-deﬁcient
mice possess a different phenotype, a mouse model for this
human disease is lacking to date.
From the Centro de Biologı´a Molecular Severo Ochoa, Consejo Superior de
Investigaciones Cientı´ﬁcas, Universidad Auto´noma de Madrid, Cantoblanco,
Madrid, Spain; the Division of Immunology, Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, MA; Max Planck-Institut fu¨r
Immunobiologie, Freiburg, Germany; and the University of Freiburg, Germany.
Submitted March 21, 2006; accepted July 9, 2006. Prepublished online as Blood
First Edition Paper,August 3, 2006; DOI 10.1182/blood-2006-03-010850.
Supported by grants BMC2002-01431 from the Spanish Ministry of Science
and Education (MEC) (E.F.-M.), GR/SAL/0168/2004 from Community of
Madrid (E.F.-M.), and Areces Foundation (to the Centro de Biologı´a Molecular
Severo Ochoa [CBMSO]). E.F.-M. is supported by the “Ramo´n y Cajal”
Program of MEC. M.P. was supported by a BEFI fellowship from the Fondo de
Investigaciones Sanitarias (FIS). W.W.A.S. was supported by the Deutsche
Forschungsgemeinschaft through the Emmy Noether program (SCHA 976/1)
and through SFB620.
The authors declare no competing ﬁnancial interests.
Reprints: Edgar Ferna´ndez-Malave´, Centro de Biologı´a Molecular Severo
Ochoa, Consejo Superior de Investigaciones Cientı´ﬁcas, Universidad
Auto´noma de Madrid, Cantoblanco, 28049 Madrid, Spain; e-mail:
efernandez@cbm.uam.es.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 USC section 1734.
© 2006 by The American Society of Hematology
3420 BLOOD, 15 NOVEMBER 2006 � VOLUME 108, NUMBER 10
62
To further dissect the roles of CD3� and CD3� in mouse and
human T-cell development, we crossed mice lacking CD3� and
CD3�, in which thymocyte development is completely arrested at
the DN stage,13 with mice transgenic for a human CD3� (hCD3�)
chain,14 resulting in the ��� � h�Tg mouse strain. These mice
incorporated the hCD3� protein in surface pre-TCR and TCR
complexes, and displayed a nearly normal-sized population of
TCR-expressing DP cells, indicative of normal pre-TCR function.
In contrast, ��� � h�Tg TCR complexes displayed an impaired
capability to signal for efﬁcient positive as well as negative
selection and differentiation of DP thymocytes into mature T cells.
Of importance, the T-cell compartment of ��� � h�Tg mice, in
contrast to the previously reported mice lacking CD3�,11 resembled
that of CD3�-deﬁcient humans. Therefore, this “humanized”
mouse strain might be an adequate model system for the human
CD3� immunodeﬁciency.
Materials and methods
Mice
CD3�-deﬁcient mice expressing a human CD3� chain (hereafter referred to
as ��� � h�Tg mice) were generated by breeding CD3�� doubly-deﬁcient
mice13 with a strain of transgenic mice, termed Tg�4, which carries a low
copy number of a human CD3� transgene.14 Double mutant mice were
identiﬁed by Southern blot and polymerase chain reaction (PCR). CD3��
doubly-deﬁcient mice expressing a mouse CD3� transgene (��� � m�Tg)
will be described in detail elsewhere. In all experiments, C57BL/6 mice
were used as wild-type (WT) controls. Mice were analyzed at 6 to 8 weeks
of age. CD3�-deﬁcient and HY, OT-I, and AND TCR transgenic mice have
been described elsewhere.11,15-17
Antibodies
For ﬂow cytometry, the following biotinylated, FITC-, PE-, or PE-Cy5–
conjugated antibodies were obtained from BD Biosciences Pharmingen
(San Jose, CA): anti-CD3��/�� (clone 145-2C11), anti-CD3�� (clone
17A2), anti-CD4 (clone RM4-5), anti-CD5 (clone 53-7.3), anti-CD8�
(clone 53-6.7), anti-CD69 (clone H1.2F3), anti-TCR� (clone H57-597),
anti-TCRV�2 (clone B20.1), anti-TCRV�3 (clone KJ25), and anti-
TCRV�8 (clone MR5-2). Streptavidin-PE-Cy5 was used as second-step
reagent. Immunoblottings were performed using the following antibodies:
anti–phosphotyrosine 4G10 (Upstate Biotechnology, Lake Placid, NY),
anti–ZAP-70 (Zap4; a gift from S. Ley), anti–Cbl-1 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), anti-LAT (Upstate Biotechnology), anti-CD3�
antibody 448,18 anti–phospho-MAPK (ERK, JNK, and p38), and anti–total
MAPK (New England Biolabs, Beverly, MA).
Flow cytometry
Cells were stained with speciﬁc ﬂuorochrome-conjugated or biotinyl-
ated antibodies and analyzed by 2- or 3-color ﬂow cytometry in a
FACSCalibur ﬂow cytometer using the CellQuest software (Becton
Dickinson, San Jose, CA).
TCR stimulation, immunoprecipitation, and immunoblotting
Thymocytes were resuspended in PBS and incubated for 10 minutes at 4°C
in the presence or absence of biotin-conjugated anti-CD3 (145-2C11) and
anti-CD4 (RM4-5) antibodies. After removal of unbound antibody, the cells
were incubated at 37°C for varying periods of time with 100 �g/mL
streptavidin. After stimulation, cells were lysed in a buffer containing 1%
Brij-96, 20 mM Tris-HCL (pH 7.8), 150 mM NaCl, and a cocktail of
protease and phosphatase inhibitors. For immunoprecipitations, lysates
were incubated overnight with speciﬁc antibodies preadsorbed to protein
G–sepharose beads. The beads were washed 4 times in lysis buffer and
resuspended in SDS sample buffer. Total cell lysates or immunoprecipitates
were resolved by sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis (SDS-PAGE), transferred to Immobilon-P (Millipore) membranes, and
immunoblotted with speciﬁc antibodies. Bound antibodies were detected
using an enhanced chemiluminescence system (Amersham).
Protein analysis
For analysis of the TCR organization under nondenaturing conditions,
blue native–polyacrylamide gel electrophoresis (BN-PAGE)19,20 was
performed. Brieﬂy, the TCR complex from digitonin lysates of pervana-
date-stimulated thymocytes was immunoprecipitated with antiphospho-
tyrosine-coupled protein G–sepharose and eluted with phenylphosphate.
After separation of the samples by BN-PAGE,21,22 the proteins were
transferred to nitrocellulose membranes and detected by immunoblot-
ting with anti-CD3� antiserum 448. Ferritin was used as the marker
protein in its 24-mer, 48-mer, and 72-mer forms (440 kDa, 880 kDa, and
1320 kDa, respectively). For antibody-shift assays, the antibody amounts
indicated were added to the samples and incubated for 30 minutes on ice
before BN-PAGE loading, as described.22
TCR-induced thymocyte death assays
Mice were injected with either vehicle alone (PBS) or anti-TCR� antibody
(H57-597). After 48 hours, thymi were removed for analysis of thymocyte
numbers and CD4/CD8 expression. For in vitro thymocyte death assay,
cells were cultured in plastic wells precoated with the indicated amount of
anti-TCR� antibody. After 48 hours, thymocytes were harvested and cell
death was assessed by propidium iodide (PI) staining followed by ﬂow
cytometry. Speciﬁc cell death (%) denotes the percentage of dead (PI
positive) cells in antibody-coated wells, normalized to control wells without
antibody as follows:
specific death� [(% PI� anti-TCR� % PI� control)/
(100%�%PI� control)]� 100%.
Calcium mobilization
Calcium mobilization was measured by ﬂow cytometry in Fluo-3-AM–
loaded thymocytes upon addition of biotin-conjugated antibodies to CD3
and CD4 followed by cross-linking with streptavidin.
Results
Restored DN-to-DP and impaired DP-to-SP transition in the
thymus of CD3�� doubly-deﬁcient mice expressing a human
CD3� transgene
��� � h�Tg mice were generated by crossing mice lacking both
CD3� and CD3�, in which thymocyte development is completely
arrested at the CD44�CD25� DN stage, with mice carrying a low
copy number of a complete human CD3� transgene controlled by
its own regulatory elements. The size of the thymi and total
thymocyte number of these ��� � h�Tg mice were relatively
normal compared with control WT mice. Total thymocyte numbers
(n � 10) were as follows: WT, 88 � 31 � 106; ��� � h�Tg,
74 � 17 � 106. Total splenocyte numbers (n � 9) were as follows:
WT, 48 � 15 � 106; ��� � h�Tg, 25 � 6 � 106. Further, all
thymocyte subsets deﬁned by expression of CD4 and CD8
coreceptors were present in ��� � h�Tg mice (Figure 1A).
More detailed analysis of the DN population revealed that
progression beyond the CD44�CD25� DN stage, severely
impaired in CD3�-deﬁcient and CD3�� doubly-deﬁcient
mice,11,13 proceeds efﬁciently in the thymi of ��� � h�Tg mice
(Figure 1B upper panel). In contrast to DP cells in CD3�-deﬁcient
mice,11 numbers of DP thymocytes were comparable between
��� � h�Tg and WT mice (Figure 1A). Further, ��� � h�Tg
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DP cells lacked surface CD25 (Figure 1B lower panel). To-
gether, these data indicate that expression of a human CD3�
transgene is able to restore pre-TCR function in the absence of
CD3� in the mouse, resulting in the generation of DP thymo-
cytes that were phenotypically normal. However, the numbers of
CD4� SP and CD8� SP thymocytes in ��� � h�Tg mice were
reduced on average to 36% and 42%, respectively, of those in
WT mice (Figure 1A). These mature thymocytes were able to
migrate to and accumulate in peripheral lymphoid organs, as
shown by the presence of CD4� and CD8� SP cells in the
spleens of ��� � h�Tg mice, in numbers averaging 50% of
those in WT mice (Figure 1A).
The pattern of ��TCR expression on the surface of mutant
thymocytes was indistinguishable from that of control WT thymo-
cytes (Figure 1C upper panel), despite the speciﬁc absence of ��
dimers in the TCRs of these cells (Figure 1C lower panel).
Furthermore, the up-regulation of ��� � h�Tg TCR expression
was normal during intrathymic development in the absence of
CD3� (Figure 1D). Yet, TCR surface expression in thymic and
splenic SP cells from ��� � h�Tg mice was reduced in comparison
with their WT counterparts (Figure 1D), although the extent of
decrease was less than that reported for CD3�-deﬁcient mice23 or
humans.24 Also, the impairment of TCR expression in peripheral
mature T cells from ��� � h�Tg mice was more prominent in
CD4� SP than in CD8� SP cells (Figure 1D). This was in contrast
with either CD3�-deﬁcient mice or humans, where TCR expression
is more markedly diminished in the CD8� lineage.23,24 Collec-
tively, these data conﬁrm previous ﬁndings indicating that CD3� is
not essential for TCR assembly and surface expression in mouse T
cells.11 Further, these results demonstrate that a human CD3�
transgene can effectively support the DN-to-DP and, albeit with
lesser efﬁciency, the DP-to-SP transition in mice lacking both
CD3� and CD3�. Rescue of intrathymic T-cell development does
not appear to be related to simply transgene overexpression, since a
mouse CD3� transgene was unable to restore thymocyte cellularity
and maturation in CD3�� doubly-deﬁcient mice (Figure 1E).
Accordingly, thymic development in this ��� � m�Tg strain
resembled that of CD3�-deﬁcient mice (Figure 1E), with most of
the thymocytes arrested at the DN stage.
Human CD3� substitutes both mouse CD3� and CD3�
in the ��� � h�Tg TCR
To determine the native structure of the TCR in ��� � h�Tg T
cells, and to characterize the impact of the CD3�-deﬁciency and
incorporation of a human CD3� on the composition and stability
of the TCR complex, we performed blue native (BN)–PAGE
analysis of the TCR expressed by WT and ��� � h�Tg
thymocytes (Figure 2A). The digitonin-extracted native TCR/
CD3 complex isolated fromWT thymocytes was visualized with
anti-CD3� as a single band with mobility just below the
440-kDa ferritin marker. It had the stoichiometry of ��������
as reported before.22,25 In contrast, anti-CD3� detected 3 bands
in the ��� � h�Tg complexes. The largest 2 bands had a size
similar to the WT TCR complex. The highest mobility band
consisted of free CD3� as a band with similar mobility appeared
upon SDS treatment of the WT TCR (data not shown). SDS is a
harsh detergent that disrupts all TCR complexes.
To characterize the subunit composition and stoichiometry of
the TCR in ��� � h�Tg T cells, we used a novel technique
combining antibody-mediated gel-shift and BN-PAGE, termed
native antibody-based mobility-shift (NAMOS) assay22 (Figure
2B). Digitonin lysates fromWT and ��� � h�Tg splenocytes were
used to purify the TCR complex. Subsequently, the puriﬁed
receptor was incubated with different amounts of the anti-CD3�
antibody 2C11 and then subjected to BN-PAGE. TheWT TCR was
Figure 2. Native structure and composition of the TCR complex expressed in
���� h�Tg T cells. (A) TheTCR complex was immunoprecipitated with antiphospho-
tyrosine antibodies from digitonin lysates of pervanadate-stimulated WT and ��� �
h�Tg thymocytes, and subsequently eluted with phenylphosphate. After separation
by BN-PAGE, proteins were transferred to a nitrocellulose membrane and blotted
with an anti-CD3� antibody. The positions of the complete TCR complex (�������� in
WT and ��(h��)2�� in ��� � h�Tg thymocytes), free CD3�, and a partial TCR
complex (arrowhead) are indicated. (B) Phenylphosphate-eluted TCR complexes
from WT and ��� � h�Tg splenocytes were incubated with the indicated amounts of
the antibodies 17A2 (anti-CD3��) or 2C11 (anti-CD3��/��), and subsequently
resolved by BN-PAGE. The Western blot membrane was developed with anti-CD3�
antibodies. The number of antibody-mediated shifts of the TCR complex is indicated
to the right.
Figure 1. Intrathymic T-cell development in ��� � h�Tg mice. (A) Thymocytes
and splenocytes from WT and ��� � h�Tg mice were surface stained with anti-CD4
and anti-CD8 antibodies and analyzed by ﬂow cytometry. Percentages of cells in
quadrants and total cell numbers are shown within and above plots, respectively. (B)
Dot plots show CD44/CD25 subsets in DN-gated cells (top panel), and CD25
expression in total thymocytes (bottom panel). TCR expression in total thymocytes
(C) and in thymic and splenic CD4/CD8 subsets (D) of WT (dotted line) and ��� �
h�Tg (solid line) mice. Numbers within histograms indicate mean ﬂuorescence
intensity (MFI) ratios of ��� � h�Tg versus WT cells. (E) Thymic CD4/CD8
subpopulations in CD3�-deﬁcient and ��� � m�Tg mice. Numbers within and
above plots represent percentages of cells in the gated region and total cell
numbers, respectively.
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shifted to 2 new bands (Figure 2B left). Since the complete
(��������) TCR complex has 2 binding sites for 2C11 (�� and ��),
and since each antibody molecule bound to the complex produces a
discrete change in electrophoretic mobility, the band appearing at
the lowest amount of antibody tested is consistent with one
antibody molecule bound to one TCR complex. The highest
antibody amount generates a band likely corresponding to 2
antibody molecules associated with a single TCR complex, with an
intermediate amount generating a mixture of the products observed
at the highest and lowest amounts of shifting antibody (Figure 2B
left). These data show that the WT TCR complex has 2 binding
sites for 2C11 and, therefore, possesses 2 CD3 dimers (�� and ��).
The 2C11 antibody also produced 2 shifted bands when the
��� � h�Tg TCR complex was analyzed (Figure 2B right). This
indicated that the mutant receptor contained 2 binding sites for
2C11 and corresponds therefore to a ��(h��)2�� complex. The shift
pattern of the band migrating immediately below the predominant
TCR complex (Figure 2A arrowhead) was consistent with a partial
TCR complex containing only one h�� dimer (��h����) (data not
shown). As expected, the TCR of ��� � h�Tg T cells was not
shifted by the anti-CD3�� antibody 17A2 (Figure 2B right),
whereas its WT counterpart was (Figure 2B left). Collectively,
these data indicate that the majority of TCRs in ��� � h�Tg T cells
incorporates 2 h�� dimers per complex, thus keeping with the
typical architecture of the WT TCR.22 Further, a minor fraction of
partial TCR containing only one CD3 dimer (h��) within the
complex was detected. To date, it is unclear whether these
complexes existed on the cell surface or were generated upon
detergent lysis. Both cases could indicate that the chimeric TCR is
less stable than the WT TCR.
Inefﬁcient positive selection of thymocytes in ��� � h�Tg mice
The decrease in the number of mature CD4� and CD8� SP
thymocytes observed in ��� � h�Tg mice suggested an impair-
ment of positive selection. To test this, 3 transgenic TCRs were
independently introduced onto the ��� � h�Tg background: HY,
OT-I, andAND. The HYTCR recognizes a male-speciﬁc peptide in
the context of MHC class I H-2b. Thymocytes expressing the HY
TCR are positively selected as CD8� SP cells in female H-2b
mice.15 Consequently, 20.7% � 7.6% of total thymocytes are
CD8� SP (Figure 3A upper panel and 3C). In contrast, only
2.3% � 1.7% CD8� SP cells were present in female HY ��� �
h�Tg mice (Figure 3A upper panel and 3C). Numbers of CD8� SP
thymocytes were also reduced by 90% in the HYTCR mutant mice
(Figure 3C). Positive selection of another MHC class I–restricted
TCR (OT-I,16 speciﬁc for an ovalbumin peptide in the context of
H-2b) was also affected in ��� � h�Tg mice, albeit to a lesser
degree (Figure 3Amiddle panel). In this case, the number of CD8�
SP cells was reduced by only 45% in OT-I transgenic ��� � h�Tg
compared with WT mice (Figure 3C).
We next used mice expressing the pigeon cytochrome-C–
speciﬁc TCR AND17 crossed with ��� � h�Tg mice to assess
whether positive selection of class II–restricted CD4� SP thymo-
cytes was also affected. In AND ��� � h�Tg mice, the percentage
and number of CD4� SP cells were reduced to 32% and 43%,
respectively, of those in WT mice (Figure 3A lower panel and 3C).
This result demonstrated that the efﬁciency of positive selection of
CD4� T cells was also decreased in ��� � h�Tg mice. Thus,
positive selection of both class I– and class II–restricted T cells
appeared to proceed less efﬁciently in ��� � h�Tg mice. Yet,
surface up-regulation of CD526 (data not shown) and the TCR
(Figure 3B) along the DP-to-SP transition was comparable in WT
and ��� � h�Tg TCR transgenics, suggesting that positive
selection is not qualitatively affected in the mutant mice.
It could be argued that the defects in positive selection observed
in ��� � h�Tg mice result from a decrease in surface TCR
expression on the DP population (Figure 3B), which is the one
subjected to this selection process. To address this issue further, we
performed functional assays of TCR signaling using the
AND.DP.��/� cell line. This cell line was established from a
thymic tumor spontaneously arising in a mouse from our ��� �
h�Tg colony bearing the AND TCR. It expresses surface CD4 and
CD8, and TCR, but not CD3� (Figure 4A). Expression of the
transgenic hCD3� was detected by PCR (data not shown). Of
interest, surface TCR expression in AND.DP.��/� was even higher
than that of DP cells from AND TCR transgenics (Figure 4B).
Despite this high TCR expression, both CD69 and CD5 up-
regulation in response to TCR ligation with antibody or peptide-
MHC,27,28 an event that correlates with positive selection,29 was
clearly impaired in the DP thymocyte line when compared with its
counterparts from WT AND TCR transgenics (Figure 4C). To
exclude that this defect was entirely due to the transformed state of
the cell line, we analyzed activation marker up-regulation in
primary DP thymocytes from ��� � h�Tg mice, in which TCR
surface expression is comparable with that of WT DP cells (Figure
1D). TCR-mediated up-regulation of CD69 and CD5 expression
was also reduced in primary ���� h�Tg DP thymocytes compared
with their WT counterparts (Figure 4D), although to a lesser extent
than in the thymocyte line. Together, these data suggest that TCR
complexes incorporating a human CD3� chain and lacking CD3�
have an impaired signaling capability, and that this defect is not
related to the TCR density on the thymocyte surface.
Figure 3. Impaired positive selection in ��� � h�Tgmice. (A) Dot plots show CD4
and CD8 expression in thymocytes from WT and ��� � h�Tg mice expressing
transgenic HY (females), OT-I, or AND TCR. Numbers within dot plots indicate the
percentage of CD8� or CD4� SP cells in the gated region. (B) Histograms depict
transgenic TCR expression, assessed with anti-TCRV� or anti-TCRV� antibodies, in
DP and positively selected CD8� (HY and OT-I) or CD4� (AND) SP cells from WT
(dotted line) and ��� � h�Tg (solid line) mice. (C) Percentages (top panel) and
absolute numbers (bottom panel) of CD8� (HY and OT-I) or CD4� (AND) SP
thymocytes in TCR transgenic WT (�) and ��� � h�Tg (f) mice. Five to 8 mice per
group were analyzed. Error bars indicate the mean plus or minus standard deviation.
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Impaired negative selection and TCR-induced thymocyte death
in ��� � h�Tg mice
To study negative selection in ��� � h�Tg mice, we analyzed male
HY TCR transgenics. In male (but not in female) H-2b mice,
thymocytes expressing the HY TCR are negatively selected as a
result of extensive apoptotic cell death at the DP stage upon
recognition of male-speciﬁc peptide and MHC.15 Indeed, only 3%
DP cells were detected inWTHYTCR mice (Figure 5A top panel).
In contrast, HY ��� � h�Tg mice exhibited a partial but clear
defect in negative selection, demonstrated by the persistent DP
population that constituted 56% of the thymocytes (Figure 5A top
panel). Moreover, splenic CD8� SP T cells that escaped intrathy-
mic clonal deletion in ��� � h�Tg mice were CD8high, in contrast
to WT mice where they expressed characteristically low levels of
surface CD830 (Figure 5A bottom panel). Furthermore, thymocyte
death induced by anti-TCR antibody in vivo31 (Figure 5B), and in
vitro (Figure 5C), was markedly reduced in ��� � h�Tg mice.
Collectively, these data indicate that effective coupling of the TCR
to death-inducing pathways in thymocytes, and resulting negative
selection, is impaired in ��� � h�Tg mice.
Reduced strength of TCR-initiated signals
in ��� � h�Tg thymocytes
To determine whether thymocytes from ��� � h�Tg mice exhib-
ited a TCR signaling defect, we analyzed several intracellular
events associated with TCR signal transduction. Early biochemical
events elicited upon TCR engagement,32 namely tyrosine phosphor-
ylation of src- and syk-kinase substrates including ZAP-70, Cbl-1,
and LAT, were markedly attenuated but not completely abrogated
in ��� � h�Tg thymocytes, and also in AND TCR transgenic
��� � h�Tg thymocytes compared with their WT counterparts
(Figure 6A). Although a reduced level of tyrosine phosphorylation
of key signal-transduction molecules was found in anti-TCR–
activated thymocytes (Figure 6A), it would appear though that no
single pathway was affected speciﬁcally. TCR-induced calcium
mobilization32 was also decreased in ��� � h�Tg thymocytes
compared with their WT counterparts (Figure 6B).
TCR-dependent transient activation of mitogen-activated pro-
tein kinases (MAPKs) ERK, JNK, and p38 has been shown to
affect thymocyte selection.33 We therefore examined the phosphor-
ylation levels of these enzymes as an indication of their activation
state. Upon in vitro TCR ligation with antibody, phosphorylation of
the ERK, JNK, and p38 kinases was diminished in ��� � h�Tg
thymocytes compared with control WT cells (Figure 6C). Thus,
��� � h�Tg mice display a general and quantitative defect in the
TCR-induced activation of all MAPK pathways in the thymus.
Taken together, these data demonstrate that proximal as well as
distal signaling events coupled to TCR stimulation in thymocytes
are markedly attenuated in ��� � h�Tg mice.
Discussion
In mice lacking CD3�, due to targeted gene disruption, the
DN-to-DP transition is severely impaired,11 most likely as a
consequence of defective pre-TCR function. Thus, mature T cells
are practically absent in the peripheral lymphoid organs of
CD3�-deﬁcient mice. In contrast, T lymphocyte numbers are
grossly normal or only slightly diminished in CD3�-deﬁcient
humans,12 suggesting that in humans, but not in mice, the highly
related CD3� chain is capable of functionally replacing CD3�
during thymopoiesis. Here, we show that human CD3� could
restore mouse T-cell development in the absence of CD3� by
expressing a hCD3� transgene in CD3�� doubly-deﬁcient mice.
In the ��� � h�Tg mouse strain, the pre-TCR–mediated
DN-to-DP transition was efﬁciently restored by hCD3� expression.
It is rather intriguing that human but not mouse11 CD3� can replace
CD3� for pre-TCR–mediated thymocyte development. In the
absence of CD3�, the amount of CD3� could be limiting with
regard to pre-TCR expression. In this scenario, enhanced expres-
sion of transgenic (relative to endogenous) CD3� would overcome
that limitation, allowing the expression of CD3�-lacking pre-TCR
complexes. This appears unlikely as the relative amount of
intracellular CD3�-containing dimers in DN thymocytes was
comparable in WT, CD3�-deﬁcient, and ��� � h�Tg mice (data
not shown). Also, CD3�� dimers present on the surface of
CD3�-deﬁcient DN thymocytes are sufﬁcient to mediate develop-
mental progression when engaged with anti-CD3 antibodies,11 or to
permit the expression of a transgenic ��TCR and rescue of the
DN-to-DP transition.34 Finally, early thymocyte development was
not restored in CD3�� doubly-deﬁcient mice expressing a mouse
Figure 4. TCR expression and signaling in a DP thymocyte line expressing hCD3� and lacking CD3�. (A) The AND.DP.��/� line was surface stained with antibodies to
CD4, CD8, TCR�, and CD3�� and analyzed by ﬂow cytometry. (B) The histogram shows surface TCR (TCR�) expression in theAND.DP.��/� line (solid line) compared with DP
thymocytes from AND TCR transgenic mice (dotted line). (C) CD69 and CD5 up-regulation in AND TCR transgenic DP thymocytes (left panels) or the AND.DP.��/� line (right
panels) after 48-hour stimulation with 1 �g plastic-bound anti-TCR� antibody or with DCEK cells preloaded with 2 �M pigeon cytochrome C (PCC) peptide 88-100. Shaded
curves represent marker expression in unstimulated cells. (D) CD69 and CD5 up-regulation (left panels) in WT and ��� � h�Tg DP thymocytes stimulated for 48 hours with
0.5 �g (solid line) or 5 �g (dotted line) anti-TCR� antibody, or in unstimulated cells (shaded curves), as determined by 3-color ﬂow cytometry. Numbers within histograms
represent the percentage of cells in the marked region for unstimulated (upper value) or anti-TCR–stimulated (0.5 �g, middle value; 5 �g, lower value) DP thymocytes. MFI
values of CD69 and CD5 expression in WT (�) and ��� � h�Tg (f) DP thymocytes stimulated with the indicated amount of anti-TCR� antibody are plotted at the right.
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CD3� transgene. In line with this, a human CD3 transgene that
encodes full-length CD3� and a truncated but functional form of
CD3� restored the defective pre-TCR function in CD3�- and
CD3��-deﬁcient mice.35 Therefore, in the absence of CD3�,
human but not mouse CD3� appears to endow the pre-TCR
complex with speciﬁc properties essential for pre-TCR function.
Whatever these properties might be, they appear to be independent
of the signal-transducing ITAMmotif, as early thymocyte develop-
ment proceeded unaffected in mice expressing a CD3� chain
lacking the ITAM motif.34 Accordingly, the differential capability
of human versus mouse CD3� to functionally replace CD3� within
the pre-TCR must map in the extracellular and/or transmembrane
domain, as it has previously been shown for CD3� regarding TCR
function and thymocyte selection.8 In the extracellular region, there
are several amino acid positions where human but not mouse CD3�
matches mouse CD3�. Whether these residues contribute speciﬁc
structural and/or functional features to the pre-TCR complex
deserves further investigation.
The reduced number of mature CD4� and CD8� SP thymocytes
in ��� � h�Tg mice suggested a defect in TCR-mediated
thymocyte selection. This was conﬁrmed by using 3 different
transgenic ��TCRs expressed in the ��� � h�Tg background.
Positive selection of both these class I– or class II–restricted TCR
transgenic T cells was markedly reduced in the mutant mouse, but
without any sign of alteration in lineage commitment. Negative
selection was similarly impaired in ��� � h�Tg mice. Further,
these defects were not likely related to decreased TCR surface
expression in mutant DP cells, as pointed out by our studies with
the AND.DP.��/� thymocyte line, which presented defects in TCR
signaling despite expressing high levels of receptor on the cell
surface. Collectively, our results demonstrate that positive and
negative selection proceeded less efﬁciently in ��� � h�Tg mice,
probably because signals from CD3�-lacking TCR incorporating
human CD3� are weaker. The latter is supported by the observation
that signaling events proximal to TCR stimulation were markedly
attenuated, but not totally abrogated, in thymocytes from ��� �
h�Tg mice. More distal TCR-triggered events were also quantita-
tively but not qualitatively affected. A recent study further supports
this notion by showing that the strength of signaling by CD4 and
CD8 coreceptor tails determines the number but not the lineage
direction of positively selected thymocytes,36 a phenotype similar
to that observed in ��� � h�Tg mice. Our results are also
consistent with the impairment in TCR-mediated tyrosine phosphor-
ylation and calcium mobilization found in T cells from CD3�-
deﬁcient patients.37,38 Similarly to mature T cells in CD3�-deﬁcient
humans,24,37 but in contrast to CD3�-null mutant mice,23 spleno-
cytes from ��� � h�Tg mice showed normal up-regulation of
Figure 6. Attenuated TCR-mediated signaling in ��� � h�Tg thymocytes. (A)
Phosphotyrosine immunoblots of total cell lysates from WT and ��� � h�Tg
thymocytes (left), or AND TCR transgenic WT and ��� � h�Tg thymocytes (right),
unstimulated (time 0) or stimulated with anti-CD3 and anti-CD4 antibodies for the
times indicated. The identities of some of the induced phosphoproteins were
determined by immunoblotting with speciﬁc antibodies, as shown for Cbl-1 and LAT in
the lower panels. (B) Calcium mobilization and (C) phosphorylated (active) MAPK
(pERK, pJNK, and pp38) induction in thymocytes stimulated with cross-linked
anti-CD3 and anti-CD4 antibodies. Fold activation of each MAPK relative to
unstimulated (time 0) cells is indicated. Protein loading was assessed with antibodies
to total ERK, JNK, and p38.
Figure 5. Impaired negative selection and antibody-induced thymocyte death in
��� � h�Tg mice. Dot plots (A) of CD4 and CD8 expression in thymocytes and
splenocytes from WT and ��� � h�Tg HY TCR male mice, or (B) of thymocytes
removed from WT (left) and ��� � h�Tg (right) mice 48 hours after intraperitoneal
injection with either vehicle alone (PBS) or 200 �g anti-TCR� antibody. Percentages
of gated cells and total thymocyte numbers are shown within and above plots,
respectively. MFI denotes mean ﬂuorescence intensity of CD8 staining in the gated
region. (C) In vitro anti-TCR antibody–induced death of WT (F) and ��� � h�Tg (E)
thymocytes cultured for 48 hours in plastic wells precoated with the indicated amount
of anti-TCR� antibody. Cell death was assessed by propidium iodide staining and
ﬂow cytometry.
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CD69 and CD25 in response to anti-TCR antibody stimulation
(data not shown). Further, like human T cells lacking CD3�,37
��� � h�Tg splenocytes exhibited defective phorbol ester–
stimulated but only slightly reduced anti-TCR antibody-induced
TCR down-regulation (data not shown). Taken together, these
results indicate that TCR signaling is grossly similar in ��� �
h�Tg mice and CD3�-deﬁcient humans.
The ��TCR complex expressed by thymocytes from ��� �
h�Tg mice retained epitopes recognized by antibodies to murine
TCR� (H57-597) and CD3��/�� dimers (145-2C11). Further, the
mutant TCR complex displayed the same stoichiometry as that of
the WT TCR. Together, these data indicate that the ��� � h�Tg
TCR topologically resembles CD3�-sufﬁcient TCR in some as-
pects. Of importance, abnormal glycosylation of hCD3� (data not
shown) was observed for the ��� � h�Tg TCR. This might explain
its slightly reduced electrophoretic mobility under native condi-
tions compared with the WT TCR, and its inability to trigger late
T-cell activation in response to the lectin concanavalin A (data not
shown). In addition, a weak association of CD3 chains, including
hCD3�/CD3� and CD3�, to the TCR�� heterodimer was observed
for the ��� � h�Tg TCR complex. These alterations in glycosyla-
tion and stability have also been reported for T cells from human
CD3�-deﬁcient individuals,39 and they could be partly underlying
the impaired signaling capability of the TCR in ��� � h�Tg
mice.40,41 Whether CD3� provides speciﬁc functions to the TCR
that are essential for thymocyte selection34 remains an open
question, awaiting the analysis of more CD3�-deﬁcient TCR
transgenic mice.
CD3� and CD3� appeared for the ﬁrst time in mammals as a
result of the duplication of an ancestral gene found in birds with
properties of both CD3 chains.42 The evolution of CD3� and CD3�
as discrete subunits in mammals suggests that they might have
some nonredundant but essential functions within the pre-TCR and
TCR complexes. The present study further demonstrates that CD3�
and CD3� play different roles in pre-TCR and TCR function in
mice and humans.
The gross phenotype of ��� � h�Tg mice, in contrast to
previously reported CD3�-deﬁcient mice,11 resembled that of
humans who lack expression of the CD3� protein.43 Thus, this
humanized CD3�-deﬁcient mouse strain may constitute a valuable
tool44 to analyze the consequences of the CD3� deﬁciency in a
more detailed way than is now possible in human patients, and for
the design and preclinical evaluation of therapeutic strategies to
correct human disorders associated with CD3 deﬁciencies.45
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T Lymphocyte Development in the Absence of CD3� or
CD3����1
Baoping Wang,2* Ninghai Wang,* Charles E. Whitehurst,† Jian She,* Jianzhu Chen,† and
Cox Terhorst*
CD3�, �, �, and � proteins together with the pre-TCR �-chain (pT�) and a rearranged TCR �-chain assemble to form the
pre-TCR that controls the double negative (DN) to double positive (DP) stages of thymopoiesis. The CD3 proteins are expressed
before pT� and TCR �-chains in prothymocytes and are expressed intracellularly in precursor NK cells, suggesting that the CD3
complex may function independent of pT� and TCR�. In this report, both the role of CD3� exclusively, and the role of CD3
proteins collectively, in thymocyte and NK cell development were examined. In a mouse strain termed ��P, a neomycin cassette
inserted within the CD3� promoter abolishes CD3� and � expression and also abolishes CD3� expression in all but a small
minority (<1%) of prothymocytes. These prothymocytes became deficient in CD3� alone upon reconstitution of CD3� expression
and were severely, but not completely, arrested at the DN stage, as small numbers of double positive thymocytes were detected.
In de facto CD3����null mice generated by crossing the ��P mice with CD3��/� mice, thymopoiesis were arrested at the
CD44�CD25� DN stage as observed in RAG�/� mice, DJ and VDJ recombination at the TCR� locus was functional, and normal
numbers of NK cells were detected. Together, the findings demonstrate that during thymocyte development, the CD3 complex
collectively is not essential until the critical CD44�CD25� DN stage in which pre-TCR begins to function, whereas CD3� is critical
for the assembly of pre-TCR. Moreover, CD3 proteins are dispensable for NK cell development. The Journal of Immunology,
1999, 162: 88–94.
I ntrathymic T lymphocyte development is defined by differentexpression patterns of a series of cell surface Ag, includingCD4, CD8, CD25, and CD44 (1–3). The most immature thy-
mocytes are CD4�CD8� double negative (DN)3 cells that com-
prise �4% of thymic cellularity, and can be further divided into
four subpopulations that differentiate in this order: CD44�CD25�
3 CD44�CD25� 3 CD44�CD25� 3 CD44�CD25� (2, 4).
The DN CD44�CD25� cells subsequently develop into immature
CD4�CD8� double positive (DP) CD44�CD25� thymocytes that
are subjected to either positive or negative selection (5–7). The
positively selected thymocytes become mature CD4� or CD8�
single positive (SP) cells and are exported to the periphery (1, 6,
8). During this process, the genes coding for TCRs, pre-TCR�
(pT�), and the associated CD3 proteins are also expressed in a
temporal order and promote T cell development (9–12).
Extensive biochemical studies have demonstrated that CD3 pro-
teins are required for the assembly and surface expression of the
TCR (13–15). In each TCR/CD3 complex, there are two copies of
CD3� and CD3�, but only one copy of CD3� and CD3� (16–21).
CD3� forms heterodimers with CD3� and CD3�, whereas CD3�
exists as a homodimer (18, 20, 22, 23). In prothymocytes, CD3
proteins associate with pT�/TCR� to form the pre-TCR/CD3 com-
plex (24–27). The pre-TCR/CD3 complex plays an essential role
in thymocyte differentiation from DN cells to DP cells, termed
�-selection, as targeted mutations in pT� (28), TCR-� (29), or
RAG (29) genes all result in an arrest of T cell development at the
DN CD44�CD25� stage (10, 11).
We, and others, have used gene knockout and transgenic ap-
proaches to study the role of CD3 proteins in T cell development
(12). In CD3��/� mice, T cell development is arrested at the im-
mature DP stage (30–33). In CD3��/� mice, T cell development
is arrested during the transition from the DP to the SP stage (34).
In CD3��/� mice, T cell development is severely arrested during
the transition from the DN to DP stage (35). However, in mice
deficient in both CD3� and CD3� genes, early thymocyte devel-
opment was arrested at the DN CD44�CD25� stage (36). There
are two independent strains of CD3� mutant mice. One is called
the CD3��5/�5 mice, in which exon 5 of the CD3� gene was re-
placed by a PGK neor cassette (37). We recently generated another
strain of CD3� mutant mice termed the CD3��P/�P (��P) mice, in
which the promoter and the first two exons of the CD3� gene were
replaced by a PGK-neor cassette (38). In both types of CD3� mu-
tant mice, early thymocyte development was arrested at the DN
CD44�CD25� stage (37, 38).
However, a specific role for CD3� in early T cell development
is still unclear because CD3� and CD3� expression were also se-
verely inhibited in both strains of CD3� mutant mice (37, 38). By
reconstitution of CD3� expression in the ��P mice with a CD3�
transgene, we recently revealed that CD3� does not regulate
CD3�� expression, and that the inhibition of CD3� and CD3�
expression was caused by the PGK-neor cassettes inserted in the
neighboring CD3� gene (38). Moreover, the study also showed
that �99% of prothymocytes in the ��P mice are deficient in
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CD3���, whereas �1% of prothymocytes express CD3� and ��1%
of prothymocytes express CD3� (38). Thus, the blockade in thymo-
poiesis in the ��P mice represents the phenotype of mice with a triple
deficiency in the CD3���-chains. Therefore, we reasoned that if
CD3� expression is restored in the ��P mice, we should be able to
follow the development of the�1% of CD3�� ���� prothymocytes.
We report here that prothymocytes deficient in CD3� alone can very
inefficiently develop to the DP stage.
In addition to the essential role of CD3 proteins for the assembly
and signal transduction of the pre-TCR and TCR, CD3 proteins are
also expressed on the cell surface as a part of a clonotype-inde-
pendent CD3 (CIC) complex in prothymocytes before the expres-
sion of pT� and TCR� (39, 40), and are expressed intracellularly
in NK cell precursors and NK cells (41–43). Because in vivo anti-
CD3� stimulation of CIC in pT��/�, TCR��/�, or RAG�/� mice
all result in thymocyte differentiation from DN cells to DP cells,
the CIC may play a role in transducing a signal for early thymocyte
development, including the onset of VDJ recombination. We have
previously reported that overexpression of CD3� in transgenic
mice results in an arrest of prothymocyte development at the DN
CD44�CD25� stages before the stage in RAG�/� mice, in addi-
tion to a complete block in NK cell development (44, 45). Thus, a
remaining question is whether mice deficient in all four CD3
chains would have a block in very early thymopoiesis, VDJ re-
combination, and NK cell development. To answer these ques-
tions, we made use of the fact that �99% of ��P thymocytes are
deficient in CD3���, and hence obtained a de facto CD3�����/�
mouse by breeding the ��P mice with CD3��/� mice. We dem-
onstrate here that: 1) prothymocytes deficient in all CD3 proteins
still arrest at the same DN CD44�CD25� stage as that of RAG�/�
mice, 2) TCR� rearrangements take place in the absence of all
CD3 proteins, and 3) CD3 proteins play no essential role in NK
cell development.
Materials and Methods
Mice
The ��P mice and the ��Pxtg� mice were generated as described (38).
��Pxtg� mice were obtained by breeding the ��P mice with a strain of
transgenic mice, termed tg�4, that carries three copies of a human CD3�
transgene (44). Double mutant mice were identified by Southern blot
analysis.
Flow cytometric analysis
Single cell suspensions of thymocytes, LN cells, and spleen cells were
prepared as described (44, 45). Three color staining of the cells was per-
formed as previously reported (44, 45). Briefly, cells were incubated with
prestaining buffer (0.5–1 � 106 cells/50 �l) (PBS, 4% BSA, 0.5% sodium
azide (SA), 15% of a mixture of normal hamster, normal rat, and normal
mouse sera, 0.5 �g anti-FcR Ab) for 5 min. The cells were then stained
with a biotinylated Ab (0.5 �g/50 �l per tube) for 30 min. The cells were
washed once with 3 ml PBS, followed by staining with 50 �l/tube of a
mixture of streptavidin-RED670 (Life Technologies, Grand Island, NY)
(0.4 �l/sample), plus phycoerythrin- and FITC-conjugated Abs (0.5 �g
each/sample), for 30 min. The cells were washed once with 3 ml PBS,
resuspended, and fixed in 200 �l of PBS/SA and 1% formaldehyde until
analyzed with a FACScan using CellQuest software (Becton Dickinson,
Franklin Lakes, NJ). To exclude contamination of dead cells as
CD4�CD8� cells in thymocyte samples, some samples were stained with
200 �l of PBS/SA containing 1 �g/ml of propidium iodide after the final
wash, and analyzed the same day. All procedures were performed on ice or
at 4°C until analysis. For each sample, at least 10,000 cells were collected.
RNA analysis
Northern blot analysis was performed as described (36, 46).
NK cytotoxicity assay
NK-mediated cytotoxic lysis was determined by a standard 51Cr-release
assay as described previously (44). Briefly, mice were injected i.p with 100
�g of poly(I:C) 16–24 h before sacrifice. Splenocytes derived from the
testing mice were mixed with 5 � 103 51Cr-labeled YAC-1 cells in tripli-
cate, at E:T ratios of 200, 100, 33, and 11, in a final volume of 200 �l in
round-bottom microtiter plate, and incubated for 4 h at 37°C.
PCR assay for TCR� DJ and VDJ rearrangements
Rearrangement of D�1. to J�1.1 through J�1.5 (DJ recombination) and
V�12 and V�14 to D�1J�1.1 through D�1J�1.5 (VDJ recombination) was
detected by a PCR-based assay (47) using the oligonucleotide primers
Db15A, 5�-CCCCAGAGGAGCAGCTTATCTG-3�; D�1–5�, 5�-GGTA
GACCTATGGGAGGGTC-3�; Jb15X, 5�-AAGACTCCTAGACTGCA
GACTCAG-3�; Jb15Y, 5�-CCAGTTTGGTCCCATAGTTTACCT-3�;
V�12PS, 5�-GCTGGAGTTACCCAGACACCC-3�; and V�14PS, 5�-GC
CCTAACCTCTACTGGTACTGGCAGGC-3�. For DJ rearrangement, a
primary PCR was performed using 100 ng of purified thymocyte DNA
from the various mouse strains and primers Db15A and Jb15X for 15
cycles, and then 5 �l was removed and used as the template in a secondary
PCR with the nested primers D�1–5� and Jb15Y for 20 cycles. For VDJ
rearrangement, a primary PCR was performed using 100 ng of purified
thymocyte DNA and primers V�12PS or V�14PS and Jb15X for 15 cycles,
and then 5 �l was removed and used as the template in a secondary semi-
nested PCR with primers V�12PS or V�14PS and Jb15Y for 20 cycles. All
reactions were in 50 �l and consisted of 10 mM Tris-HCl, (pH 8.8), 50 mM
KCl, 2 mM MgCl2, 0.2 mM dNTPs, 0.1% Triton X-100, 0.5 U Taq poly-
merase, and 125 ng of each primer. For all reactions, cycle conditions were
as follows: 1 cycle of 95°C for 5 min, 62°C for 2 min, and 72°C for 2 min,
followed by 15 or 20 cycles of 95°C for 1 min, 62°C for 1.5 min, and 72°C
for 2 min. Secondary reactions were electrophoresed on 1.5% agarose gels,
transferred to Immobilon nylon membrane (Bio-Rad, Richmond, CA), and
all DNA products were detected by Southern blot hybridization with an
end-labeled oligonucleotide probe specific for the 3� coding region of the
J�1.5 gene segment (5�-GAACAGAGAGTCGAGTC-3�) (48). The m.w.
of the resultant products in these assays accurately corresponded to the
expected m.w. for rearrangements to J�1.1 through J�1.5 based on the
known TCR� gene sequence.
Results
A small number of prothymocytes in ��P mice express CD3�
In addition to the absence of CD3� expression in ��P mice, the
expression of the CD3� and CD3� genes was also suppressed by
the neor cassette inserted in the neighboring CD3� gene (38). The
suppression of CD3� expression was more severe than that of
CD3� possibly because the neor cassette is closer to the CD3�
gene than to the CD3� gene (38). As shown in Fig. 1A, CD3� and
CD3� mRNA were apparently absent in ��P thymocytes (38).
However, a minor CD3� mRNA band could be visualized in ��P
thymocytes upon longer exposure, whereas CD3� mRNA was un-
detectable even when overexposed (Fig. 1B). Nevertheless, a
minute level of CD3� transcription could be detected by a more
sensitive RT-PCR method (38). We have shown recently that the
detected CD3� and CD3� expression is restricted to a very small
fraction of ��P thymocytes, whereas the majority of ��P thymo-
cytes are deficient in both CD3� and CD3�. Taken together, a very
small fraction of the ��P thymocytes (�1%) do express CD3�, and
a much smaller fraction of the ��P thymocytes may express both
CD3� and CD3�.
Developmental block of prothymocytes deficient in CD3� per se
Thymocytes that express both CD3� and CD3� in ��P mice should
represent the phenotype of thymocytes deficient in CD3� per se.
However, the extremely small number of such cells precluded a
conclusive examination of this issue in the ��P mice. We reasoned
that because there are more CD3�-expressing cells than CD3�-
expressing cells in the ��P thymus, we should be able to obtain a
detectable number of prothymocytes deficient in CD3� only if
CD3� expression is restored in the ��P mice (Figs. 1C and 2).
Thus, we bred the ��P mice with a strain of transgenic mice termed
tg�4�/� (tg�) that express a human CD3� transgene (45) (Fig. 1C).
Indeed, a small but genuine population, averaging 0.4% (up to
2%), of DP cells was consistently detected in the ��Pxtg� mice
89The Journal of Immunology
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(Fig. 3). These DP cells were CD44�CD25�, similar to the im-
mature DP cells in wild type (wt) mice (data not shown). The
majority (�98%) of thymocytes in the ��Pxtg� mice (which are
CD3��tg���� cells) were still DN cells, with most of them being
CD44�CD25� cells, the same as those in RAG�/� or ��P mice
(Figs. 2 and 3) (38, 49). However, thymic cellularity remained the
same in ��Pxtg� mice as compared with the ��P mice (Fig. 4), and
no mature T cells (TCR-��� SP cells) were detected in the thymus
or in the periphery of these mice (data not shown). Therefore, these
data demonstrated that prothymocytes deficient in CD3� per se can
become DP cells, whereas prothymocytes deficient in both CD3�
and CD3� are arrested at the DN CD44�CD25� stage.
Having established that prothymocytes deficient in CD3� per se
can differentiate from DN cells to DP cells, we wished to deter-
mine how efficient this transition was in comparison with wt pro-
thymocytes. For this purpose, ��P mice were reconstituted for
CD3� expression by crossing them with a CD3� transgenic line
termed tg�600�/� (tg�), in which thymocyte development is close
to normal (Fig. 2) (38). We reasoned that in the resulting ��Pxtg�
mice, the small numbers of CD3�-expressing prothymocytes
would be CD3��tg��, and the majority of prothymocytes would
be CD3��tg��. All of DP thymocytes in the resulting ��Pxtg�
mice would in fact be derived from the CD3��tg�� prothymo-
cytes, because CD3�� prothymocytes essentially could not differ-
entiate into DP cells (35) (Fig. 2). Of note, each CD3��tg�� pro-
thymocyte is equivalent to a CD3����tg�� prothymocyte for the
generation of DP cells, because CD3� is not essential for the de-
velopment of DP cells (34). It was observed that in ��Pxtg� mice,
an average of 16.7% (up to 40%) of thymocytes were DP cells
(Fig. 3), although thymic cellularity of the ��Pxtg� mice was sim-
ilar to the ��P and ��Pxtg� mice (Fig. 4). Thus, every CD3��tg��
prothymocyte would give rise to more than 40-fold DP cells (i.e.,
16.7% vs 0.4%) as compared with a CD3���� prothymocyte (Fig.
FIGURE 1. CD3�� deficiency in the ��P mice. A, Northern blot analysis
of thymocytes from wt, ��P, and RAG�/� mice for the expression of CD3�
and �. The blotting of �-actin was used as an RNA quantity control. The
respective probes are indicated on the left, and the sizes of the RNA tran-
scripts are indicated on the right. B, Longer exposure of the Northern blots
shown in (A). C, Northern blot analysis of thymocytes from wt, ��P, and
��Pxtg� mice for the expression of murine CD3�, �, and the transgenic
human CD3�. Of note, the introduction of the human CD3� transgene did
not restore the expression of the endogenous murine CD3� and �
expression.
FIGURE 2. Schematic diagram of the rationale and outcome of the ex-
periments. Top panel, The rationale. The relative numbers of different sub-
populations of cells were estimated as described (38). The patterns of CD3
expression are indicated (for reasons of simplicity, positively expressed
CD3 subunit(s) is omitted in some cases). The horizontal bars at the tip of
arrows represent blockades in T cell development. Bottom panel, The out-
come. Blockades in T cell development from prothymocytes deficient in
the expression of CD3 genes. See text for details. Of note, the number of
16.7 or 0.4% represents the average frequency of DP thymocytes in the
whole thymus from ��Pxtg� or ��Pxtg� mice, respectively.
FIGURE 3. Thymocyte development in the ��Pxtg�, ��Pxtg� and
��PxCD3��/� mice. Left panel, Profile of CD4 and CD8 expression. Right
panel, Expression of CD44 and CD25 in the software-gated DN
thymocytes.
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2). Therefore, differentiation from DN to DP stages by prothymo-
cytes deficient in CD3� per se was very inefficient.
T cell and NK cell development in ��PxCD3��/� mice
To investigate the collective role of CD3 proteins in very early
thymopoiesis, we bred the ��P mice with CD3��/� mice. The re-
sulting ��PxCD3��/� mice represent de facto CD3�����/� mice,
because prothymocytes expressing CD3� or CD3� would be too
few to give a detectable phenotype (without reconstitution of some
CD3 expression) (Fig. 2). Nonetheless, early T cell development
was arrested at the very same DN CD44�CD25� point in the
��PxCD3��/� mice as in the ��P mice (Figs. 3 and 4). Flow cy-
tometric analysis of thymocytes for the expression of c-kit, Sca-1,
and Thy-1 revealed the same Thy-1�Sca-1�c-kit� phenotype in
the ��PxCD3��/� mice as in the RAG-2�/� mice (data not
shown).
To assess the role of CD3 proteins in NK cell development, we
analyzed the NK cell compartment in the spleen of the ��P and
��PxCD3��/� mice. NK cells from certain strains of mice such as
C57BL/6, but not other strains including 129/sv (in which embry-
onic stem cells were originated), express the NK1.1 marker (50).
Nonetheless, NK cells from all strains express DX5 Ag (51). As
the colony of knockout mice was maintained by sib-breeding, NK
cells could express both NK1.1 and DX5, or DX5 only. As shown
in Fig. 5, splenocytes derived from the ��P mice contained normal
percentages of NK1.1�DX5� cells and possessed normal level of
cytotoxicity against NK cell-sensitive YAC-1 target cells. Al-
though splenocytes derived from six of six ��PxCD3��/� mice
were negative for NK1.1 expression, which was in part due to the
fact that NK cells in the CD3��/� mice used in this study were
mostly negative for NK1.1 expression (data not shown), these
spleen cells contained normal percentages of DX5� cells (Fig. 5A),
and importantly, these splenocytes killed YAC-1 target cells effi-
ciently (Fig. 5B). We conclude that NK cell development was nor-
mal in both the ��P and ��PxCD3��/� mice. Taken together, CD3
proteins do not play an essential role in early thymocyte develop-
ment before the DN CD44�CD25� stage or in NK cell
development.
TCR �-chain rearrangements
Lastly, we examined the effect of a deficiency in CD3 proteins on
TCR �-chain rearrangements using a DNA-PCR assay (47). To
this end, genomic DNA was isolated from the thymocytes derived
from the ��P and ��PxCD3��/� mice, as well as from mice defi-
cient in CD3�� (36). Thymocyte DNA isolated from wt mice and
RAG-2�/� mice were included in these experiments as controls.
TCR� D3 J rearrangements were assessed by nested PCR using
5� primers complementary to upstream of D�1 and two 3� primers
immediately downstream of J�1.5, allowing the detection of D�1
to J�1.1 through J�1.5 rearrangements. The V3DJ rearrange-
ments were assessed by nested PCR using two 5� primers com-
plementary to V�12 and V�14, respectively, and the same 3�
primers downstream of J�1.5. The amplified PCR products were
visualized with an oligonucleotide that specifically hybridizes to
the J�1.5 gene segment. As illustrated in Fig. 6, TCR� gene re-
arrangements in the mutant thymocytes were as efficient as those
in wt counterparts. Thus, CD3 proteins are not required to signal
initiation of TCR-� gene rearrangements.
Discussion
An important observation in this report is that small numbers of
DP cells could be detected in the ��Pxtg� mice. One interpretation,
which we favor, is that prothymocytes deficient in CD3� per se
FIGURE 4. Thymic cellularity of the mutant mice. Each symbol repre-
sents the total number of thymocytes from a mouse. The average number
of thymocytes from mutant mice was compared with that from wt (includ-
ing CD3��P/�) littermates or age-matched wt mice. For comparison, data
from tg� and ��Pxtg� mice are also shown.
FIGURE 5. NK cell development in the ��P
and ��PxCD3��/� mice. A, Flow cytometric anal-
ysis of splenocytes for surface expression of
NK1.1 and DX5. B, Cytotoxicity of spleen cells
against NK-sensitive YAC-1 target cells. The per-
centages of NK cells in these splenocytes are rep-
resented in A.
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could differentiate to the DP stage, albeit very inefficiently. An
alternative explanation is that the DP phenotype was induced by an
artificial signal caused by ectopic expression of the CD3� trans-
gene. However, this latter possibility could be ruled out because:
1) the level of human CD3� transgene expression, driven by its
own promoter and enhancer, in thymocytes from the ��Pxtg� and
tg� mice, was similar to or lower than that of the endogenous
CD3� gene (Fig. 1C; N. Wang, B. Wang, and C. Terhorst, unpub-
lished observation), and 2) no distortion of thymic development
was observed in the tg� transgenic mice, whereas distortion of
thymic development was observed in the tg� transgenic mice de-
pending on the level of transgene expression (45).
No mature TCR��� SP cells were detected in the thymus or the
periphery of more than 10 ��Pxtg� mice analyzed. One might ar-
gue that because only a very small number of CD3�-deficient pro-
thymocytes were present in these mice, the SP cells derived from
the CD3��/� prothymocytes were too few to be detected. This
argument is unlikely because the same number of CD3��/� pro-
thymocytes, upon restoration of CD3� expression with a CD3�
transgene in ��Pxtg� mice, were able to give rise to up to 40% of
the wt level of TCR��� SP cells in the periphery (Fig. 2) (38). For
instance, among more than 20 ��Pxtg� mice examined, in 1 mouse
only 0.5% of the 3� 106 thymocytes were DP cells, whereas 15%
of its spleen cells were TCR��� SP cells (data not shown). More-
over, in recently reported CD3��/� mice, 5% of thymocytes in the
small thymus were DP cells, whereas the absolute number of SP
cells accounted for 20% of the T cell number in wt mice in the
spleen (35). Therefore, we conclude that CD3��/� DP thymocytes
could not differentiate into the SP stage.
Based on the numbers of DP cells observed in the ��Pxtg� mice
vs those observed in ��Pxtg� mice, we can estimate the thymic
cellularity of a CD3� deficient mouse as follows: because every
CD3��tg�� prothymocyte would give rise to more than 40-fold
(16.7% vs 0.4%) DP cells as compared with a CD3�� (i.e.,
CD3��tg����) prothymocyte, thymic cellularity of potential
CD3��/� mice would be �40-fold less than the cellularity of tg�
mice (which is �43% of the cellularity in wt mice (38). Thus, the
total number of thymocytes in potential CD3��/� mice would be
�1% of wt mice (i.e., 1 to 5 � 106 cells/thymus). In other words,
thymic cellularity of potential CD3��/� mice would be similar to
that of a number of mutant mice in which pre-TCR function is
severely impaired, such as TCR��/� (29), pT��/� (28), or
CD3��/� (35) mice. Therefore, we conclude that differentiation
from DN to DP stages would be severely, but not completely,
blocked in CD3��/� mice, similar to the block in pT��/� (28) or
CD3��/� (35) mice. This conclusion could be examined further
by generating another CD3��/� mouse with targeted embryonic
stem cells in which the neor cassette is deleted by cre-loxP-medi-
ated recombination (52, 53).
The conclusion of a severe block of pre-TCR-mediated early T
cell development in CD3��/� mice is consistent with the large
body of biochemical evidence for a critical role of CD3� in the
assembly of pre-TCR/CD3 complexes. It is known that CD3� as-
sociates with CD3� and CD3� to form the CD3�� and CD3��
cores in the pre-TCR/CD3 complexes (18, 22, 23, 39, 54). Thus,
absence of CD3� would severely impair the formation of the pre-
TCR/CD3 complexes. On the other hand, because all other com-
ponents of pre-TCR/CD3 complexes are expressed (probably at
very low levels for TCR�), it is likely that a partial pre-TCR can
be assembled and expressed on cell surface, albeit very poorly, and
this partial pre-TCR could mediate a very weak signal that induces
inefficient transition of DN cells to DP cells.
The appearance of DP cells in the ��Pxtg� mice differs from the
DN phenotype of CD3-��5/�5 and ��P mice, suggesting that the
arrest in the latter CD3� mutant mice was caused by an accumu-
lative deficiency of CD3� and CD3��. Because significant expres-
sion of CD3� was observed in the CD3��5/�5 mice (37), these
mice may be considered CD3��-deficient mice (CD3���/�). The
overwhelming majority of the ��Pxtg� thymocytes were
CD3���/�. Moreover, because the frequency of the potential
CD3�/�-expressing DN cells was very low in the ��P mice, these
mice can be considered CD3���-deficient mice (CD3����/�).
Likewise, ��PxCD3��/� mice can be viewed as animals deficient
in all CD3 proteins (CD3�����/�) (Fig. 2). In all of these cases,
thymocyte development is completely arrested at the DN
CD44�CD25� checkpoint (Fig. 2). Combining the data from this
study and those from mice deficient in CD3� (35), CD3� (34),
CD3� (30–33), and CD3�, and � (36), we conclude that during T
cell development, CD3 proteins are dispensable up to the DN
CD44�CD25� stage in which pre-TCR begins to function, but
they play an essential, yet partially overlapping, role in further T
cell development (Fig. 7). Because it has been shown that under
artificial circumstances, either CD3� or CD3� cytoplasmic do-
mains alone can independently generate signals for thymocyte de-
velopment to DP stage (55), the primary role of CD3 proteins in
FIGURE 6. DNA-PCR assay for TCR
�-chain rearrangements. Left panel, D�1 to
J�1.1 through J�1.5 rearrangements. Middle
and right panels, V�12 and V�14 to J�1.1
through J�1.5 rearrangements. ��P/�P � ��P.
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early stages of T cell development is likely their structural contri-
bution for the assembly and surface expression of pre-TCR/CD3,
whereas individual CD3 chains may execute distinctive functions
in later stages of T cell ontogeny.
It is currently unknown which proteins play an important role
for the early thymocyte differentiation steps from CD4low precur-
sors to the DN CD44�CD25� cells, but it had been shown that the
CD3 genes are expressed before CD44�CD25� stage, i.e., in the
CD4low precursors, and in the CD44�CD25� and CD44�CD25�
prothymocytes (9). Although we illustrate here that the CD3 pro-
teins are dispensable up to the CD44�CD25� stage, we could not
rule out the possibility that the CD3 proteins are normally involved
in the earlier transitions before CD44�CD25� stage, but in the
CD3-deficient mice their role was compensated by other molecules
in the pre-TCR complex (40). A mutant mouse, deficient in all
components of pre-TCR, may give a better answer to this question.
Moreover, we could not rule out another possibility that some mi-
nor populations of prothymocytes before the CD44�CD25� stage
may be absent in the ��PxCD3��/� mice, although this is unlikely
because analysis for the expression of Sca-1, c-kit, and Thy-1 in-
dicated the same phenotype in the ��PxCD3��/� mice as in the
RAG�/� mice (data not shown).
We demonstrated here that TCR� rearrangements take place in
the absence of all CD3 proteins. Of note, the phenotype of thy-
mocytes and TCR �-chain rearrangements observed in the
��PxCD3��/� mice are consistent with those observed in the
CD3��5/�5xCD3��/� mice described recently (56). However,
since a significant CD3� expression and minute amounts of a trun-
cated CD3� polypeptide were detected in the CD3��5/�5 mice (37),
the ��PxCD3��/� mice may better represent animals deficient in
all CD3 proteins.
Whereas earlier work using blotting techniques suggested that
CD3 genes were not expressed in murine splenic NK cells (57),
recent studies using more sensitive PCR-based approach demon-
strated that CD3 genes were expressed in some mouse fetal liver or
fetal thymus-derived immature NK cell lines (43). Moreover, hu-
man fetal NK cells also express CD3�, �, and � (41, 42, 58). Thus,
it was plausible that CD3 proteins may be involved in NK cell
development. However, normal numbers of functional NK cells
were detected in mice deficient in CD3�� (36), CD3��� (��P) and
CD3���� (��PxCD3��/�). Therefore, CD3 proteins play no es-
sential role in NK cell development.
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Abstract Human CD150 (SLAM) is a glycoprotein ex-pressed on the surface of T, B, natural killer, and dendrit-ic cells. The extracellular domain of CD150 is the recep-tor for measles virus and CD150 acts as a co-activator onT and B cells. We characterized the mouse and human
CD150 genes, each of which comprises seven exonsspanning approximately 32 kb. Mouse CD150 mRNAwas detected in T cells and in most thymocyte subsets,except CD4ñ 8ñ cells. Surprisingly, the CD4ñ 8ñ thymo-cytes of CD3γδnull mice, but not of Ragnull or severecombined immunodeficiency mice, expressed CD150.Whereas high levels of CD150 were found in Th1 cells,only small amounts were detectable in Th2 cells. CD150expression was up-regulated upon in vitro activation ofmouse T cells by anti-CD3. The complete mouse CD150gene is highly homologous to its human orthologue interms of nucleotide sequences and intron/exon organiza-tion. The human genomic sequences indicate that all iso-forms detected so far have arisen from alternative splic-ing events. As judged by fluorescence in situ hybridiza-tion, mouse CD150 mapped to Chromosome (Chr) 1,band 1H2.2ñ 2.3, and human CD150 was found on
Chr 1q22. Human and mouse CD150 share sequence ho-mologies with six other genes, five of which ñ CD84,
CD229 (Ly-9), CD244 (2B4), CD48, and 19A ñ  are lo-calized in a 250-kb segment in close proximity to the hu-man gene. Their location and their sequence similaritiesstrongly suggest that the CD150 family of cell surfacereceptors arose via successive duplications of a commonancestral gene.
Keywords SLAM ·  CD150 ·  SAP/SH2D1A ·  XLP ·Lymphocyte
Introduction
In response to antigen recognition, resting T lympho-cytes undergo a complex series of events known as T-cell activation, which initiates signal transductionpathways leading to T-cell proliferation, activation-in-duced cell death, cytokine production, or cytolysis. Thesignal provided by engagement of the T-cell antigen re-ceptor (TCR) alone is not sufficient to control activationof and return to a resting stage of T lymphocytes: co-stimulatory signals need to be provided in addition to theaccessory signals provided by CD4 and CD8. A numberof co-stimulatory sets of T-cell surface molecules appearto play a role in positive or negative regulation of TCRsignaling. In a major well-studied co-stimulatory system,CD28/CTLA4 interaction with their ligands B7.1 andB7.2 provides for either an enhancement (CD28) or aninhibition (CTLA4) of antigen-driven TCR signal trans-duction. This system controls accessory signals thatboost or suppress response to antigen by cytokine pro-duction or DNA synthesis. During the initial events of T-cell activation, CD28 ligation by its natural ligandsCD80 and CD86 expressed on antigen-presenting cellsappears to be the major T-cell co-stimulatory pathway(Lenschow et al. 1996). Studies of CD28-deficient mice,however, have indicated that CD28 is not required for allT-cell responses in vivo, since these mice were still ableto mount delayed-type hypersensitivity and cytotoxic
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lymphocyte responses, and their T cells could still betriggered by anti-CD3 stimulation (Green et al. 1994;Shahinian et al. 1993). These observations indicate thatCD28-independent T-cell co-stimulation pathways existand suggest that other co-stimulatory molecules, distinctfrom CD28, are used by T cells during T-cell activation.CD150, or SLAM (signaling lymphocyte activationmolecule) (Cocks et al. 1995; Sidorenko and Clark1993), a glycoprotein found on the cell surface of T, B,and dendritic cells, which is a self-ligand (Mavaddat etal. 2000; Punnonen et al. 1997), is another T- and B-cellco-stimulatory molecule (Aversa et al. 1997). Since trig-gering of CD150 co-activates T- or B-lymphocyte responses, it is considered to play a major role in bidi-rectional T-B cell stimulation (Carballido et al. 1997; Isomaki et al. 1997; Punnonen et al. 1997). Monoclonalantibodies directed to CD150 induce proliferation of hu-man CD45ROhigh memory T cells in a CD28-indepen-dent manner, while resting T cells are unresponsive(Cocks et al. 1995). Anti-CD150 acts as a co-activator,together with anti-TCR antibodies or peptide/MHC com-plexes on the surface of antigen-presenting cells, in stim-ulating resting T cells to synthesize DNA and/or initiatecytokine gene activation cascades (Cocks et al. 1995).Importantly, triggering by anti-CD150 antibodies induc-es the gene for interferon (IFN)-γ and redirects T helper(Th)2 responses of antigen-specific T-cell clones to aTh1 or Th0 phenotype (Carballido et al. 1997; Castro etal. 1999; Isomaki et al. 1999).Different CD150 isoforms have been detected in acti-vated T cells, including two transmembrane forms thatdiffer in their cytoplasmic tails and a secreted form thatlacks the transmembrane part of the molecule (Isomakiet al. 1999; Punnonen et al. 1997). Exposure of B cells toa soluble form of the CD150 ectodomain or to L cellstransfected with membrane-bound CD150 dramaticallyenhances B-cell proliferation and production of IgM,IgG, and IgA in conjunction with anti-CD40 monoclonalantibodies (mAbs) or other co-stimuli (Punnonen et al.1997). Interestingly, anti-CD150 antibodies alone fail toenhance B-cell proliferation producing, if anything, aninhibitory effect (Cocks et al. 1995; Punnonen et al.1997). Thus, CD150-induced signal transduction eventsin T lymphocytes are different from those in B cells.CD150 serves as the second receptor for measles virus(Tatsuo et al. 2000).The importance of CD150 signaling in T lymphocytesis derived from the observation that the SLAM-associat-ed protein (SAP or SH2D1A) is mutated or deleted inpatients with X-linked lymphoproliferative disease(XLP) (Coffey et al. 1998; Nichols et al. 1998; Sayos etal. 1998). XLP disease is a fatal immunological disorderwhich renders T lymphocytes, and sometimes naturalkiller (NK) cells, unable to respond effectively to Epstein-Barr virus infection (Howie et al. 2000; Morra et al.2001; Nakajima and Colonna 2000; Parolini et al. 2000;Purtilo et al. 1975; Sayos et al. 2000; Tangye et al.1999). Some of the other typical clinical phenotypes ofXLP include malignant lymphoma, dysgammaglobuline-
mia, aplastic anemia, vasculitis, and pulmonary lympho-matoid granulomatosis (Seemayer et al. 1995; Sullivan etal. 1983). Interestingly, SAP binds to at least three otherreceptors found on the surface of hematopoietic cells, in-cluding T and B cells: CD244 (Nakajima and Colonna2000; Parolini et al. 2000; Sayos et al. 2000; Tangye etal. 1999), CD229 (Ly-9), and CD84 (De la Fuente et al.1997, 1999; Sayos et al., 2001). Thus, in T cells, SAPcontrols signaling through four receptors. Moreover,SAP controls the effector phase in NK cells through itsassociation with CD244 (Benoit et al. 2000; Parolini etal. 2000; Tangye et al. 2000a, 2000b). This suggests thatthe complex phenotypes of XLP could be due to a com-bination of altered signaling pathways initiated by thesefour cell surface receptors. Here we describe the genom-ic organization of the mouse and human CD150 geneand the precise genomic location of CD150, CD229,
CD244, and CD84. Expression of the CD150 gene isstudied in the context of expression of the SAP gene.
Materials and methods
cDNA cloning and sequencing
Screening of the mouse CD150 cDNA from mouse (C57BL6) thy-mus libraries was performed according to a standard protocol(Sambrook et al. 1989), using the human CD150 cDNA full-lengthsequence as probe. The probe was labeled with [α-32P]dCTP to1×109 cpm/µg using the Prime-IT random primer Kit (Stratagene).The stringency conditions of hybridization were as follows:4×SSPE, 10×Denhard solution, 2% SDS, 0.2 mg/ml salmon spermDNA, and 32P-labeled cDNA at 65° C overnight. The filters werewashed twice at 65° C for 30 min with 0.1×SSC, 0.1% SDS.Twelve positive clones were obtained, which were CD150. Toconfirm that they were full-length cDNA clones, we designed twoprimers toward the 5′ and 3′ ends of the fragment, and performedrapid amplification of cDNA ends analysis using a mouse spleencDNA library (Clontech). The primers used were as follows: for5′-end PCR, 5′-GCT GTCCTGCCG AGC TGA TCT GAG-3′; for3′-end PCR, 5′-CAG TCC AGC AAA GAG TGA GAT GCC-3′.Two PCR products, representing the full-length 5′- and 3′-end se-quences of mouse CD150 cDNA, were subcloned into the pCR2.1vector and sequenced. The sequences obtained collectively re-vealed the full-length mouse cDNA sequence.
Genomic library screening and restriction mapping
A genomic library from the mouse 129/SVJ strain (Genome Sys-tems) containing DNA partially digested with HindIII and ligatedinto a BAC vector was screened by PCR using the following threepairs of primers from mouse CD150 cDNA:
1. forward primer, 5′-ATG GAT CCC AAA GGA TCC-3′; re-verse primer, 5′-TCC ACC TGT TCC GTA GCT-3′2. forward primer, 5′-GTT GGC CTG CAC AGT GAA GAA-3;reverse primer, 5′-GAT TCT GAG GAG GAT TCC TGC-3′3. forward primer, 5′-GTG TGA CAC TGC CAG AGA GCC-3′;reverse primer, 5′-GGT TCT TCT ATC CTC CTT CAA-3′
The ì Down-To-The-Wellî  pools of genomic clones were subject-ed to PCR screening according to the manufacturerí s instructions.The DNA of the positive clones was prepared using the Qiagenminiprep kit and subjected to restriction enzyme mapping analy-sis. The number and position of exons were identified within themouse CD150 gene through hybridization with seven probes ac-
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cording to predicted exons. Exons and the junctions between ex-ons and intervening sequences were sequenced after subcloning ofappropriate fragments into pBlue-scriptII SK+ (Stratagene) andpCR2.1 (Invitrogen). Specific oligonucleotides chosen from thecoding sequence of the mouse CD150 cDNA were used. The com-plete mouse CD150 cDNA sequences and the intervening se-quences have been deposited in the GenBank database (accessionnumbers AF164519, AF164520, AF164521, AF164522, andAF164523).
Chromosome localization by fluorescence in situ hybridization
The direct R-banding fluorescence in situ hybridization (FISH)method was used for chromosomal assignment of the mouse
CD150 gene. R-banded chromosomes were prepared and FISHwas performed as described by Matsuda and Chapman (1995).DNA from the mouse CD150 gene was labeled with digoxigenin-dUTP by nick translation. The labeled probe was combined withsheared mouse DNA and hybridized to normal metaphase chromo-somes derived from mouse embryo fibroblast cells in a solutioncontaining 50% formamide, 10% dextran sulfate, and 2×SSC.Specific hybridization signals were detected by incubating the hy-bridized slides in fluoresceinated anti-digoxigenin antibodies fol-lowed by counter-staining with DAPI.
Northern blot analysis
To examine the expression of the mouse CD150 gene at themRNA level, total RNA for Northern blot analysis was isolatedfrom mouse tissues or cell suspensions using Trizol reagent (LifeTechnologies). Ten micrograms RNA was then electrophoresed onformaldehyde denaturing agarose gels and transferred to a nylonmembrane. The membranes were prehybridized at 65° C for30 min using ExpressHyb buffer (Clontech) and hybridized withrandom primer-labeled mouse CD150 probe at 65° C for 1 h.Membranes were then washed in 2×SSC/0.1% SDS at room tem-perature for 30 min. and autoradiographed for 2 h.
Cell preparation, purification, and activation
Single-cell suspensions of splenic and lymph node cells weremade, red blood cells were lysed, and cell yields and viabilitywere determined using Trypan Blue exclusion. For T-lymphocytepurification, B cells, monocytes, and granulocytes were depletedfrom single-cell suspensions by incubating with biotinylated anti-CD11b and anti-Ly-6G mAb at 10 µg/1×107 cells in 100 µlDMEM (Gibco/BRL) medium for 15 min on ice, washing once inPBS, and incubating with a mixed solution of superparamagneticmicrobeads conjugated with anti-B220 mAb and streptavidin(Miltenyi Biotec, Sunnyvale, Calif.) each at 10 µl/1×107 cells in100 µl DMEM for 15 min on ice. After a final washing, the T lym-phocytes were purified by passage through a high-gradient MACSseparator (She et al. 1999). Samples of purified cells were stainedwith anti-CD4-FITC and anti-CD8a-phycoerythrin mAb, and puri-ty determined by fluorescence-activated cell sorter analysis. Thisprocedure leads to cell suspensions containing >96% T lympho-cytes. The purified T cells were then transferred to 24-well plates,which had been coated with anti-CD3ε mAb (2C11) (Pharmin-gen), and maintained in a 37° C, 5% CO2 incubator for 2, 8, 24,48, or 72 h. Then the cells were collected, total RNA was extract-ed using Trizol reagent (Life Technologies), and Northern blotanalysis was performed as described above.
Generation of Th1 and Th2 effector cells
Mice expressing the transgene for the DO11.10 αβ-TCR, whichrecognizes residues 323ñ 339 of chicken ovalbumin (OVA) in asso-ciation with H2-d, were provided by Dr. Dennis Loh (Washington
University, St. Louis, Mo.). DO11.10 TCR-transgenic CD4+ Tcells were cultured in complete RPMI 1640 with OVA 323ñ 339(1 mM) and mitomycin C-treated splenocytes. For Th1 phenotypedevelopment, recombinant mouse interleukin (IL)-12 (10 ng/ml)and neutralizing anti-IL-4 mAb (11B11, 40 µg/ml; R&D systems)were added, and for Th2 development, recombinant murine IL-4 (10 ng/ml) and neutralizing polyclonal anti-mouse IL-12(TOSH-2, 3 µg/ml; Endogen, Cambridge, Mass.) were used. Cellswere cultured for three rounds of antigenic stimulations under po-larizing conditions and then stimulated on plate-bound anti-CD3in the presence of hIL-2 (Endogen) for 6 h. Poly(A)+ RNA wasisolated from activated cells using the FastTrack mRNA Kit (Invi-trogen), and 1.0 µg RNA was loaded per lane for Northern blotanalysis. The membrane was probed sequentially with probes for
CD150, IFN-γ, IL-4 (Clontech), and β-actin. The IFN-γ probeconsisted of a 344-nt fragment of mouse IFN-γ covering the re-gion from position 532 to 876 (GenBank accession numberM28621).
Reverse transcription-polymerase chain reaction and analysis
Mouse CD150 mRNA was quantified with reverse transcription-polymerase chain reaction (RT-PCR) enzyme-linked immunoassayaccording to the manufacturerí s instructions (Roche). Briefly,equal amounts of total RNA (0.1ñ 1 µg) from different sampleswere used in RT-PCR. The RT-PCR product was labeled with dig-oxigenin (DIG) during the reaction, and immobilized onto strepta-vidin-coated 96-well plates using a biotinylated oligonucleotideprobe complementary to an internal sequence of the RT-PCR prod-uct. horseradish peroxidase-conjugated anti-DIG was then addedto the plate. After incubation and washing, the samples were de-veloped with the manufacturerí s developing solution (Roche), anddetected with a microplate reader at 415 nm. A standard curve wasconstructed for each mRNA species using different RT-PCR andassay conditions to ensure that the sample readings were withinthe proper range. Each sample reading was also normalized withCD3ε (for T cells), and β-actin or GAPDH. Samples were assayedin triplicate.
Results
Characterization of the mouse CD150 gene
To investigate the importance of CD150 in immunephysiology, we determined the structure of mouse
CD150, thereby permitting in-depth genetic and physio-logical studies in this species. A full-length mouse
CD150 cDNA was isolated from a C57/B16 mouse thy-mus cDNA library using human CD150 cDNA as aprobe, and its nucleotide sequence was determined. The1032-bp cDNA clone contained open reading frames of343 amino acids. The predicted mature protein has anextracellular domain with 218 residues, a 31-amino acidhydrophobic membrane-spanning domain, and a 72-ami-no acid cytoplasmic domain. The sequence is identical tothat published elsewhere (Castro et al. 1999). The mouse
CD150 cDNA sequence is 80% identical with that of hu-man CD150, including 5′ untranslated (UT) coding and3′ UT regions (Fig. 1A). The deduced amino acid se-quence of mouse CD150 is 57% identical to that of thehuman and 56% to cotton top tamarin (Saguinus oedi-
pus) CD150 (Tatsuo et al. 2000) (Fig. 1B).Three pairs of oligonucleotide primers were used toisolate three mouse genomic clones in pBAC using a
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Fig. 1A,B Mouse CD150 (=SLAM) cDNA and protein sequenc-es. A Alignment of the mouse and human SLAM cDNA nucleo-tide sequences. Exon boundaries are marked by: L leader peptide,
V variable region, C constant region, TM transmembrane region,
CP1, CP2, and CP3, cytoplasmic domain 1, 2, and 3, respectively
(GenBank accession numbers AF164519, AF164520, AF164521,AF164522, and AF164523). B Comparisons of the predicted ami-no acid sequences of mouse, human, and cotton top tamarinCD150. The SLAM-associated protein (SAP)-binding motifs inthe SLAM cytoplasmic tails are boxed
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Fig. 1B Legend see page 385
Fig. 2 Genomic organization of the mouse and human CD150genes. The mouse genomic pBAC clone (ES 129 SVJ, clone15972) was used for the restriction enzyme mapping. Boxes re-present the seven exons that encode the mouse CD150 gene. Hori-
zontal lines show introns (GenBank accession numbersAF164519, AF164520, AF164521, AF164522, and AF164523).
Uppercase letters below the mouse gene indicate recognition sitesfor the restriction endonucleases that were used in this analysis.The human CD150 (exon Iñ V) was mapped in AL121985.13,
which is a finished product of the genome sequence project (Land-er et al. 2001). Distances between exon IV, V, VI, and VII werederived from AC 27082.3, as they were found in one finishedcontig with 100% sequence homology to the cDNA. This wasconfirmed in pBAC AC 355996.3. Boxes represent the seven ex-ons that encode the human CD150 genes. Horizontal lines showintrons. Predicted recognition sites for restriction endonucleasesare indicated: B BamHI, E EcoRI, H HindIII, S SacI, X XhoI, P
PstI
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mouse 129SV genomic library. These primers were se-lected from seven sets of primers that had been designedbased on the presumed intron/exon boundaries in the hu-man cDNA (Cocks et al. 1995). Three pBAC clones,which were positive with all three sets of primers, wereobtained from the genomic library and were thereforepresumed to contain the complete mouse CD150 gene.One of those clones (pBAC clone 15972), which was ap-proximately 45 kb in length, was further analyzed for itsintron/exon organization using restriction enzymes andSouthern blotting with a large number of specific probes.To this end, restriction fragments of the positive pBACclone 15972 were subcloned into the pCR2.1 and pBlue-script II SK+ vectors. The restriction map was deter-mined by Southern blotting with cDNA, genomic, andspecific oligonucleotide probes (Fig. 2). DNA sequenc-ing on both DNA strands using synthetic oligonucleo-tides chosen from the mouse CD150 cDNA sequencesidentified exon/intron boundaries. All splice junction se-quences for the donor and the acceptor are in agreementwith the GT/AG rule (Table 1). Thus, the CD150 gene consists of seven exons divid-ed by six introns, spanning 32 kb. One exon encodes thesignal sequence (5′UT region and the peptide leader),two code for the extracellular domains of CD150, oneencodes the transmembrane domain, and three encodethe cytoplasmic domain and 3′UT region of CD150.There is a canonical TATA box at 478 nucleotides up-stream of the ATG. The 1200-nucleotide region 5′ to theATG contains several potential binding sites for tran-scription factors that may control expression in hemato-poietic cells, e.g., one potential binding site for AP-2,two potential binding sites for PU.1, and a site for IRF-1.IRF-2 (data not shown).
Expression of CD150 mRNA
Equal amounts of total RNA prepared from a variety ofsources expressing or lacking the CD150 molecule wereelectrophoresed in denaturing agarose gels and trans-
Table 1 Exon-intron organiza-tion of mouse and human
CD150 genes
Exon 3′ splice acceptor Exon size (bp) 5′ splice donor
1 Mouse 76 ACGGAACAG gtgagtgtcHuman 76 ACGGAACAG gtgagtgtt
2 Mouse ttccctcag GTGGAGGTG 342 AGCTTTATG gtaaaaatgHuman ctcccacag GTGGGCGCA 339 GGCTTTATG gtaataatg
3 Mouse tcctgacag AACAGGTCT 297 CCTCCTCAG gtgatcactHuman tcctgacag AGCAGGTCT 285 ACCCCTCAG gtgagtaca
4 Mouse gtttttcag AATCGAGTC 96 AAAGACAAG gtaggctgtHuman tttttccag AAACAAAAC 90 GAAGAAGAG gtaggtgtc
5 Mouse tttcttcag GTAAATCAA 74 AAATCAGGG gtacgttctHuman tttcaccag GTAAAACGA 74 AAACCAGGT gtaagttct
6 Mouse cttgtgtag CCTCAAGAG 96 TCTGTCCAG gtgacatatHuman ctcttgtag CCTCTTCAG 93 TCTGTCCAG gtgaggcat
7 Mouse tgcccacag GAACCAAAC 48 CCAGAGAGC tgacccataHuman tgtcccag GAAACAAAT 48 CCAGAGAGC tgacaccag
ferred to nylon. Hybridization of the transferred RNAwith an antisense probe prepared from a pCR2.1 clonecontaining a CD150 cDNA insert revealed that the larg-est amount of CD150 mRNA was expressed in the thy-mus and lesser amounts in lymph nodes and spleen.Barely detectable levels were recorded in RNA extractedfrom brain, colon, kidney, liver, and small intestine(Fig. 3A). To further analyze CD150 mRNA expressionin lymphoid organs, several mutant mice, i.e., CD3γδnullthat are deficient in T cells and severe combined immu-nodeficiency (SCID) and Ragnull mice, which are defi-cient in T and B lymphocytes were used for Northernblot analysis. In all three mutant mice (Fig. 3B), T-celldevelopment was arrested at the transition from double-negative (DN) CD44ñ CD25+ to the double-positive (DP)stage (Shinkai et al. 1993; Wang et al. 1998). CD150 isexpressed in the DN thymocyte population of theCD3γδnull mouse, but not in the equivalent cells of theSCID or Ragnull mouse. This result suggests that theblock in thymocyte development of the CD3γδnull mouseis less severe than in SCID or Ragnull mice. To assess theexpression of CD150 in the major subsets of mouse Tcells, we analyzed the expression of CD150 mRNA fromCD4+, CD8+, CD4+CD8+ DP and CD4ñ CD8ñ DN cells.As shown in Fig. 3C, CD150 was detected in all thymo-cyte subsets, except in CD4ñ CD8ñ DN cells. We con-clude that CD150 is expressed in all thymocytes, but athighest levels in DP thymocytes.
Regulation of CD150 expression during T-cell activation
To investigate regulation of CD150 expression in acti-vated T cells, purified T cells from BALB/c mousespleen were stimulated with anti-CD3. By Northern anal-ysis, Spleen cells displayed a dramatic increase in ex-pression of CD150 mRNA within 2 h of anti-CD3 treat-ment compared to unstimulated cells (Fig. 4A), reachingmaximal amounts of CD150 within 8 h (Fig. 4A). The
CD150 mRNA level then began to decrease to a levelsimilar to that of unstimulated cells at day 7. In sharp
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contrast, under the same condition, SAP expression wasdecreased 2 h after T-cell activation (Wu et al. 2000). Wenext investigated the changes in expression of CD150mRNA in specialized Th1 or Th2 cells upon antigenicstimulation (Fig. 4B). Th1 or Th2 cells were activated invitro with plate-bound anti-CD3 ε in the presence of IL-
2. The expression level of CD150, as judged by Northernanalysis, is much higher in Th1 cells stimulated for 6 h,while antigenic stimulation did not affect the levels of
CD150 mRNA in Th2 cells. As expected, SAP expres-sion decreased in both Th1 and Th2 cells after 6 h stimu-lation (data not shown).
Chromosomal localization of the mouse CD150 gene
Chromosomal localization of the mouse CD150 gene wasdetermined by direct R-banding FISH using a representa-tive CD150 genomic pBAC clone (no. 15972) as a probe.The initial experiment resulted in specific labeling of thedistal portion of a large chromosome that was believed tobe Chromosome (Chr) 1 on the basis of DAPI staining. Asecond experiment was conducted in which a probe spe-cific for the centromeric region of Chr 1 was co-hybrid-ized with the cloned mouse CD150 gene. This experi-ment resulted in the specific labeling of the centromericand distal regions of Chr 1 (Fig. 5). Measurements of tenspecifically hybridized Chr 1s demonstrated the CD150gene is located at position which is 84% of the distancefrom the heterochromatic-euchromatic boundary to thetelomere of Chr 1, an area that corresponds to band1H2.2ñ 2.3. A total of 80 metaphase cells were analyzed,with 72 exhibiting specific labeling.
Fig. 3Añ C Tissue distribution of mouse CD150 (SLAM). A North-ern blotting of RNA from different mouse tissues. RNAs weresubjected to electrophoresis in a 10% formaldehyde agarose geland transferred to nitrocellulose. The filters were hybridized with32P-labeled mouse CD150 or 18S cDNA. B CD150 (SLAM) ex-pression in thymocytes, splenocytes, and lymph node cells fromC57Bl/6 (wt), CD3γδnull, Rag-2null, and severe combined immuno-deficiency (SCID) mice. C CD150 expression in subsets ofC57Bl/6 thymocytes. Thymocyte subsets were isolated by fluores-cence activated cell sorter using anti-CD4 and anti-CD8 antibod-ies and total RNA was prepared and assayed for SLAM using theDIG-PCR method as described in Materials and methods (DPdouble positive, DN double negative)
Fig. 4A,B Regulation of mouse CD150 (SLAM) RNA expressionin activated mouse T cells. A Northern blotting of RNA from acti-vated mouse T cells with the mouse SLAM (mSLAM) cDNAprobe. Splenocytes were stimulated in vitro with an anti-CD3monoclonal antibody (2c11) and mRNA was purified from thecells that were collected at different time points. B Expression ofmouse CD150 in polarized T helper (Th)1 and Th2 cells. Northernblotting of SLAM (=CD150) upon in vitro activation of polarizedTh1 and Th2 cells. The phenotype of Th1 and Th2 was conformedby Northern blots for IFN-γ and IL-4
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The human CD150 gene
Intron/exon organization and nucleotide sequences of thehuman CD150 gene were derived from an extensive dat-abase search. The first five exons of human CD150 werefound at the end of a finished pBAC (AL121985.13)(Fig. 6). All seven exons of the human CD150 gene werefound on two unfinished pBACs (AL355996.3 andAC027082.3) with nucleotide sequences of the exons(100%) identical to those of the published cDNA (Cockset al. 1995). Because combinations of exons were foundin finished contigs of these and two additional pBACs(AL 138930.8 and AC012471.7 in Fig. 6), the distancesbetween the exons could be determined exactly.Several of the pBACs, e.g., AC027082.3, mapped toChr 4. However, in addition to the complete CD150gene, AC027082.3 contains the complete genes for
CD48 and CD84, which have been mapped to Chr 1.And because there is 99ñ 100% identity between the se-quences of the three genes (introns and exons) on pBACAC027082.3 and the sequences on pBACs that havebeen mapped to Chr 1, these are unlikely to be gene du-plications of parts of Chr 1.Intron/exon boundaries of the human genomic se-quence are shown in Table 1 and the genomic organiza-tion is compared to that of the mouse gene in Fig. 2. Thesequences and genomic organization of human CD150also show that the various transcripts discovered in theoriginal cloning paper are caused by alternative splicingevents, indeed eliminating either the first exon or thefourth exon in SLAM22 and SLAM7, respectively Theectodomain- and transmembrane domain-encoding exonsof isoform SLAM3 are identical to those of full-length
SLAM4. But SLAM3 contains only the first cytoplasmicexon and a 10-amino acid stretch which is encoded bythe intron immediately following exon 5 (=C1). We notonly conclude that the genomic organization of the hu-man and mouse CD150 genes are extremely similar, but
Fig. 5 Chromosome mapping of mouse CD150 using fluores-cence in situ hybridization (FISH). FISH of normal mouse meta-phase chromosomes using the mouse CD150 genomic pBACclone (no. 15972) as a probe. Arrows indicate positive staining onChr 1, in an area that corresponds to band 1H2.2ñ 2.3
Fig. 6 Genomic organization of the human CD150 (SLAM) locusin Chr 1q22. Six genes belonging to the CD150 family are clus-tered in a genomic segment of approximately 260 kb. The genom-ic map reflects information derived from the analysis of BACclones, AL 121985.13, AL27082.2, AL 155984.4, and AC
068728.4, each of which contains at least three genes with 100%sequence homology to the cDNAs. The other pBAC genomicclones further confirmed the organization. Filled boxes represent acomplete set of exons of a gene, while empty boxes indicate partialgene segments
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Fig. 7Añ C Sequence compari-sons of the members of theCD150 family. A Phylogenetictree of the ectodomains ofCD150-related proteins. A phy-logenetic tree of the ectodomainprotein sequences of CD150family members was obtainedusing the Align X program(Vector NTI Suite). Obviously,the closest homologies are be-tween the same molecule of dif-ferent species. Interestingly, theectodomain of the 2B4 andCD48 molecules are closely re-lated. (SLAM=CD150 Ly-9=CD229, 2B4=CD244). No CDnumbers have been assigned tothe new gene 19A (accessionnumber AJ276429) and
BCM1-L (accession numberAF146761). B Alignment of theamino acid sequences of the ex-tracellular domains of themouse and human CD150 fami-ly members. Blocks of colorsindicate different levels of simi-larity among the different genesaccording to the AlignX pro-gram (Vector NTI Suite; yellowidentity of residues, greenblocks of similarity, blue con-served positions). Yellow verti-
cal lanes identify extremelyconserved residues of criticalfunction in the architecture ofthe immunoglobulin-like do-mains. The sequence of the hu-man and mouse Ly-9 proteinswas aligned starting at position190 to include only the secondset of immunoglobulin-like do-mains. C Schematic representa-tion of the cytoplasmic domainsof the CD150 family memberswith their SAP-binding motifs.
Lines indicate the cytoplasmicdomain of the CD150 familymembers of length proportionalto their amino acid sequences.Real or putative SAP-bindingmotifs are reported. Blocks la-beled with # are putative motifsthat are unable to bind SAP.Motifs that are known to bindSAP are indicated with an aster-isk. The Bcm1-L gene does notcontain a putative SAP-bindingsite
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that the various isoforms of human and mouse CD150can be readily explained by alternative splicing events.
The CD150 gene family
Based on nucleotide and amino acid sequence compari-sons, the CD150 gene appears to belong to what hasbeen called the CD2 subfamily of the Ig superfamily.However, CD2 and CD58 map to the short arm of Chr 1(Brown et al. 1987; Sewell et al. 1988), whereas theChr 1 pBAC clones containing CD150 map to the longarm of Chr 1 in the 1q22 area (Fig. 6). Moreover, exten-sive sequence comparisons of the protein and nucleotidesequences of CD150 using the standard algorithms uti-lized by NCBI show that human CD150 is related to
CD84 (31% identity; De la Fuente et al. 1997), CD48(30% identity; Fisher and Thorley-Lawson 1991), 19A(28% identity; accession number AJ276429), BCM1-like(31% identity; accession number AF146761), CD229(24% identity; Sandrin et al. 1996) and CD244 (25%identity; Mathew et al. 1993; Stepp et al. 1999) in termsof their ectodomains (Fig. 7A, B), but no significant ho-mologies were detected between human CD150 and CD2or CD58 ectodomains.Using the available nucleic acid and protein sequenc-es and a series of pBAC clones, this set of genes hasbeen mapped to a 260-kb segment of the long arm ofChr 1 as shown in Fig. 6. Moreover, all of the exons andintron/exon boundaries were identified. Again some ofthe pBACs, e.g., AL354714.7, were not assigned toChr 1, but the extensive high-level nucleotide homo-logies precluded any other interpretations. The genomicorganization of human CD84, CD48, 19A, CD229, and
CD244 is in principle the same as that of CD150. The V-
and C-like domains are encoded by separate exons andthe cytoplasmic tail is encoded by at least three or moreexons, as has been reported before (De la Fuente et al.1997, 1999; Sandrin et al. 1996), CD229 has four immu-noglobulin-like domains. The two C-terminal domains ofCD229 show the highest homology with the other mem-bers of this subfamily (see Fig. 7B).A comparison of the ectodomain sequences of theseseven genes shows their relatedness and also indicates amore distant relationship with CD2 and CD58 (Fig. 7A,B). The latter two genes map to another area of Chr 1p(Brown et al. 1987; Sewell et al. 1988). Perhaps, moreimportantly, it has now been shown that CD150, CD84,CD229, and CD244 bind SAP using specificT.I/V.pY.x.x.V/I recognition motifs present in the cyto-plasmic tails of these proteins (Fig. 7C; Morra et al.2001; Poy et al. 1999). Furthermore, CD48 is the ligandfor CD244, and CD150 has been reported to be a self-li-gand (Punnonen et al. 1997), although the affinity wasfound to be low (Mavaddat et al. 2000).The hallmark of the CD150 family is that their ecto-domains are related in the respective human and inmouse orthologues and that the genes map to a veryshort segment of Chr 1. CD150, CD84, CD244, andCD229 were previously shown to bind to SAP (Benoit etal. 2000; Parolini et al. 2000; Sayos et al. 1998, 2000, inpress; Tangye et al. 1999). Moreover, 19A has a putativeSAP-binding site, but SAP binding has not yet been con-firmed in vivo. The location of the known SAP-bindingmotifs in the cytoplasmic tails of SLAM and CD229 isnot fixed in terms of their distances to the cytoplasmicpart of the plasma membrane (Fig. 7C). However,CD150, CD84, CD244, and CD229 all bind to the tyro-sine phosphatase SHP-2.
Fig. 7C Legend see page 390
103
Naturally, CD48, which does not have a cytoplasmicdomain, cannot bind to SAP. CD48 is known to be at-tached to the plasma membrane via a lipid tail (Fisherand Thorley-Lawson 1991). Because no cytoplasmic tailsequences have been detected in any of the BCM1-likeexpressed-sequence tags, this protein, like CD48, mayact as a ligand.Taken together, the data provided here support the no-tion that the genes described belong to a small subfamilywithin the Ig superfamily, which is related to the CD2subfamily.
Discussion
Here we report molecular cloning of the mouse ortho-logue of the human signaling lymphocytic activationmolecule SLAM (=CD150) cDNA, the complete mouseand human genes, expression of mouse CD150 in differ-ent tissues isolated from wild-type and immunodeficientmice, and a comprehensive molecular analysis of themolecule. Mouse CD150 is expressed on the surface ofthymocyte subsets, activated T cells and Th1 cells. Theexpression of CD150 in the thymus provided an unex-pected insight into a subtle difference between Rag-2nulland CD3γδnull DN thymocytes. DN thymocytes isolatedfrom wild-type mice do not express CD150, while DP thymocytes do. Whereas both mutant mice arethought to have a block at the transition of DN(CD44ñ CD25+CD4ñ CD8ñ ) to DP thymocytes (Shinkai etal. 1993; Wang et al. 1998), the thymocytes isolatedfrom the CD3γδnull mouse express CD150. We concludethat T-lineage development has progressed further inCD3γδnull than in the Ragnull or SCID mice. Whether thisdifference represents a distinct difference in cell cycleprogression is not known. Regulation of CD150 expres-sion upon activation with anti-CD3ε is very differentfrom that of SAP: CD150 mRNA levels increase rapidly(Fig. 4), whereas SAP mRNA levels decrease (Wu et al.2000). CD150 expression is associated with the Th1 phe-notype and increases after activation. Only smallamounts of CD150 mRNA were detected in the polar-ized Th2 cells.The genomic organization of mouse CD150 was de-rived by a classical approach: extensive restriction en-zyme digestion of a mouse pBAC clone. The intron/exonorganization of mouse CD150 is reflective of othermembers of the Ig superfamily. Its ectodomain is encod-ed by three exons, two of which are predicted to have animmunoglobulin fold. In addition to an exon encodingthe transmembrane domain, mouse CD150 containsthree cytoplasmic exons. Each of the cytoplasmic-do-main exons of mouse CD150 contains one tyrosine resi-due. However, only two of the tyrosine residues are lo-cated within a SAP-binding motif. The sizes of the int-rons are similar to those reported for the CD150 geneelsewhere (Castro et al. 1999).The organization of the human CD150 gene was de-termined rapidly with the help of the abundant informa-
tion available in the public database provided by the hu-man genome project (Lander et al. 2001). Intron/exon or-ganization of human CD150 is identical to that in themouse and the sequence homologies with the mouse ex-ons are extensive. Several hypothetical transcription fac-tor-binding sites are shared between the nucleotide se-quence upstream of the ATG in the human and themouse CD150. These include TATA boxes at approxi-mately ñ 480 and a variety of AP1, NFAT and PU1 sites.Although the transcription start site was not determined,it is likely to be positioned in the proximity of the TATAbox. Because the human sequence contains an additionalTATA box at ñ 404, an additional start site may exist. Ingeneral, the putative binding sites are known to be uti-lized by other genes that are expressed in hematopoieticcells (Green 2000).Although CD150 clearly belongs to the Ig superfami-ly, the existing notion that the gene belongs to the CD2subfamily (Boles and Mathew 2001; Boles et al. 1999;Chuang et al. 1999; De la Fuente et al. 1997, 1999; Hogarth et al. 1980; Johnson et al. 2000; Kingsmore et al. 1995; Kubota et al. 1999; Mathew et al. 1993;Nakajima and Colonna 2000; Peck and Ruley 2000;Sandrin et al. 1996; Staunton et al. 1989; Tangye et al.2000a; Wong et al. 1990) needs to be reconsidered forthree compelling reasons:
1. The ectodomain of CD150 is more closely related tothe ectodomains of CD84, CD48, 19A, CD229,
CD244, and BCM1-l than to CD2 or CD58, which-ever alignment program is being applied.2. These genes map in two clusters: human CD2 and
CD58 to 1p13, whereas the others map very closely toChr 1q22. In fact in the mouse, CD2 maps to Chr 3,whereas CD150, CD244, CD229, CD48, and 19Amap to Chr 1 (Clayton et al. 1988; Lander et al. 2001;Tangye et al. 2000a)3. CD84, CD150, 19A, CD229, and CD244 bind SAP.
Obviously, CD48 and BCM1-l do not bind SAP. ButCD48 is a ligand for CD244 in humans and mice (Brownet al. 1998). Similarly, CD2 binds to CD58, although on-ly in humans. In rodents, CD48 appears to be the ligandfor CD2, but the affinity of CD2 for CD48 is nine timesless than that of the CD48/CD244 interaction. The gly-cosyl phosphatidyl inositol-linked CD48 and CD58 arepossibly promiscuous ligands or the affinity for their li-gands determines a different role (Brown et al. 1998;Kingsmore et al. 1989). CD2 and CD58 may belong tothis family of genes, because they may have similarstructural properties. Moreover, CD2 binds CD48 in ro-dents (Brown et al. 1998). The precise relationship be-tween CD2 and CD58 and the genes mapping in theproximity of CD150 therefore awaits further functionaland structural studies.All the genes mentioned here are expressed on thesurface of hematopoietic cells. The notion that at least allof the SAP-binding genes are expressed in T cells, whiletheir ligands or putative ligands are on the surface of an-
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tigen-presenting cells suggests that the SLAM CD2 fam-ily (or families) of Ig-like molecules may play an impor-tant role at the interface of these cells. Certainly, CD150and CD244 have been implicated in T-cell and NK-cellfunctions
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SLAM in T Cells and Macrophages1256
receptors. To dissect the individual contribution of SLAM
signaling to immune responses, we generated a mouse that
is defective in SLAM. Here we show that SLAM, like SAP
(9, 10), is involved in the regulation of Th2 development.
In contrast to the SAP�/� C57BL/6 mice, SLAM�/�
C57BL/6 mice also have impaired macrophage functions
and consequently a defective immune response to infection
with the parasite Leishmania major.
Materials and Methods
Generation of SLAM-deficient Mice. A targeting construct was
constructed from a 129/Sv mouse pBAC clone (11) and was
placed into the plasmid vector pPNT, which includes a thymi-
dine kinase gene expressed from the PGK promoter (PGK-tk) for
positive selection. The second and third exons of the SLAM
gene, IgV and IgC, encoding the complete ectodomain of
SLAM, were replaced with the neomycin-resistance gene (Neo).
An 8.2- and a 3.8-kb genomic DNA fragment flank the neomy-
cin-resistance gene.
The targeting vector was linearized at a unique NotI site and
electroporated into J1 embryonic stem (ES) cells (9). G418 and
FIAU-resistant ES cell colonies were screened using Southern
blot analysis. KpnI digestion of genomic DNA generated a 13-kb
band from the endogenous WT SLAM allele, whereas the cor-
rectly targeted SLAM allele generated an additional 8.8-kb band
(see Figs. 1, A and B). The single integration site was confirmed
with the internal 5� probe upon SacI digestion of the DNA (un-
published data). A SLAM�/� ES cell clone was injected into
C57BL/6 and BALB/c blastocysts. Chimeric mice were bred
into the appropriate background. F1 mice with germline trans-
mission of SLAM�/� F1 mice (129/Sv � BALB/c or 129/Sv �
C57Bl/6) were bred to homozygocity. SLAM�/� mice were
backcrossed with WT BALB/c or C57Bl/6 mice six times and
were kept under specific pathogen-free conditions.
RT-PCR. RT-PCR was performed as previously described
(11) using a 5� UT forward primer encoding the signal peptide in
the first exon, 5�-GATCCCAAAGGATCCCTTTCCTGG-3�,
and a reverse primer derived from the last exon CP3, 5�-GGTC-
CAGTTCAGTGTGGATTTTGG-3�, defining a 1.1-kb prod-
uct containing full-length SLAM cDNA (see Fig. 1 C).
Mice. SAP�/� C57BL/6 mice (9), SLAM�/� BALB/c and
SLAM�/� C57BL/6 mice, and TCR transgenic DO11.10
BALB/c mice (12) were kept under specific pathogen-free con-
ditions. SAP�/� � DO11.10 BALB/c mice and SLAM�/� �
DO11.10 BALB/c mice were generated by crossing mice that
were homozygous for each mutation until double homozygocity
was reached. This was judged by the appropriate PCR reactions
(9 and this paper) or by staining with monoclonal antibody KJ-
126 that detects the �� TCR, which is expressed on the surface
of the OVA-specific CD4� cells of DO11.10 (12).
Flow Cytometry. Surface staining analysis was performed as
previously described (13, 14). In brief, cells were suspended at
5 � 106 cells/ml in PBS. Anti-mSLAM (9D1) was used at 10 �g/
ml and detected with 10 �g/ml biotin-conjugated goat poly-
clonal anti–rat Ig (BD Biosciences), followed by 1 �g/ml strepta-
vidin-conjugated Red 670 (Invitrogen).
For cytoplasmic staining of IFN-� production, splenic T cells
were resuspended at 106/ml and stimulated with 5 �g/ml plate-
bound anti-CD3� for 3 d. 2 h before harvesting, 1 �g/ml Bre-
feldin A was added to the cultures. Cells were stained with
FITC-conjugated anti-CD4 or biotin-conjugated anti-CD8 (BD
Biosciences) for 30 min at 4�C in a balanced salt solution supple-
mented with1% FCS. Cells were then washed twice in buffered
saline before fixation in buffered saline/4% paraformaldehyde for
10 min at room temperature. After fixation, cells were washed
twice with balanced salt solution/1% FCS and resuspended in
permeabilization buffer (PBS, 0.1% saponin, and 1% FCS) con-
taining anti–IFN-� monoclonal antibody (BD Biosciences) for 30
min. The percentage of cells expressing cytoplasmic IFN-� was
determined by flow cytometry.
ELISA Assays for Cytokine Secretion. All cytokine ELISA kits
were obtained from BD Biosciences. Tissue culture supernatants
were stored at �80�C until analysis. ELISA assays were per-
formed according to the manufacturer’s instructions. Standard
curves were generated using known amounts of purified murine
rIL-4, rIL-6, rIL-12p40, rIL-12p70, or TNF-� (BD Biosciences).
In Vitro T Cell Assays. CD4� cells were purified using nega-
tive selection columns (9) cultured with 5 �g/ml anti-CD3� an-
tibody (2C11)–coated plates and 5 �g/ml soluble anti-CD28 or
with a combination of 10 ng/ml PMA and 1 �M ionomycin in
the presence of 10 ng/ml recombinant IL-2 (BD Biosciences) for
72 h. Supernatants were analyzed for IL-4 or IFN-� by ELISA as
previously described (9). IFN-� production was determined by
cytoplasmic staining and by flow cytometry as previously de-
scribed (9).
In Th1- or Th2-polarized experiments, exogenous cytokines
or anti-cytokine antibodies were added to the anti-CD3 and anti-
CD28 antibody, as indicated. Th2 cell differentiation was pro-
moted in the presence of 100 ng/ml IL-4 and 10 �g/ml anti–IL-
12 antibody, and Th1 differentiation was promoted by 10 �g/ml
anti–IL-4 antibody and 1 ng/ml IL-12 (all from BD Biosciences).
After the cells were cultured for 4 d, they were washed and resus-
pended at 106 cells/ml. The secondary culture used only plate-
bound anti-CD3 and lasted for 24 h. As described above, 10 ng/
ml IL-2 (BD Biosciences) was added to all cultures (9).
For IL-4 and IFN-� secretion by CD4� T cells isolated from
SLAM�/� � DO11.10 or DO11.10 mice, the percentage of KJ-
126� CD4� cells from each mouse was determined by flow cy-
tometry using KJ-126 FITC (Caltag) and CD4-PE (BD Bio-
sciences). Equal numbers of KJ-126� CD4� cells were plated in
complete media at 2 � 105 cells/well in a 24-well plate for 3 d in
the presence of 2 � 106 APCs and 1.0 �g of an OVA peptide,
OVA 323–339. Surface staining analysis was performed with
anti–mouse SLAM (9D1) as previously described (13). Secondary
stimulations were performed for 24 h under the same conditions.
IL-4 and IFN-� secretion was determined at day 3 of the primary
stimulation and 24 h after the secondary stimulation by ELISA.
Cytokine Production by In Vitro–stimulated Macrophages. Rest-
ing or thioglycollate-elicited macrophages were obtained by peri-
toneal lavage as previously described (13). Macrophages were
stimulated in a medium containing 2 ng/ml LPS, 200 U/ml IFN-�,
2 ng/ml LPS plus 200 U/ml IFN-�, and 10 �M CpG or 25 �g/
ml peptidoglycan.
In other experiments, 2 � 106 macrophages were activated
with increasing amounts of LPS (1, 10, or 100 ng/ml). After the
cells were incubated for 24 h, supernatants were assayed for IL-
12p70, IL-12p40, TFN-�, or IL-6 by ELISA (BD Biosciences).
For antibody stimulation of macrophages, cells were cultured
for 24 h with rat anti–mouse SLAM (9D1) at concentrations
ranging between 0 to 10 �g/ml in the presence of blocking Fc
fragments (13). To each well, a rat anti–mouse IgG1 isotype con-
trol antibody was added (BD Biosciences) in a concentration
range from 10 to 0 �g/ml resulting in a final concentration of 10
�g/ml Ig at each experimental point.
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Nitric oxide (NO) production was quantified by the accumu-
lation of nitrite (as a stable end product) in the supernatants by
the standard Griess reaction as previously described (15). In brief,
50 �l of the supernatants was removed from 24-well plates and
incubated with an equal volume of Griess reagent (1% sulfanil-
amide/0.1% naphthalene diamine dihydrocloride/2.5% H3PO4)
at room temperature for 10 min. The absorbance at 570 nm was
determined with a microplate reader. Conversion of absorbance
to micromolar concentration of NO was deduced from a stan-
dard curve using a known concentration of NaNO2 diluted in
DMEM medium. All determinations were performed in quadru-
plicate and expressed as micromolar concentration of NO.
Antigen Presentation by Macrophages. To quantify the in vitro
proliferative response to OVA peptide, thioglycollate-elicited
macrophages (2 � 105/well) from SLAM�/� or SLAM�/�
mice were cocultured with KJ-126� CD4� splenic T cells from
DO11.10 mice (105/well) in DMEM medium supplemented
with 2 mM l-glutamine, 100 U/ml penicillin, 100 �g/ml strep-
tomycin, and 10% FCS for 3 d. OVA peptide was added at the
indicated concentrations (from 0.01 to 1.0 �g/ml). The cells
were cultured for 72 h and [3H]TdR (1 �Ci /well) was added for
the last 18 h of the assay. The cells were harvested onto filters us-
ing an automated cell harvester.
Phagocytosis of Escherichia coli F18 by Macrophages. After mac-
rophages were plated at 106 cells/ml E. coli, F18 bacteria were
added to the culture media at a concentration of 107 bacteria/ml.
After 1 h incubation at 37�C, the cells were washed three times
with PBS and lysed using 1% Triton in H2O for 10 min at 4�C.
Dilutions of the lysate were streaked onto LB plates and incu-
bated for 24 h. Phagocytosis rates were obtained by counting col-
onies after 24 h (16, 17).
Infection with L. major. Mice were infected subcutaneously
into one hind footpad with 2 � 106 L. major stationary phase pro-
mastigotes in a final volume of 50 �l as previously described (18).
The development of lesions was monitored with a vernier cali-
per, measuring increase in footpad thickness compared with the
uninfected footpad. To determine parasite loads, infected mice
were killed and their footpads were collected and homogenized.
The number of amastigotes in each footpad was counted with a
Nuebaer hemocytometer. Data are expressed as mean � SEM
number of amastigotes per footpad. Leishmaniacidal activity was
determined as previously described (18–20).
T Cell Assays after Infection with L. major. The draining in-
guinal lymph nodes from mice infected with L. major were re-
moved aseptically and cell suspensions were prepared, as previ-
ously described (18–20). 100 �l aliquots containing 3 � 105
lymph node cells in complete RPMI medium were added in trip-
licate to the wells of 96-well flat-bottomed tissue culture plates
containing 20 �g/ml soluble L. major antigen per well in different
concentrations (18–20). After incubation at 37�C in 5% CO2 for
60 h, 100 �l of the culture supernatant was removed from each
well and stored at �70�C for cytokine assays and replaced with
100 �l complete medium containing the appropriate �Ci of triti-
ated thymidine. After an additional 12 h of incubation at 37�C, it
was harvested onto filter paper with a cell harvester. Thymidine
uptake was measured by liquid scintillation using a � counter
with 1 ml Optiscint added to the filter discs in vials and counted
for 5 min each. The stimulation index values at the end of the L.
major infection were calculated as the quotient of antigen stimu-
lated/unstimulated cells.
Online Supplemental Material. Results of experiments, which
complement the data presented in the paper, are shown in Figs.
S1–S6. In Fig. S1, IL-4 and IFN-� secretion by resting and
anti-CD3/CD28 activated SLAM�/� C57BL/6 and SLAM�/�
BALB/c T cells. In Fig. S2, IL-4 and IFN-� secretion by resting
and anti-CD3/CD28 activated CD4� cells purified from the
spleens of SLAM�/� BALB/c mice. Secretion of IL-4 and IFN-�
by SLAM�/� C57BL/6 and WT C57BL/6 CD4� cells cultured
under Th1- and Th2-polarizing conditions is shown in Fig. S3.
In Fig. S4, secretion of IL-4 and IFN-� by SLAM�/� BALB/c
Figure 1. Targeted disruption of the mouse
SLAM gene. (A) The targeting vector. Config-
uration of the WT SLAM genomic locus, the
targeting vector, and the chromosomal locus
after homologous recombination with the tar-
geting vector is shown. The second and third
exons of the SLAM gene, IgV and IgC, encod-
ing the complete ectodomain of SLAM, were
replaced with the neomycin resistance gene
(Neo). An 8.2- and a 3.8-kb genomic DNA
fragment flank the neomycin resistance gene.
The locations of the two probes used in the
Southern blotting analysis are shown. SP, signal
peptide; TM, transmembrane region; CP1,
CP2, and CP3, cytoplasmic domains; S, SacII;
K, KpnI. (B) Southern blot analysis. Screening
for homologous recombination events by South-
ern blotting of tail DNA samples used the 3�
probe in conjunction with a KpnI (K) digest. A
13-kb band is detected in WT and heterozy-
gote mice. An 8.8-kb band, which results from
a new KpnI site in the targeting vector, is de-
tected in heterozygotes (�/�) and homozy-
gotes (�/�). (C) RT-PCR analysis. RT-PCR
products were generated with RNA from the
thymus or spleen of SLAM�/� or SLAM�/�
mice. Although an SP plus CP3 primer pair detects a 1.1-kb RT-PCR product in SLAM�/� thymocytes (T) or splenocytes (S), no RT-PCR product is
detected in the thymus or spleen of SLAM�/� mice. (D) Absence of SLAM surface expression in SLAM-deficient thymocytes. SLAM�/� or SLAM�/�
thymocytes were stained with a monoclonal rat anti–mouse SLAM antibody (9D1) and analyzed by flow cytometry.
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and WT BALB/c CD4� cells cultured under Th1- and Th2-
polarizing conditions is shown. In Fig. S5, T cell receptor–medi-
ated Ca2� entry in CD4� T cells of WT SLAM�/� and SAP�/�
C57BL/6 mice is identical. Altered IL-12, TNF-�, IL-6, and
NO production by peritoneal macrophages from SLAM�/�
BALB/c mice is shown in Fig. S6. Figs. S1–S6 are available at
http://www.jem.org/cgi/content/full/jem.20031835/DC1.
Results
Deviation of Cytokine Production by SLAM�/� CD4� and
CD8� T Cells. A mouse with a targeted disruption of the
second and third exon of the SLAM gene was generated by
homologous recombination in ES cells (Fig. 1, A and B).
SLAM-deficient mice were fertile, morphologically indis-
tinguishable from WT littermates, and no defects in their
T, B, or NK cell development were detected by cell sur-
face marker analyses. No SLAM mRNA was detected in
mice that were homozygous for the gene defect (Fig. 1 C)
and SLAM-deficient thymocytes, which are the highest
SLAM expressors in WT mice, do not stain with the anti–
mouse SLAM antibody 9D1 (Fig. 1 D).
To determine whether SLAM�/� CD4� T cells deviated
in their cytokine production along the lines of SAP�/� T
cells, several in vitro assays were performed. First, total T
cells purified from the spleen of SLAM�/� C57BL/6 and
WT C57BL/6 mice were triggered with a combination of
anti-CD3 and anti-CD28. Production of IFN-� was then
measured by cytoplasmic staining and cytofluorimetric
analyses using anti-CD8 and anti-CD4 antibodies. Al-
though SLAM�/� CD8� T cells produce more IFN-� than
WT C57BL/6 CD8� T cells, this difference is less dramatic
in CD4� cells (unpublished data). A modest increased
IFN-� secretion by T cells was found by ELISA, regard-
less of the genetic background (Fig. S1, B and D, which is
available at http://www.jem.org/cgi/content/full/jem.
20031835/DC1). Stimulation of total T cells from either
SLAM�/� C57BL/6 or SLAM�/� BALB/c mice with anti-
CD3 alone or with a combination of anti-CD3 and anti-
CD28, also resulted in a reduced production of IL-4, pre-
sumably by CD4� cells (Fig. S1, A and C).
Indeed, purified CD4� cells isolated from SLAM�/�
C57BL/6 mice activated with a combination of anti-CD3
and anti-CD28 secreted reduced amounts of IL-4 in a pri-
mary stimulation compared to WT C57BL/6 CD4� cells
(Fig. 2 A). Using the same stimulation conditions, we
consistently observed a slight increase in IFN-� secretion
by SLAM�/� C57BL/6 CD4� cells versus WT C57BL/6
CD4� cells (Fig. 2 B). Upon primary or secondary stimula-
tion with anti-CD3 and anti-CD28, CD4� cells from puri-
Figure 2. Deviation of cytokine production by CD4� and CD8�
SLAM�/� T cells. (A) IL-4 secretion by CD4� cells purified from
SLAM�/� or SLAM�/� C57BL/6 mice. SLAM�/� or SLAM�/� C57BL/6
CD4� cells were purified using negative selection columns. In the primary
stimulation (�1��) CD4� cells were stimulated with 5 �g/ml anti-CD3�
antibody (2C11)–coated plates and 5 �g/ml soluble anti-CD28, or with a
combination of 10 ng/ml PMA and 1 �M ionomycin in the presence of
10 ng/ml recombinant IL-2 (BD Biosciences; P/I) for 72 h. IL-4 in the
cell culture supernatants was determined by ELISA. (B) IFN-� secretion
by CD4� cells purified from SLAM�/� or SLAM�/� C57BL/6 mice.
SLAM�/� or SLAM�/� C57BL/6 CD4� cells were purified using negative
selection columns. CD4� cells were stimulated as described in A and
IFN-� in the cell culture supernatants was determined by ELISA. (C) Im-
paired IL-4 secretion by SLAM�/� � DO11.10 CD4� and SAP�/� �
DO11.10 CD4� cells upon stimulation with APCs and OVA peptide. IL-4
secretion after primary (�1��) and secondary (�2��) stimulation of
CD4� T cells isolated from SLAM�/� � DO11.10, SAP�/� � DO11.10,
or DO11.10 TCR transgenic mice were determined. Equal numbers of
purified KJ-126�/CD4� T cells isolated from SLAM�/� � DO11.10,
SAP�/� � DO11.10, or DO11.10 TCR transgenic BALB/c mice (2 � 105
cells/well) were stimulated for 3 d with APCs (2 � 106) pulsed with 1.0 �
of the OVA peptide OVA 323–339. Secondary stimulations were per-
formed for 24 h under the same conditions. IL-4 secretion was deter-
mined at day 3 of the primary stimulation and 24 h after the secondary
stimulation by ELISA. (D) IFN-� secretion by SLAM�/� � DO11.10
CD4� and SAP�/� � DO11.10 CD4� cells upon stimulation with APCs
and OVA peptide. Cells described in C were analyzed for IFN-� by
ELISA after primary (�1��) and secondary (�2��) stimulation. (E) Tran-
scription of IL-4 and IFN-� in NKT cells after anti-CD3 administration.
RT-PCR products of IL-4, IFN-�, and GAPDH were generated with
spleen RNA samples isolated from anti-CD3 or PBS-injected mice.
SLAM�/� C67BL/6 and WT C67BL/6 littermates as well as SLAM�/�
BALB/c and WT BALB/c were used. The RT-PCR products were ana-
lyzed on a 1% agarose gel and visualized by UV light.
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fied SLAM�/� BALB/c mice also produced less IL-4 than
their WT counterparts (Fig. S2, which is available at
http://www.jem.org/cgi/content/full/jem.20031835/DC1).
However, when polarizing Th2 conditions were used,
SLAM�/� C57BL/6 and WT C57BL/6 CD4� cells se-
creted comparable amounts of IL-4 (Fig. S3, which is
available at http://www.jem.org/cgi/content/full/jem.
20031835/DC1). Using polarizing Th2 conditions in the
second stimulation, SLAM�/� BALB/c and WT BALB/c
CD4� cells also secreted comparable amounts of IL-4 (Fig.
S4, which is available at http://www.jem.org/cgi/content/
full/jem.20031835/DC1). The IFN-� production re-
mained slightly higher when the cells were cultured under
Th1-polarizing conditions (Figs. S3 and S4). Taken
together, these results were indicative of an impaired pro-
duction of IL-4 by CD4� cells purified from SLAM�/�
C57BL/6 and SLAM�/� BALB/c mice in primary and sec-
ondary stimulations. However, IL-4 secretion by purified
CD4� cells readily reaches a WT level in the presence of
IL-4. These SLAM�/� C57BL/6 and SLAM�/� BALB/c
Figure 3. Altered IL-12, TNF-�, IL-6, and NO pro-
duction by peritoneal macrophages from SLAM�/�
C57BL/6 mice. (A) IL-12 production by SLAM�/�
C57BL/6 or WT SLAM�/� C57BL/6 peritoneal macro-
phages. Resting peritoneal macrophages from 12 SLAM��
C57BL/6 or WT SLAM��� C57BL/6 mice were stimu-
lated with 200 U/ml IFN-�, 2 ng/ml LPS, or with IFN-�
plus LPS for 24 h. IL-12p70 was determined by ELISA as
described in Materials and Methods. M, cells incubated in
medium only. (B) TNF-� production by SLAM�/�
C57BL/6 or WT SLAM�/� C57BL/6 peritoneal macro-
phages. Resting peritoneal macrophages from SLAM���
C57BL/6 or WT SLAM��� C57BL/6 mice were stimu-
lated as described in A. TNF-� was determined by ELISA
in the same culture supernatants as described in Materials
and Methods. M, cells incubated in medium only. (C) IL-6
production by SLAM�/� C57BL/6 or WT SLAM�/�
C57BL/6 peritoneal macrophages. Resting peritoneal
macrophages from SLAM��� C57BL/6 or WT SLAM���
C57BL/6 mice were stimulated as described in A. IL-6
was determined by ELISA in the same culture supernatants
as described in Materials and Methods. M, cells incubated
in medium only. (D) NO production by SLAM�/�
C57BL/6 or WT SLAM�/� C57BL/6 peritoneal macro-
phages. Resting peritoneal macrophages from SLAM���
C57BL/6 or WT SLAM��� C57BL/6 mice were stimu-
lated as described in A. NO was determined in the same
culture supernatants as described in Materials and Methods.
M, cells incubated in medium only. (E) IL-12p40 production
is impaired in thioglycollate-induced peritoneal macrophages
from SLAM�/� C57BL/6 mice, but not from SAP�/�
C57BL/6 mice. Thioglycollate-elicited macrophages were
isolated from the peritoneal cavity of SLAM�/�, SAP�/�,
or WT SLAM�/� C57BL/6 mice. 2 � 106 macrophages
were activated with increasing amounts of LPS (at 1, 10, or
100 ng/ml). Supernatants were collected after 24 h and
IL-12p40 was determined by ELISA. (F) IL-12p40 pro-
duction by macrophages in response to CpG and PGN.
Thioglycollate-elicited peritoneal SLAM�/� or SLAM�/�
BALB/c macrophages (106 per well) were treated with 10
�M CpG or 25 �g/ml peptidoglycan for 24 h. Superna-
tants were removed and IL-12p40 levels were determined
by ELISA. (G) TNF-� production by macrophages in re-
sponse to CpG and PGN. Thioglycollate-elicited peritoneal
SLAM�/� or SLAM�/� BALB/c macrophages (106 per
well) were treated with 10 �M CpG or 25 �g/ml pepti-
doglycan for 24 h. Supernatants were used to determine
IL-12p40 levels by ELISA. (H) Antigen presentation by
macrophages. 2 � 105 thioglycollate-elicited peritoneal
SLAM�/� or SLAM�/� BALB/c macrophages were pulsed
with 0.01–1 �g/ml of the OVA peptide OVA 323–339.
Next, antigen-pulsed macrophages were incubated for 3 d
with 105 KJ126� CD4� T cells isolated from DO11.10 TCR transgenic mice. To determine DNA synthesis, cultures were pulsed with [3H]thymidine in
the final 18 h. (I) Phagocytosis of F18 E. coli by macrophages. Thioglycollate-elicited peritoneal SLAM�/� or SLAM�/� BALB/c macrophages were
incubated with E. coli F18 bacteria. After 1 h, cells were lysed and phagocytosis rates were obtained by counting colonies after 24 h of incubation. CFU,
colony-forming units.
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CD4� cells also consistently produce more IFN-� than WT
cells. As in SAP�/� mice, the increase in IFN-� production
by SLAM�/� CD8� cells appears more robust than that of
SLAM�/� CD4� cells.
Because the results obtained with SLAM�/� mice indi-
cated impaired development of Th2 cells and were similar
to those previously observed with SAP�/� CD4� cells (9,
10), we compared the antigen responses of SLAM�/�
CD4� cells and SAP�/� CD4� cells. Reduced levels of IL-4
secretion were detected after triggering of both SLAM�/�
DO11.10 CD4� cells (KJ-126� cells) or SAP�/� DO11.10
CD4� cells (KJ-126� cells) with OVA peptide–pulsed
APCs (Fig. 2 C). The defect in IL-4 secretion by SLAM�/�
KJ-126�/CD4� cells was less robust than that of SAP�/�
KJ-126�/CD4� cells because after a secondary stimulation
with antigen-pulsed APCs, WT levels of IL-4 secretion were
detected (Fig. 2 C). IFN-� secretion by either SLAM�/� or
SAP�/� DO11.10 CD4� cells was similar to that by WT
BALB/c DO11.10 CD4� cells (Fig. 2 D).
It is well established that shortly after injection of WT
mice with anti-CD3, large amounts of IL-4, IFN-�, and
other key cytokines are produced immediately by NKT
cells (21, 22). To test whether IL-4 gene activation was de-
fective in SLAM�/� NKT cells, SLAM�/� BALB/c and
SLAM�/� C57BL/6 mice were injected intravenously with
anti-CD3 and cytokine mRNA levels were analyzed 90
min after injection by RT-PCR. As shown in Fig. 2 E, IL-4
and IFN-� mRNA levels in SLAM-deficient NKT cells
were indistinguishable from those of the corresponding
WT mice, regardless of the strain background.
Taken together, the data indicate that the coreceptor
SLAM positively regulates TCR-induced IL-4 production
by naive and activated CD4� T cells, but not by NKT cells.
By contrast, SLAM signals negatively interfere with TCR-
induced IFN-� secretion by CD8� and to a lesser extent by
CD4� cells.
The SLAM-induced signals that are involved in coactiva-
tion of the IL-4 gene are as yet unknown. Signal transduc-
tion by SLAM is in part governed by SAP, which is an adap-
tor that links the src kinase FynT to the SLAM receptor. SAP
appears to bind to the SH3 domain of FynT and it therefore
directly couples FynT to SLAM (6, 7). Thus, triggering of
the SLAM receptor by anti-SLAM induces SAP-dependent
tyrosine phosphorylation of a number of targets, including
SHIP, Dok1, Dok2, and RasGAP (5). The SLAM/SAP sig-
nal transduction pathway that interferes with TCR-induced
activation of the IL-4 gene in CD4� cells does not involve
Ca2�-dependent mechanisms, as judged by single cell Ca2�
influx experiments (Fig. S5, which is available at http://
www.jem.org/cgi/content/full/jem.20031835/DC1).
Impaired Responses to LPS by SLAM�/� Macrophages.
Because SLAM is also expressed on activated macrophages
(13, 23), we examined whether SLAM controls macro-
phage functions. To this end, purified resting peritoneal
macrophages were stimulated with LPS, IFN-�, or with a
combination of LPS and IFN-�. As shown in Fig. 3, A and
B, the levels of secreted TNF-� and IL-12 by activated
SLAM�/� C57BL/6 macrophages are reduced when com-
pared with those of WT mice. Similarly, NO production
was impaired in LPS/IFN-�–stimulated SLAM�/� C57BL/6
macrophages (Fig. 3 C). By contrast, LPS-stimulated
SLAM�/� macrophages secrete IL-6 at levels that are
higher than WT levels (Fig. 3 D).
Using purified resting peritoneal macrophages from
SLAM�/� BALB/c mice, the same results were obtained
(Fig. S6, which is available at http://www.jem.org/
cgi/content/full/jem.20031835/DC1). Importantly, when
macrophages from the peritoneal cavity of thioglycollate-
treated SLAM�/� BALB/c mice were stimulated with LPS,
a low level of IL-12 secretion was again detected (Fig. 3 E).
This result indicates that the impaired cytokine production
is not dependent upon the method of isolation of the mac-
rophages. As expected from the absence of SAP in macro-
phages (4, 8), SAP�/� BALB/c (Fig. 3 E) macrophages did
not display a defect in IL-12 production.
The possibility that SLAM�/� peritoneal cavity macro-
phages lack one of the members of the known LPS recep-
tor complex, i.e., Toll-like receptor (TLR)-4/MD-2 and
CD14, or the IFN-� receptor, was excluded by FACS®
analyses (unpublished data). Importantly, when SLAM�/�
macrophages were stimulated with CpG or peptidoglycan,
TNF secretion was comparable to that of WT macrophages
(Fig. 3 F). Thus, TLR-2 and TLR-9 receptor–initiated sig-
nal transduction is intact in SLAM�/� macrophages. The
collective results obtained were consistent regardless of
whether the macrophages were isolated from SLAM�/�
C57Bl/6 or SLAM�/� BALB/c mice and of the method of
preparation of peritoneal macrophages.
Figure 4. Monoclonal anti-SLAM antibody
regulates IL-6 and IL-12 production by WT
macrophages. IL-12 and IL-6 production by
SLAM�/� or SLAM�/� C57BL/6 thioglycollate-
elicited peritoneal macrophages was determined
in response to the anti-SLAM antibody 9D1. 106
peritoneal macrophages from SLAM�/� or
SLAM�/� C57BL/6 mice were treated for 24 h
with 9D1 at the concentrations indicated. To each
well, a rat anti–mouse IgG1 isotype control anti-
body was added (BD Biosciences) in a concen-
tration range from 10 to 0 �g/ml, resulting in a
final concentration of 10 �g/ml Ig in each experi-
mental point. Supernatants were collected and
analyzed for IL-12 p40 (A) or IL-6 (B) by ELISA.
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Two sets of experiments showed that there is no global
defect in the SLAM�/� macrophages. First, SLAM�/� and
WT BALB/c peritoneal macrophages, pulsed with OVA
peptide, were used to induce proliferation of KJ-126�
CD4� T cells derived from the DO11.10 mouse, which is
specific for H-2d class II and OVA peptide. SLAM�/�
BALB/c and WT BALB/c peritoneal macrophages were
equally efficient in stimulating DNA synthesis of DO11.10
CD4� cells (Fig. 3 H). Second, phagocytosis of E. coli F18
bacteria by SLAM�/� BALB/c macrophages was intact
(Fig. 3 I). Together, these analyses demonstrate that SLAM
specifically regulates the production of IL-12, TNF-�,
NO, and IL-6 upon triggering of TLR-4 by LPS.
To test whether SLAM functions as a coreceptor on the
surface of WT macrophages, the anti–mouse SLAM mono-
clonal antibody 9D1 (13) was used. As shown in Fig. 4 A,
9D1 induces IL-12 secretion by WT macrophages, whereas
incubation with increasing concentrations of 9D1 nega-
tively interferes with IL-6 production by WT macrophages
(Fig. 4 B). Importantly, SLAM�/� BALB/c macrophages
served as negative controls, thus excluding the possibility
that anti-SLAM affected IL-6 and IL-12 production by
nonspecific Fc receptor binding. Furthermore, an isotype
control antibody was included in these experiments.
Results of the antibody experiments support the notion
that SLAM confers a positive signal to LPS-induced IL-12
production by macrophages. The antibody data combined
with the SLAM�/� macrophage studies also support the hy-
pothesis that SLAM negatively controls IL-6 production. To-
gether, the in vitro and in vivo data demonstrate that in both
SLAM�/� C57BL/6 and SLAM�/� BALB/c mice, macro-
phage functions related to SLAM signaling are impaired.
SLAM�/� C57Bl/6 Mice Are Susceptible to Infection with L.
major. To determine the in vivo effect of the absence of
the coreceptor SLAM, SLAM�/� BALB/c mice were in-
fected with L. major. Initial foodpad lesions in BALB/c
mice in response to the parasite L. major result in part from
a rapid response by CD4� T and NKT cells producing
large amounts of IL-4 early after infection (24). In spite of
the reduced in vitro IL-4 production by SLAM�/� T cells
(Fig. S2), SLAM�/� BALB/c mice responded to the para-
site in the same manner as WT BALB/c mice (Fig. 5 A).
Thus, a minimal in vivo IL-4 production during the initial
phase of infection of SLAM�/� BALB/c mice with L. major
appears to be sufficient for the typical BALB/c response.
The WT level of IL-4 production by the SLAM�/� NKT
cells (Fig. 2 E), is likely to be a source of this key cytokine.
By contrast, the size of the footpad lesions in the SAP�/�
BALB/c mice was significantly smaller than that of the WT
BALB/c mice throughout the course of infection because
of the low level of IL-4 secretion by all CD4� T cells, in-
cluding NKT cells (9).
C57Bl/6 mice respond differently to infection with the
parasite L. major than BALB/c mice, as C57Bl/6 mice
eventually remove the parasite by mechanisms that in-
volve Th1 cells as well as activated macrophages (24). As
judged by measuring the size of footpad lesions, SLAM�/�
C57BL/6 mice did not efficiently heal the infection with
L. major (Fig. 5 B). This impaired ability to clear the para-
site was confirmed by increased parasite titers in infected
SLAM�/� C57BL/6 mice (log parasite titer, 4.16 � 1.03),
compared with WT C57BL/6 mice (log parasite titer,
1.82 � 0.72; P � 0.005) at the end of the experiment.
The inability of SLAM�/� C57BL/6 mice to heal the L.
major lesions is consistent with defective IL-12 and TNF-�
production by SLAM�/� macrophages because secretion of
Figure 5. SLAM�/� C57BL/6 mice are not resistant to infection with
L. major. (A) Response to L. major infection by SLAM�/� BALB /c mice.
SLAM�/� or SLAM�/� BALB/c mice were infected in one footpad with
106 L. major stationary phase promastigotes. The size of footpad lesions of
10 infected mice of each strain was measured until 9 wk after infection
and the change in footpad depth was plotted against time (in weeks).
(B) Response to L. major infection by SLAM�/� C57BL/6 mice.
SLAM�/� or SLAM�/� C57BL/6 mice were infected with L. major as
described in A. 30 mice were used in 3 experiments. A representative
independent experiment with 12 mice is shown. �, SLAM�/� mice; �,
SLAM�/� mice. (C) Response to L. major infection by SAP�/� C57BL/6
mice. 10 SAP�/� or WT (SAP�/�) C57Bl/6 mice were infected with L.
major as described in A. �, SAP�/� mice; �, WT SAP�/� mice.
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IL-12 and TNF-� is known to be required for sustain-
ing the “healing phenotype” in C57BL/6 mice (24–26).
Moreover, the in vitro leishmaniacidal activity of SLAM�/�
peritoneal macrophages was markedly reduced. SLAM�/�
C57BL/6 macrophages were less efficient in killing para-
sites in vitro (73 � 8% infectivity) than WT macrophages
(37 � 12%). Because our in vitro studies showed impaired
NO production (Fig. 3), and as NO plays a major role in
the removal of L. major by macrophages (26), the inability
of SLAM�/� C57BL/6 mice to combat L. major infection
provides further evidence for a macrophage defect.
Based upon our in vitro CD4� T cell analyses (Fig. 2),
the abnormal response to L. major by SLAM�/� C57BL/6
mice was unlikely to have been caused by a defective Th1
response. Indeed, when SLAM�/� and WT C57BL/6 T
cells isolated from the lymph nodes of infected animals
were examined at the end of the experiment, both mutant
and WT CD4 cells secreted comparable amounts of IFN-�
(SLAM�/�, 6,905 � 1,426 pg/ml; WT, 9,213 � 120 pg/
ml). As expected for C57BL/6 mice (24–26), at the end of
the infection only very low levels of IL-4 (�20 pg/ml)
were secreted either by mutant or by WT T cells in
response to L. major antigen. DNA synthesis of these
SLAM�/� T cells was similar to that of WT C57BL/6 T
cells. The stimulation index was 6.14 � 1.41 for SLAM�/�
T cells (n � 12) and 7.2 � 4.87 for WT T cells (n � 12).
Thus, upon infection of C57BL/6 mice with L. major, the
relevant macrophage responses, but not the T cell re-
sponses, were affected by the SLAM mutation. This con-
clusion was indirectly supported by analysis of an L. major
infection of SAP�/� C57BL/6 mice, which have a T cell
defect similar to that of the SLAM�/� C57BL/6 mice (Fig.
2 D; references 9 and 10) The SAP�/� C57BL/6 mice
were able to remove the parasite and heal the footpad le-
sions with the same kinetics as WT C57BL/6 mice (Fig. 5
C). Taken together, the data strongly support the notion
that the abnormalities observed in macrophages, but not
those found in T cells, account for the impaired responses
by the SLAM�/� C57BL/6 mice to infection with L. major.
Discussion
These analyses of SLAM�/� T cells demonstrate that
SLAM-induced signal transduction differentially modu-
lates TCR-induced IFN-� and IL-4 production. SLAM
negatively interferes with IFN-� production in CD8� T
cells and to a lesser extent in CD4� T cells. By contrast,
SLAM augments IL-4 secretion induced by engagement of
TCR on the surface of CD4� T cells. As the absence of
SAP influences TCR responses in a very similar manner, it
appears that SLAM and SAP cooperate toward the same
sets of signals. Thus, the SLAM/SAP receptor–adaptor
complex is one of the few cell surface–signaling units that
contributes to cell fate during terminal differentiation into
Th1 and Th2 cells. Because the adaptor SAP operates as a
control element of signal transduction pathways of at least
six members of the SLAM family of T cell surface recep-
tors, the less stringent control of IL-4 production in
SLAM�/� mice compared with SAP�/� mice can be ex-
plained by overlapping functions of the other receptors (2).
The notion that SLAM is a coreceptor in TCR-driven
functions was originally developed in studies with anti-
SLAM antibodies. As stimulation of TCR in the presence
of anti-SLAM antibody results in increased IFN-� pro-
duction (1, 2), both antibody treatment and removal of
the SLAM receptor appear to eliminate the negative co-
stimulatory signal. However, the present data also show
that TCR-induced IL-4 secretion by SLAM-deficient T
cells is impaired, whereas treatment with anti-SLAM has
no effect on IL-4 gene activation (1, 2). It is conceivable
that anti-SLAM interrupts the interaction of SLAM with
its ligand SLAM on a second cell, i.e., APC. It is also con-
ceivable that anti-SLAM causes clustering of SLAM mole-
cules on a T cell, which then brings SLAM clusters in
proximity of the TCR. In general, differences between
antibody effects and findings in knockout mice have been
reported. For example, in the case of the cell surface re-
ceptor CD2, anti-CD2 has an effect on T cell functions,
but disruption of the CD2 gene does not have functional
consequences for the T cell (27). Furthermore, anti–
CTLA-4 had been thought at first to have costimulatory
properties until further studies and results with the CTLA-
4�/� T cells showed that the antibody inhibited a negative
signal (28, 29). In addition, triggering a receptor with anti-
bodies can also give different outcomes than the use of a
soluble form of ligand, as shown in studies of SLAM.
Triggering of human SLAM either by its ligand (i.e., Fc-
SLAM) or by anti-SLAM antibody has different outcomes.
Punnonen et al. (30) show that a soluble human SLAM
Ig protein induces responses in T and B cells that differ
dramatically from the responses induced by anti–human
SLAM monoclonal antibodies.
The signal transduction events that are initiated by en-
gagement of SLAM use a pathway that leads to activation
of the Ser/Thr kinase Akt (23). Furthermore, signal trans-
duction by SLAM is in part governed by SAP, which is an
adaptor that links the src kinase FynT to the SLAM recep-
tor. SAP appears to bind to the SH3 domain of FynT and it
therefore directly couples and activates FynT to SLAM
(5–7, 31). In addition, overexpression experiments and
analysis of Fyn�/� T cells clearly show that SLAM can be
phosphorylated by other src kinases in a SAP-dependent
manner (31). But how SLAM-induced or SAP-controlled
signaling networks are involved in activation of the IL-4
gene is unknown. Because the SLAM- and SAP-controlled
signal transduction pathways do not involve Ca2�-depen-
dent mechanisms (Fig. S5), a further dissection of the mo-
lecular underpinnings of the role of SLAM or SAP in gov-
erning TCR-induced IL-4 production is required.
The role of SLAM as a TLR-4 coreceptor on the surface
of macrophages was established by experiments with LPS
and SLAM�/� BALB/c and SLAM�/� C57BL/6 macro-
phages as well as by the use of an anti-SLAM monoclonal
antibody. In response to antibody, IL-12 secretion by puri-
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fied macrophages is induced and IL-6 production is im-
paired. In the SLAM�/� macrophage, LPS induced IL-12
and TNF secretion is impaired and SLAM�/� macrophages
overproduce IL-6 even in the absence of any extraneous
stimuli. The two types of responses suggest that SLAM
signaling negatively influences IL-6 production and aug-
ments IL-12 secretion. Moreover, both SLAM�/� BALB/c
and SLAM�/� C57BL/6 macrophages produce reduced
amounts of NO upon stimulation with LPS.
The inefficiency of SLAM�/� C57BL/6 macrophages in
killing L. major is consistent with both an impaired NO pro-
duction and reduced levels of IL-12 and TNF production.
The signaling pathways involved in the coreceptor function
of SLAM with respect to production of IL-12, TNF-�, and
NO in response to LPS is currently being explored.
Infection of SLAM�/� BALB/c mice with L. major fol-
lowed the typical BALB/c response, i.e., uncontrolled in-
crease of footpad swelling. The WT level of IL-4 produc-
tion by the SLAM�/� NKT cells and the residual in vivo
IL-4 production are undoubtedly factors in the early re-
sponses to the parasite (24–26). We speculate that a contri-
bution of the macrophage defect of SLAM�/� BALB/c
mice may also contribute to the sustained response. By con-
trast, as previously reported (9), the size of the footpad le-
sions in the SAP�/� BALB/c mice was significantly smaller
than that of the WT BALB/c mice throughout the course
of infection because of the low level of IL-4 secretion by all
CD4� T cells and the absence of a macrophage defect.
The use of SLAM as one of the two receptors for mea-
sles virus suggests that SLAM functions are required for
both innate and acquired immune responses. Although
engagement of the measles virus receptors CD46 and
SLAM on dendritic cells or macrophages has been linked
to regulation of IL-12 production, the role of IL-12 in the
immunosuppression is not understood. As measles virus–
induced immune suppression has a strong T cell compo-
nent as well (32–34), further studies to elucidate the mo-
lecular mechanisms of SLAM signaling in T cells and
APCs are needed. In that regard, the availability of well-
defined transgenic mouse strains that correctly express hu-
man SLAM on a SLAM�/� background will be invaluable
for the study of aberrant immune responses to measles vi-
rus. Thus, the availability of SLAM-deficient mice will al-
low for studies that provide a better understanding of the
role of innate and adaptive immune responses to both par-
asites and viruses.
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Supplementary Figures for Chapter 7 
Supplementary Figure 1. IL-4 and IFN-� secretion by SLAM C57BL/6 and SLAM 
Balb/c T cells. (A) T cells isolated from the spleen of SLAM or SLAM Balb/c mice were 
stimulated with 5 µg/ml anti-CD3� antibody (2C11)-coated plates or with a combination 
of 5 µg/ml anti-CD3� antibody (2C11)-coated plates and 5 µg/ml soluble anti CD28 for 
72 h. IL-4 was determined in the culture supernatant. (B) The culture supernatant 
described in A was also used for ELISA to determine the IFN-� concentration. (C) T cells 
isolated form the spleen of SLAM or SLAM C57BL/6 mice were stimulated with 5 
µg/ml anti-CD3� antibody (2C11)-coated plates or with a combination of 5 µg/ml anti-
CD3� antibody (2C11)-coated plates and 5 µg/ml soluble anti-CD28 for 72 h. IL-4 was 
determined in the culture supernatant. (D) The culture supernatant described in C was 
also used for ELISA to determine the IFN-� concentration. M, cells incubated in medium 
alone.
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Supplementary Figure 2. IL-4 and IFN-�  secretion by resting and anti-CD3/CD28-
activated CD4+ cells purified from the spleens of SLAM BALB/c or WT BALB/c mice. 
(A) IL-4 secretion by CD4+ cells purified from SLAM or SLAM BALB/c mice. SLAM 
or SLAM BALB/c CD4+ cells were purified using negative selection columns (R&D 
Systems). In the primary stimulation (10) CD4+ cells were stimulated with 5 µg/ml anti-
CD3� antibody (2C11)-coated plates and 5 µg/ml soluble anti-CD28 in the presence of 
recombinant 10 ng/ml IL-2 (BD Biosciences; P/I) for 72 h. The secondary culture (20)
used only plate-bound anti-CD3� and IL-2 and lasted for 24 h. IL-4 in the cell culture 
supernatants was determined by ELISA. (B) IFN-� secretion by CD4+ cells purified from 
SLAM or SLAM BALB/c mice. SLAM or SLAM BALB/c CD4+ cells were purified 
using negative selection columns. CD4+ cells were stimulated as described in A and IFN-
� in the cell culture supernatants was determined by ELISA 
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Supplementary Figure 3. Secretion of IL-4 and IFN-�  by SLAM C57BL/6 and WT 
C57BL/6 CD4+ cells cultured under Th1- and Th-2 polarizing conditions. (A) Secretion 
of IL-4. CD4+ cells purified from the spleen of SLAM or SLAM C57BL/6 mice were 
primed under three conditions: neutral (anti-CD3�  5 µg/ml), Th1 (anti-CD3�   and IL-12 
plus anti-IL-4), and Th2 (anti-CD3� and IL-4 plus anti-IL-12). After 4 d, the cells were 
washed, counted, and restimulated with 5 µg/ml plate-bound anit-CD3�  and 5 µg/ml 
anti-CD28. The supernatants were harvested after 24 h and IL-4 was determined by 
ELISA. (B) Secretion of IFN-� . Supernatants from the CD4+ cells in A were harvested 
after 24 h and IFN-� was determined by ELISA. M, cells incubated in medium alone; 
Neutral, without IL-12 plus anti-IL-4 or IL-4 plus anit-IL-12.
120
Supplementary Figure 4. Secretion of IL-4 and IFN-� by SLAM BALB/c and WT 
BALB/c CD4+ cells cultured under Th1- and Th-2 polarizing conditions. (A) Secretion 
of IL-4. CD4+ cells purified from the spleen of SLAM or SLAM BALB/c mice were 
primed under three conditions: neutral (anti-CD3�  5 µg/ml), Th1 (anti-CD3� and IL-12 
plus anti-IL-4), and Th2 (anti-CD3� and IL-4 plus anti-IL-12). After 4 d, the cells were 
washed, counted, and restimulated with 5 µg/ml plate-bound anti-CD3�    and 5 µg/ml of 
anti-CD28. The supernatants were harvested after 24 h and IL-4 was determined by 
ELISA. (B) Secretion of IFN-�. The supernatants of the cells described in A were 
harvested after 24 h and IFN-� was determined by ELISA. M, cells incubated in medium 
alone; Neutral, without IL-12 plus anti-IL-4 or IL-4 plus anti-IL-12.  
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Supplementary Figure 5. T cell receptor-mediated Ca2+ entry in CD4+ T cells of WT, SLAM, and 
SAP C57BL/6 mice is identical. Mononuclear cells from whole lymph node preparations of WT, SLAM, 
and SAP C57BL/6 mice, respectively, were tested for Ca2+ influx after cross-linking with anti-CD3 or a 
combination of anti-CD3 and anti-CD4. Cells were labeled with 1 µM Fura-2 AM for 30 min at room 
temperature and then incubated with 2.5 µg/ml biotinylated anti-CD3 abs (2C11; BD Biosciences) or anti-
CD3 plus anti-CD4 abs (Rm4-4; BD Biosciences) for 15 min at room temperature. Lymphocytes were 
mounted in an RC-20 flow chamber (Warner Instruments) on poly-L-lysine-coated cover slips and perfused 
with 2 mM Ca2+ Ringer solution (155 mM NaCl, 4.5 mM KCl, 10 mM D-glucose, 5 mM Hepes, pH 7.4, 1 
mM MgCl2, 2 mM CaCl2). Cell stimulation was achieved by CD3 or CD3/CD4 cross-linking using 2.5 
µg/mL streptavidin (SA; Pierce Chemical Co.) followed by 1 µM ionomycin (Io; Calbiochem), respectively, 
to induce maximal Ca2+ influx. Elevations in intracellular Ca2+ concentrations were recorded by single cell 
video imaging on a Zeiss Axiovert S200 inverted epifluorescence microscope (Carl Zeiss MicroImaging, 
Inc.) using OpenLab imaging software (Improvision). Fura-2 emission was detected at 510 nm after 
excitation at 340 and 380 nm, respectively. Image acquisition and 340:380 ratios were obtained in 5-s 
intervals after background subtraction. Calibration values (Rmin, Rmax, Sf) were derived from cuvette 
measurements as previously described (Grynkiewicz, G., M. Poenie, and R.Y. Tsien. 1985. J. Biol. Chem..
260:3440-3450). At the end of each Ca2+ recording, cells were stained with anti-CD4 abs (Rm4-5; BD 
Biosciences) in the flow chamber. For each experiment, ~100 CD4+ ionomycin-responsive cells were 
analyzed with gray traces representing Ca2+ responses of individual cells and the bold black trace 
representing the mean response.  
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Supplementary Figure 6. Altered IL-12, TNF-�, IL-6, and nitric oxide production 
by peritoneal macrophages from SLAM BALB/c mice. (A) IL-12 production. Resting 
peritoneal macrophages from 12 SLAM BALB/c or WT SLAM BALB/c mice were 
stimulated with 200 U/ml IFN-�, 2 ng/ml LPS, or with IFN-� plus LPS for 24 h. IL-12p70 
was determined by ELISA. (B) TNF-� production. Resting peritoneal macrophages from 
SLAM BALB/c or WT SLAM BALB/c mice were stimulated as described in A. TNF-�
was determined by ELISA. (C) IL-6 production. Resting peritoneal macrophages from 
SLAM BALB/c or WT SLAM BALB/c mice were stimulated as described in A. IL-6 
was determined by ELISA in the same culture supernatants as in A. (D) Nitric oxide 
production. Resting peritoneal macrophages from 12 SLAM BALB/c or WT SLAM 
BALB/c mice were stimulated as described in A. Nitric oxide was determined by ELISA 
in the same culture supernatants as in A. M, cells incubated in medium alone.  
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T-cell activation plays an essential role in the generation of the
pulmonary inflammation that is manifest in allergic asthma. Opti-
mal T-cell activation requires not only presentation of antigen with
themajor histocompatibility complex, but also concurrent signaling
through costimulatory molecules. The costimulatory molecule
SLAM (Signaling Lymphocytic Activation Molecule, CD150) is a
glycoprotein expressed on activated lymphocytes and antigen-
presenting cells. Disruption of the SLAM gene demonstrated that
SLAM-induced signal transduction pathways regulate cytokine pro-
duction by T helper (Th)2 cells and macrophages. Here we tested
the postulate that the costimulatory molecule SLAMmay be critical
for allergic inflammation in a murine model. SLAM-deficient mice
did not manifest allergen-induced bronchoalveolar lavage eosino-
philia, increased serum IgE, or heightened airway responses com-
pared with wild-type mice. Allergen-induced Th2 cytokines and
Th1 cytokines were decreased in SLAM-deficient mice. These data
support the concept that SLAM plays a crucial role in allergic
responses.
Keywords: allergic inflammation; asthma; costimulatory molecules;
murine; SLAM
T-cell activation plays a critical role in the initiation and media-
tion of the airway inﬂammation observed in allergic asthma. The
recognition of allergen in the context of major histocompatibility
complex on the surface of an antigen-presenting cell and an
antigen-speciﬁc T-cell receptor (TCR) is a critical ﬁrst step to-
ward immune activation. In addition, costimulatory molecules
on the T cell and antigen-presenting cell interact for complete
T-cell activation. Pathways involving the costimulatory mole-
cules CD28 and CD80/86 are the best-described costimulatory
interactions and have been shown to play an important role in
the pathogenesis of allergic asthma in murine models (1–4).
These costimulatory molecules may be only partially responsible
for allergic responses because blocking or deﬁciency of these
molecules does not equally affect all allergic parameters. The
recently described costimulatory molecule SLAM (Signaling
Lymphocytic Activation Molecule, CD150) has been shown to
have modulatory effects during T-cell activation (5). The role of
SLAM in allergic inﬂammation has not been previously analyzed.
SLAM, a type I transmembrane glycoprotein, is a member
of a small CD2 subfamily of the Ig superfamily. SLAM is consti-
tutively expressed on CD45ROhigh memory T cells, B cells, den-
dritic cells, and macrophages; it is rapidly induced on naive
T cells after activation (6). A stimulating anti-SLAM antibody
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evokes antigen-speciﬁc T-cell proliferation and IFN-� produc-
tion by CD4� T cells (7). SLAM directly induces proliferation
of preactivated T cells in the absence of CD28 involvement or
other stimuli. CD4� T cells from SLAM-deﬁcient mice have a
defect in TCR-mediated production of IL-4 (7). SLAM also
promotes the proliferation and differentiation of human B cells
(8). SLAM-deﬁcient macrophages exhibit abnormal functions,
as evidenced by the reduced production of IL-12, TNF-�, and
nitric oxide and the inability to clear Leishmania major infection
(7, 9).
SLAMhas been viewedwith importance as a distinct costimu-
latory molecule. We tested the postulate that the costimulatory
molecule SLAM may be critical for allergic inﬂammation in a
murine model. We analyzed allergic parameters including serum
IgE, bronchoalveolar lavage (BAL) cytokines, and lung inﬂam-
mation in a model of pulmonary inﬂammation with SLAM-
deﬁcient mice. Our results indicate that expression of SLAM is
essential for allergic pulmonary inﬂammation and local pulmo-
nary cytokine production.
MATERIALS AND METHODS
Mice
Eight-week-old, speciﬁc pathogen–free, SLAM�/� (BALB/c) mice
were generated as previously described (6, 9). Eight-week-old wild-
type (BALB/c) mice were purchased from Jackson Laboratory (Bar
Harbor, ME). The mice were maintained according to the guidelines
of the Committee on Animals of the Harvard Medical School and the
Committee on the Care and Use of Laboratory Animals of the Institute
of Laboratory Animal Resources National Research Council.
Protocol for Allergen Sensitization and Challenge
Mice were sensitized and challenged with allergen ovalbumin (OVA)
as previously described (4, 10–15). Brieﬂy, mice were sensitized by
intraperitoneal injection with 10 �g chicken OVA and 1 mg Al(OH)3
(alum) on Days 0 and 7. On Days 14–20, mice received aerosolized
OVA challenge with 6%OVA for 20 min/d. OVAwas dissolved in 0.5�
PBS. Control mice received 1 mg alum in 0.5� PBS via intraperitoneal
injection on Days 0 and 7 and received aerosolized PBS on Days 14–20.
An ultrasonic nebulizer (Model 5000; DeVilbiss, Somerset, PA) was
used for nebulizations into a plastic chamber.
Serum IgE
Blood was withdrawn by cardiac puncture and centrifuged to recover
serum at 13,000 rpm for 20 min. Total serum IgE levels were determined
by ELISA as previously described (12–14). Total serum IgE concentra-
tions were calculated using a standard curve generated with commercial
IgE standard (BD Pharmingen, San Diego, CA).
BAL and Histologic Analysis
Twenty-four hours after the ﬁnal challenge, mice were anesthetized
with ketamine/xylazine intraperitoneally and killed by cardiac puncture.
Each mouse underwent BAL, as previously described (4, 10–15). Cells
were resuspended in RPMI. Slides for differential cell counts were
prepared with Cytospin (Shandon Inc., Pittsburgh, PA) and ﬁxed and
stained with Diff-Quik (Dade Behring, Newark, DE). For each sample,
an investigator blinded to the treatment groups performed two counts
of 100 cells. For histopathologic assessment, lungs were removed from
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Figure 1. SLAM�/� OVA mice have significantly reduced BAL eosino-
phils when compared with SLAM�/� OVA mice. Each mouse under-
went BAL after OVA sensitization and challenge as described inMATERIALS
AND METHODS. Cell counts were determined by differential staining of
cells isolated from the BALF. Data are shown as percentage of total
cells � SEM (n � 2 experiments; 6–11 mice per group).
the thoracic cavity, placed in formalin, cut, and stainedwith hematoxylin
and eosin. The level of lung inﬂammation was evaluated by comparison
with known positive and negative sections and ranked from mild to
severe on a scale of 0–3, based on quantity and uniformity of inﬂamma-
tion (0� no inﬂammation; 1� 1–5, 2� 5–10, and 3�� 10 inﬂammatory
cells per high-power ﬁeld). An investigator blinded to group classiﬁca-
tion evaluated lung tissue inﬂammation.
BAL Cytokines
BAL ﬂuid (BALF) cytokine concentrations were measured by ELISA
according to the manufacturer’s speciﬁcations (R&D Systems, Minne-
apolis, MN). Brieﬂy, BALF samples were aliquoted in duplicate into
96-well plates that were precoated with antibody to speciﬁc cytokines
and assayed according to the manufacturer’s instructions. Optical den-
sity was measured at 450–540 nm. Cytokine concentrations were deter-
mined by comparison with known standards. The sensitivities of the
ELISA kits used in this study are as follows: IL-4, 2 pg/ml; IL-13, 1.5
pg/ml; IL-10, 4 pg/ml; IL-12p70, 2.5 pg/ml, TNF-�, 5.1 pg/ml.
Figure 2. SLAM�/�OVA mice show de-
creased pulmonary inflammation com-
pared with SLAM�/�OVA mice. Mice
were sensitized and challenged with aller-
gen OVA or PBS control. Hematoxylin/
eosin of right lung was reviewed as de-
scribed in MATERIALS AND METHODS. Origi-
nal magnification: �20.
Determination of Airway Measurements
Twenty-four hours after the ﬁnal aerosol challenge, airway measure-
ments were assessed using whole-body plethysmography. Mice were
placed in individual chambers, and 100 mg/ml methacholine was nebu-
lized into the chambers via an inlet for 2 min as previously described
(10, 15–17). Readings were averaged over 7 min from the beginning of
the nebulization. The whole-body plethysmography system measures
changes in box pressure during expiration and inspiration, peak expir-
atory pressure (PEP), peak inspiratory pressure (PIP), inspiratory time
(Ti), expiratory time (Te), and relaxation time (Tr � time of the pres-
sure decay to 36%of total box pressure during expiration) and generates
a value called enhanced Pause (Penh) (Penh � PEP/PIP � [{Te � Tr}/
Tr]), which is associated with airway resistance (10, 15, 18). We have
previously analyzed the identical OVA allergic model with classical
measures of lung resistance using tracheostomized and anesthetized
mice in Balb/c and C57/BL6 strains (3, 4, 11, 13).
Statistical Analysis
Statistical analysis of data was performed by t test using Sigma Stat
software. Nonparametric data were analyzed using a Mann-Whitney
test. Data are reported as means � SEM. Statistical signiﬁcance was
deﬁned by P � 0.05.
RESULTS
SLAM�/� OVA Mice Have Reduced Allergen-Induced
Eosinophil Recruitment and Inflammation in the Lung
The presence of eosinophils in theBALF and lungs after allergen
sensitization and challenge is an important indicator of airway
inﬂammation. Wild-type (SLAM�/� OVA) mice have in-
creased total cell counts and high levels of eosinophils in the
BALF after sensitization and challenge with OVA (**P� 0.01)
(Figure 1). In contrast, SLAM�/� OVA sensitized and chal-
lenged mice (SLAM�/� OVA mice) have signiﬁcantly de-
creased allergen-induced BAL eosinophils when compared with
SLAM�/� OVA mice (*P � 0.029).
To determine whether allergic lung inﬂammation was also
affected by SLAM deﬁciency, histologic sections of lung were
examined (Figure 2). Lungs from SLAM�/� OVA mice had
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Figure 3. Levels of total serum IgE are significantly reduced in SLAM�/�
OVA mice compared with SLAM�/� OVA control mice. Blood was
extracted by cardiac puncture, and total serum IgE was measured by
ELISA 24h after aerosol challenge as described inMATERIALS ANDMETHODS.
Data are shown as mean IgE concentration in ng/ml � SEM (n � 2
experiments; 6–11 mice per group).
less pulmonary inﬂammation than SLAM�/� OVA mice.
Pathology-averaged scores by an investigator blinded to the
groups were as follows: SLAM�/� OVA, 3; SLAM�/� PBS,
0; SLAM�/� OVA, 1.2; SLAM �/� PBS, 0. The scores were
on a scale of 0–3 (n � 4 mice per group).
SLAM�/� Mice Have Decreased Levels of Total Serum IgE
after OVA Allergen Sensitization and Challenge
OVA sensitization and challenge resulted in an increase in total
serum IgE in SLAM�/� OVA mice (**P � 0.001). SLAM�/�
OVAmice had diminished IgE levels compared with SLAM�/�
OVA mice (*P � 0.001) (Figure 3).
Figure 4. (A–C) Secretion of allergen-induced Th2 cytokines IL-4, IL-10, and IL-13 measured in the BALF was significantly decreased in SLAM�/�
OVA mice when compared with SLAM�/� OVA mice. (C and D ) Secretion of allergen-induced Th1 cytokines TNF-� and IL-12p70 measured in
the BALF was significantly decreased in SLAM�/� OVA mice when compared with SLAM�/� OVA mice. Cytokine concentration in the BALF was
measured by ELISA (R&D systems) according to the manufacturer’s instructions. Data are shown as pg/ml � SEM (n � 2 experiments; 4–12 mice
per group).
SLAM�/� Mice Do Not Produce Th2 or Th1 Cytokines in
Response to OVA Allergen Sensitization and Challenge
Previous data indicate the importance of Th2 cytokine produc-
tion in the development of allergic inﬂammation (11, 13, 19).
SLAM�/�OVAmice had increased secretion of Th2 cytokines
(IL-4, IL-13, IL-10) in the BALF compared with SLAM�/�
PBS control mice (**P � 0.05) (Figures 4A–4C). This increase
in cytokine secretion was absent in SLAM�/� OVAmice com-
pared with SLAM�/�OVAmice (*P� 0.05) (Figures 4A–4C).
Cytokines associated with a Th1 response were also analyzed.
Concentrations of TNF-� and IL-12p70 were signiﬁcantly re-
duced in the BALF of SLAM�/� OVA compared with
SLAM�/� OVA mice (Figures 4D and 4E). Levels of IL-4, IL-
13, IL-10, TNF-�, and IL-12p40 in the BALF of SLAM�/�
OVA mice were not signiﬁcantly increased compared with
SLAM�/� PBS control mice.
Allergen-Induced Airway Measurements Are Decreased in
SLAM�/� Mice
To determine whether SLAM plays a role in the development
of allergen-induced airway measurements, responsiveness to
methacholine was measured in SLAM�/� OVA and
SLAM�/� OVA mice. SLAM�/� OVA mice had decreased
allergen-induced airway measurements (Penh) relative to
SLAM�/� OVA mice (P � 0.04) (Figure 5).
DISCUSSION
Pulmonary allergic inﬂammation is dependent upon T-cell acti-
vation with engagement of the antigen-speciﬁc TCR and costi-
mulatory molecules. Previous studies have focused primarily
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Figure 5. Airwaymeasurements in SLAM�/�OVAmice are significantly
decreased compared with SLAM�/� OVA mice. Airway measurements
(Penh) were assessed using whole-body plethysmography, challenged
with methacholine, as described in MATERIALS AND METHODS. Data are
shown as proportion of baseline Penh � SEM (n� 2 experiments; 8–10
mice per group).
on the costimulatory pathways involving CD28 and the ligands
CD80 and CD86 and have found them to be essential for allergic
responses (1, 3, 20–22).
We postulated that additional costimulatory pathways that
involve SLAM might be crucial for allergic asthma. Using a
murine model of allergen OVA–induced inﬂammation, allergic
responses were attenuated in the absence of SLAM. BAL eosin-
ophilia and total serum IgEwere signiﬁcantly reduced in SLAM-
deﬁcient mice compared with wild-type control mice. Allergen-
induced Th2 cytokine secretion in SLAM-deﬁcient mice was
reduced to levels typically seen only in non–allergen-sensitized
control mice. Allergic inﬂammation in the lung (as characterized
by eosinophils) and perivascular and peribronchial inﬂammation
were decreased, suggesting that SLAM deﬁciency impairs tissue
inﬂammation and circulating mediators of inﬂammation.
Previous analysis of SLAM-deﬁcient mice showed that
SLAM interactions are necessary for Th2 and macrophage func-
tions (7). CD4� cells from SLAM-deﬁcient mice after stimula-
tion with anti-CD3 and anti-CD28 secreted reduced amounts of
IL-4 compared with wild-type mice (7). Our data suggest an
essential role of SLAM pathways in allergic responses that are
classically presumed to be mediated by Th2 cytokines. Modiﬁca-
tion of the cytokine secretion could be a possible mechanism
for the reduction of allergic responses in SLAM-deﬁcient mice.
Our data also indicate that Th1 cytokines (TNF-� and IL-12p70)
are signiﬁcantly decreased in the absence of SLAM. Although
asthma has been characterized as predominantly a Th2 disease,
recent data suggest a role for Th1 responses, consistent with
the notion that Th1 and Th2 responses may be critical for the
generation of allergic responses (23). Our analysis of SLAM-
deﬁcient mice showing reduction of Th1 and Th2 allergen–
induced cytokines is consistent with this concept. SLAM is ex-
pressed on macrophages and on lymphocytes. Recent data have
focused onmacrophages and their mediators in the ampliﬁcation
of allergic responses (24–26). Given that macrophage functions
in SLAM-deﬁcient mice have previously been shown to be im-
paired (7), we cannot exclude the possibility that this cell type
may contribute to the failure of SLAM-deﬁcient mice to develop
allergic responses. A recently described receptor for SLAM,
termed SLAM-associated protein, has been identiﬁed (27).
Whether SLAM-mediated effects in allergic asthma predomi-
nate by lymphocyte, macrophage, or SLAM-associated protein
signaling–mediated mechanisms warrants further investigation.
We report our analysis of the role of the newly described
costimulatory molecule, SLAM, in mediating allergic immune
responses. Our results indicate that the expression of SLAM is
essential for allergic pulmonary inﬂammation and the develop-
ment of local pulmonary cytokine production. These ﬁndings
suggest that SLAM-mediated pathways involving Th1 and Th2
responses are present in the genesis of allergic responses. These
data suggest that multiple costimulatory signaling pathways
should be considered in the generation of pulmonary allergic
inﬂammation.
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The goal of this thesis was to analyze the role of CD3 components in T cell development 
and the contribution in T cell activation of the coactivator SLAM (signaling lymphocytic 
activation molecule). For the purpose of these investigations we have generated new 
mouse models by using targeted gene disruption and transgene technologies. In Chapters 
2-5, we have dissected the roles of CD3 components in assembly of the TCR/CD3 
ensemble and in T cell development. In Chapter 6 the isolation and characterization of 
the mouse SLAM gene are discussed and its immune regulatory functions were studied in 
vitro and in vivo as discussed in Chapters 7 and 8.   
 
 
CD3� and CD3� genes are essential for development of thymocytes, but their 
orthologs between mouse and human have differential effect on the development of 
thymocytes 
   
      CD3-� and CD3-� are the most closely related CD3 components. Previous studies 
demonstrated that the lack of mouse CD3-� blocks ��-T development at the second 
checkpoint from CD4+CD8+ double positive (DP) to CD4+CD8
-
 or CD4
-
CD8+ single 
positive (SP) stage, while at the same time these CD3-�-deficient mice develop normal or 
display elevated numbers of ��-T cells (1). However, the absence of CD3-� shows that 
the transition from DN to DP stage is severely but not completely blocked, while leaving 
��-T cells relatively unaffected (2). To explore the consequences of CD3-� and CD3-� 
double deficiency for ��-T and ��-T cell development, the CD3-� and CD3-� genes were 
targeted simultaneously in the mouse germ line (Chapter 2) ( 3). The resulting CD3-�� 
double-deficient mouse strain shows that T cell development is arrested at the CD44
-
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CD25+ DN stage, such that the more mature subsets of CD4+CD8+(DP), CD4+CD8
-
, and 
CD4
-
CD8+(SP) thymocytes normally present in the thymus of adult mice are absent in 
these mice. As a consequence of this developmental block, total thymocyte numbers are 
markedly reduced in the mutant mice and mature T cells are undetectable in the 
peripheral lymphoid organs. In contrast to CD3-� or CD3-�-deficient mice, the 
development of ��-T cells is completely blocked in CD3��-deficient mice. Therefore, 
based on the phenotypes of CD3-�- , CD3-�-, and CD3-��-deficient mice, the conclusion 
is that the absence of CD3-� and CD3-� collectively compromises more severely and 
earlier ��-T and ��-T development, suggesting that CD3-� and CD3-� play an essential, 
yet to some extent overlapping role in the early development of T cells (Chapter 2) ( 3). 
 
      In sharp contrast to CD3-�-deficient mice, humans lacking the CD3-� subunit exhibit 
a mild �� T lymphopenia, but have normal T cells (4-5), suggesting that in humans, but 
not in mice, the highly related CD3-� chain is capable of functionally replacing CD3-� 
during thymopoiesis. We tested whether human CD3-� could restore mouse T cell 
development in the absence of CD3-� by expressing a human CD3-� transgene in CD3-�� 
double-deficient mice ( Chapter 3 ) (6). It was surprising to find that the novel mouse 
strain, CD3-��-/- x CD3h�Tg, displayed a nearly normal-sized population of TCR-
expressing DP cells, indicative of restored pre-TCR function, mimicking a phenotype 
similar to CD3-� deficient humans. Although the overall structure and functioning of the 
pre-TCR and TCR complex in mice and humans are quite similar, the deficiency of CD3-
� and CD3-� results in markedly difference between mice and humans. In contrast to 
mice lacking CD3-�, CD3-�-deficient patients have a complete deficiency in peripheral T 
cells, including �� T cells (7-8). How the differential effect of the mouse and human 
CD3-� orthologue on thymocyte development is achieved is not clear at the moment. 
During early thymocyte development, transcriptional activation of CD3-� is delayed and 
of lower magnitude compared to that of CD3-� (9). Accordingly, in the absence of CD3-
�, CD3-� could be the limiting factor for assembly and expression of the pre-TCR, as 
observed in CD3-� null-mutant mice (2). In this scenario, overexpression of a transgenic 
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 CD3-� would overcome the expression of CD3-�-lacking pre-TCR complex. This appears 
unlikely as similar amounts of CD3-� mRNA were detected in CD3-��-/- x CD3h�Tg 
thymocytes compared with CD3-�-deficient and wild type mice. Moreover, the relative 
amount of intracellular CD3-�� dimer in DN thymocytes was comparable in CD3-� 
deficicent and CD3-��-/- x CD3h�Tg mice. More importantly, early thymocyte 
development was not restored in CD3-�� double-deficient mice expressing a mouse CD3-
� transgene (Chapter 3 and Terhorst et al unpublished data). Therefore, in CD3-��-/- x 
CD3h�Tg mice, human, but not mouse CD3-� endows the pre-TCR with specific 
properties essential for pre-TCR functional and development progression. The capacity of 
the CD3-� and CD3-� chains to substitute for one another seems quite logical, as they are 
relatively more homologous to each other than to the other components of the receptor 
complex. In the extracellular (EC) region, there are several amino acid positions where 
human but not mouse CD3-� matches murine CD3-�. Whether these amino acids 
contribute specific structural/functional features to the pre-TCR complex deserves further 
investigation.  
       The size of the thymi and total thymocyte number of CD3-��-/- x CD3h�Tg mice are 
relatively normal compared to control mice. All thymocyte subsets defined by expression 
of CD4 and CD8 coreceptors are present in CD3-��-/- x CD3h�Tg mice, although 
reduced CD4+ and CD8+ single positive thymocytes are detected. The consistent 
reduction in the number of mature CD4+ and CD8+ SP thymoctyes observed in CD3-��-/- 
x CD3h�Tg mice suggested a block in positive selection. This prompted us to test the 
impact of CD3-� deficiency on the positive selection of T cells that recognized defined 
antigens. To that end, three transgenic TCRs were independently introduced onto CD3-
��-/- x CD3h�Tg background. Mice lacking CD3-� showed deficient positive selection of 
antigen-specific MHC class I- and MHC class II-restricted T cells. Negative selection of 
antigen-specific thymoctyes was also markedly impaired, concomitantly with a reduced 
sensitivity to antibody-induced apoptosis. Collectively, these data indicate that CD3-� is 
required effectively for positive and negative selection.  
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       To understand the molecular basis of defective thymocyte selection in CD3-��-/- x 
CD3h�Tg mice, we analyzed intracellular events associated with TCR signal 
transduction. Early biochemical events elicited upon TCR engagement were markedly 
attenuated but not completely abrogated in CD3-��-/- x CD3h�Tg mice. Thus, this CD3-
��-/- x CD3h�Tg strain provides a unique mouse model for the detailed analysis of 
thymocyte selection in the absence of CD3-�. 
 
Altered thymocyte development in CD3 mutant mouse models 
  
      The generally accepted stoichiometry for the TCR/CD3 complex is TCR-�� or TCR-
��/CD3-��/CD3-��/CD3-��. Given that CD3-� is represented twice in the TCR/CD3 
complex serving as a component of both CD3�� and CD3�� dimers, CD3-� is the most 
likely candidate for performing a critical role in the TCR/CD3 complex formation and 
signaling response. This pivotal role of CD3-� seems supported by an arrest in thymocyte 
development at an early stage. The thymus from CD3-�-deficient mice contains a 
dramatically reduced cell number relative to littermate controls (Chapter 4 and 5) (10, 
12, 13). FACS analysis showed that CD3-� deficient mice are unable to progress beyond 
the CD44
-
CD25+ stage, the same block checkpoint as RAG-, TCR�-, and pT�-deficient 
mice (69-72). Unexpectedly, CD3-� and CD3-� expression is also severely inhibited in 
CD3-�-deficient mice, which were generated by us (Chapter 4 and 5) (12, 13) and by 
Malissen et al (10). Thus, it is unclear whether the arrest in CD3-�-deficient mice is 
caused by CD3-�-deficiency alone, or by the collective deficiency in CD3-��� chains. It 
could be argued that inhibition of CD3-�� expression is caused by the insertion of the 
PGK-neo in CD3-� locus, thereby affecting transcription of the CD3-�� genes. However, 
same PGK-neo cassette appears to have no effect on the expression of CD3-�/CD3-� or 
CD3-�/CD3-� in the CD3-�- or CD3-�-deficient mice (1, 2). Thus, this raises an 
interesting question as to whether CD3-� is involved in the transcriptional regulation of 
the CD3-� and CD3-� genes. To answer these questions, we reconstituted CD3-� 
expression in CD3-�-deficient mice by the introduction of a CD3-� transgene. The 
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 reconstitution of CD3-�-deficient mice with a CD3-� transgene did not restore CD3-�� 
expression, which excludes that CD3-� is somehow involved in the transcriptional control 
of the head to head arranged CD3-� and CD3-� genes (Chapter 5) (13). However, CD3-� 
reconstitution led to a very efficient differentiation and maturation of the minute number 
of prothymocytes that did express CD3-� and CD3-�, resulting in the appearance of a 
significant T cell population in the periphery (Chapter 5) (13). As an alternative 
explanation, the suppression of CD3-�� expression could be attributed to introduction of 
PGK-Neo cassette in the CD3-� gene locus. This notion was confirmed by removing the 
PGK-Neo cassette from the targeted CD3� gene via Cre/LoxP mediated recombination 
(11). Collectively, these results thus demonstrate that CD3-� does not regulate CD3-�� 
expression, and underscores the vast capacity of each prothymocyte to give rise to a large 
number of peripheral mature T cells.  
       It is known that the CD3 proteins are expressed before pT� and TCR-� chains in 
prothymocytes (12). Mice lacking CD3-�, CD3-�, CD3-�, or CD3-� exhibit various 
degrees of developmental arrest, demonstrating a clear role for these proteins in T cell 
maturation (1-3, 10-11, 12-13, 15-17). In order to appreciate the collective contribution of 
all individual CD3 components, we took advantage of the fact that the vast majority of 
thymocytes in the CD3-�-deficient mice are deficient in CD3-��� expression. Therefore a 
CD3����-deficient mouse was generated by breeding the CD3-�-deficient mice with 
CD3-�-deficient mice (Chapter 4) (13). The resulting mouse strain exhibits an arrest of 
thymocytes at CD44
-
CD25+ stages as observed in RAG-deficient mice (69-70). 
Moreover, surface �� TCR and ��TCR complexes are undetectable in both the thymus 
and peripheral lymphoid organs (Chapter 4 and Wang /Terhorst unpublished data) (13). 
      Expression of the pre-TCR on the thymocyte surface is preceded by expression of 
CD3 complexes that lack clonotypic components, the so-called clonotype-independent 
CD3 complexes (CIC). The biochemical studies show that CD3-�� and CD3-�� dimers 
exist in CIC which is detected in TCR-� negative immature thymocytes (18). In mice 
genetically unable to generate a TCR-� chain, treatment with anti-CD3-� induced most 
known pre-TCR-dependent developmental responses (19-22). Moreover, requirement of 
CD3 signaling for allelic exclusion at TCR-locus is shown by studying CD3-mutant mice 
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 and anti-CD3-induced premature shutdown of TCR-gene rearrangement (19). CD3-� 
cross-linking studies have suggested a role for the Src family protein tyrosine kinase Lck 
in CIC signaling (25). However, TCR-� gene rearrangements do occur in CD3-�-
deficient, CD3-�� double deficient, and even in de facto CD3����-deficient thymocytes 
(Chapter 2, 4, 5,) (3, 10, 13-14). This has been taken as evidence against a functional role 
of CD3 complexes before the expression of the TCR-� chain and the formation of the 
pre-TCR. 
      Taken together, CD3 subunits start to function only immediately before the CD44
-
CD25+ to CD44
-
CD25
-
 transition in which pre-TCR begins to function. Although the 
data from our CD3-� knock-out mice suggest that CD3-� is critical for the assembly of 
the pre-TCR, we cannot formally exclude that the other CD3 subunits are also a 
prerequisite for TCR-� gene rearrangement and T cell development as these mice display 
strongly downregulated expression of the CD3-� and CD3-� chains. Moreover the 
absence of TCR-� gene rearrangement and deficient T cell development in the de facto 
CD3-����-deficient mice is in favor for an important role of the entire functional CD3 
complex in these processes. 
 
Co-stimulatory molecules located in SLAM locus represent a new family of 
immune-cell receptors 
 
      Apart from analyzing the genomic organization of the mouse SLAM/CD150 gene, 
determining its tissue distribution and regulation of expression of SLAM in response to 
anti-CD3 stimulation, the mouse SLAM gene was mapped to Chromosome 1 band 1q2.2-
2.3 in which CD244, CD229, CS1, CD48, CD84, Ly108, SF2001, and BLAME are 
clustered in a 260 kb fragment (Chapter 6) (25). Like CD2 (27), these molecules are 
characterized by an N-glycosylated extracellular region composed of two 
immunoglobulin fold domains: the non disulfide-bonded N-terminal IgV, involved in 
ligand-binding, and the membrane-proximal IgC, with its two disulfide bonds. The 
structure of CD229 is divergent because it has two tandem V-C domains (26). These 
genes share a common genomic structure: exon 1 encodes the 5’untranslated region and 
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 the signal sequence, and exon 2 and 3 (which are repeated in CD299, exons 4 and 5 
respectively) encode the extracellular Ig domains. The transmenbrane region in contained 
in exon 4 (6 in CD229) and finally, the remaining exons encode the cytoplasmic regions 
involved in downstream signaling by these receptors. Therefore it is believed that these 
genes have arisen by gene duplication from a single gene (44). Sequence alignment 
shows that SLAM/CD150 shares higher homology with CD84, CD48, CD319, CD229, 
CD244, and BLAME than with CD2 or CD58 (Chapter 6) (25). Although human CD2 
and CD58 are mapped to Chromosome 1, mouse CD2 maps to Chromosome 3. More 
importantly, SLAM, CD84, CD229, CD244, Ly108, and CD319 bind SAP and EAT-2, 
whereas CD2 doesn’t. Based on these differences between CD2 and the genes in the 
SLAM locus, SLAM/CD150, CD84, CD229, CD244, CD319, Ly108, CD48, SF2001, 
and BLAME are grouped into the SLAM family of immune receptors, as SLAM/CD150 
is the prototypic member of these receptors (Chapter 6) (25).   
 
SLAM regulates Th2 differentiation via a SAP-FynT related signaling pathway 
 
      SLAM/CD150 is found to be a self-ligand mediating molecular and cellular 
homophilic interaction, which is detected on multiple immune cells and functions as a 
costimulatory molecule (28-29). Initial studies suggested that antibody-mediated 
engagement of SLAM can enhance antigen-specific T cell proliferation and directly 
induces proliferation of T helper cell clones or reactivated T cells (30, 31). Further events 
which indicate that SLAM signaling regulates Th1 cell differentiation is from the 
observations that costimulation through SLAM during Ag-specific stimulation 
preferentially induces IFN-� production, whereas no induction of IL-4 production was 
seen by trigging of SLAM (30-33). Interestingly, the engagement of SLAM by specific 
mAb reverses the highly polarized Th2 cell populations into Th0/Th1 cell populations, as 
judged by intracellular IFN-� production of individual cells and the inability of 
supernatants of the activated Th2 clones to support IgE synthesis by purified B cells (33). 
In line with the effect on Th1 function, we and another group found that SLAM is 
expressed on polarized Th1 and Th2 cells, but is maintained only on Th1 cells and not 
Th2 cells (Chapter 6) (25, 32). Therefore, these findings lead to the idea that SLAM 
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 promotes Th1 cell responses during T cell activation. However, the studies with SLAM-
deficient mice indicate that SLAM plays an opposite role in Th1/Th2 differentiation as 
suggested previously by specific antibody-mediated ligation of SLAM (Chapter 7) (34). 
In SLAM-deficient mice, the levels of Th2 cytokine expression (IL-4 and IL-13) are low 
or barely detectable in response to triggering of the T-cell receptor complex following 
ligation with specific antibodies. This defect in IL-4 production is also evident from 
stimulation studies of antigen-specific TCR-transgenic T cells with APCs and peptides. 
In contrast to the effect of anti-mSLAM mAb on the induction of IFN-�, the deficit in 
SLAM only marginally affects the capacity of polarized Th1 cells to enhance IFN-� 
production(chapter 7) (34).  
 
     The mechanisms by which the specific antibody treatment and the gene deletions give 
rise to the contradictory effects on Th1/Th2 differentiation are unclear at the present time. 
However, since most of gene targeted mice are found to provide more reliable 
phenotypes for the targeted genes, it appears that the homophilic SLAM interaction 
primarily transduces negative signaling for IFN-� production and delivers a positive 
signal for Th2 cytokine productions. Therefore, anti-SLAM mAbs may block 
transduction of negative effects triggered by SLAM, rather than provide an activating 
signal for IFN-� secretion.  
 
      Although  the molecular basis in which SLAM regulates Th2 responses is not clearly 
established, SAP-mediated signaling may be, at least in part, involved in those responses. 
Accumulated evidence shows that SAP is required for mediating intracellular tyrosine 
phosphorylation signaling implicating SLAM, SHIP1, and the adaptor molecules Dok-1, 
Dok-2, and Shc (35-37). Biochemical and crystallographic studies clearly demonstrated 
that the SH2-domain in SAP has both a FynT binding site (R78) and a phosphotyrosine-
binding fold (38-39). This molecular feature of SAP allows a single SAP molecule to 
bind simultaneously to SLAM family members and FynT. Therefore, as an adaptor, SAP 
induces SLAM-triggered protein tyrosine phosphorylation by recruiting and activating 
FynT. On the other hand, SAP, as a natural blocker, prevents binding of SLAM or other 
SLAM-related members to the SH2 domain-containing protein tyrosine phosphatases 
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 such as SHP-2. On the basis of these observations, it is conceivable that 
SLAM/SAP/FynT signaling plays a crucial role in controlling Th2 cytokine productions. 
In agreement with the idea, the genetic deficiencies of SAP and FynT show a serious 
defect in Th2 cell responses (40-41). Furthermore, in the context of regulation of Th2 cell 
responses, the functional link between SLAM/SAP and FynT is strengthened by evidence 
from studying SAPR78A mice in which Arginine 78, a key residue for interaction between 
SAP and Fyn, is mutated to an Alanine in the germ line (41). In SAPR78A mice, SAP 
R78A is able to associated with SLAM in a manner that is similar to that seen in SAP, 
but the ability of SAP R78A to recruit FynT is abolished due to this key residue mutation. 
Not surprisingly, the ability of TCR stimulation to trigger Th2 cytokines in CD4+ T cells 
was markedly compromised in SAPR78A T cells. In addition, SAP-deficient and FynT-
deficient mice exhibit a much more severe defect in Th2 responses as compared with 
SLAM-, Ly108-, or Ly9-deficient mice, indicating that SLAM family members have 
overlapping functions in regulating Th2 cytokine production during T cell 
activation (Chapter 7) (34, 42, 43).  
 
      It has been well established that the genetic difference of mouse strains contributes to 
predisposition to the way in which immune responses are mounted. Th2-dominant 
responses are readily induced in the BALB/c mouse strain, whereas Th1-dominant 
responses are usually observed in C57BL/6 mice (45-47).  Since SLAM-, Ly108-, and 
Ly-9-deficient mouse strains are generated from 129 ES cells and backcrossed to 
C57BL/6 mice, there is the possibility that the defect in Th2 responses in SLAM-, Ly108-, 
and Ly9-deficicnt mice is due to mixed 129-C57BL/6 background. In our studies, 
however, the SLAM-deficient mouse strain was extensively backcrossed to C57BL/6 or 
BALB/c wild type. In both cases the resulting SLAM-deficient C57BL/6 and BALB/c 
mouse strains exhibited the same defect in Th2 responses in comparison to their 
littermates. Therefore, the possibility of the background-induced Th2 deficits can be 
excluded from the SLAM-deficient mice that we have generated. 
 
 
SAP independent signaling via SLAM-SLAM interaction 
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      As shown in Chapter 7, the deletion of the SLAM gene not only compromises Th2 
responses, but also leads to alterations in cytokine production by macrophages in SLAM-
deficient mice. Production of IL-12, TNF-�, and nitric oxide in response to LPS was 
diminished in SLAM-deficient peritoneal macrophages in vitro. By contrast, SLAM-
deficient macrophages have an increase in the level of IL-6 secretion with or without 
stimulation of LPS, which implicates that SLAM signaling negatively influences IL-6 
production and augments IL-12 and TNF-� secretion. Since the induction of IL-12, TNF-
� and nitric oxide can be achieved by engagement of other Toll-like receptors (TLRs) on 
macrophages, the question as to whether SLAM deficiency influences cytokine 
production was evaluated by triggering TLR2 and TLR 9 with peptidoglycan (PGN) and 
CpG, respectively. The cytokine production surprisingly was not reduced in SLAM-
deficient macrophages via TLR2 and TLR9 triggering. Upon binding of TLR ligands, all 
of the TLRs, except TLR3, recruit the adaptor molecule MyD88 through the TIR domain, 
activating the so-called MyD88-dependent pathway (48-49). MyD88 then recruits the IL-
1R-associated kinase (IRAK) 4, a serine-threonine kinase (50-51) and IRAK 1 (52-53). 
The mechanisms by which the engagement of TLR4 gives rise to alterations in cytokine 
production by SLAM-deficient macrophages are unclear at the present time. However, 
several potential mechanisms exist, such as interaction of SLAM and TLR4 at the cell 
surface upon LPS stimulation or the involvement of adaptor molecules linking SLAM to 
TLR4 signaling pathways. 
.  
      Upon experimental infection with Leishmania major (L. major), susceptible Balb/c 
mice develop progressive lesions and disseminated visceral disease resulting in death. 
Resistant mice (C57BL/6) are able to contain cutaneous infection and heal from their 
lesions. CD4+ T cells from infected BALB/c mice secrete high levels of IL-4 (54), 
whereas T cells from resistant strains characteristically produce IFN-� (45). In addition to 
Th1 or Th2 cytokines, effector molecules that are involved in macrophage activation and 
microbicidal response pathways contribute to immunity against L. major ( 55-56). To 
determine the in vivo effect of the absence of SLAM, we compared L. major infection in 
mice lacking SLAM on the C57BL/6 and BALB/C backgrounds. SLAM
-/-
C57BL/6 mice 
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such as SHP-2. On the basis of these observations, it is conceivable that 
SLAM/SAP/FynT signaling plays a crucial role in controlling Th2 cytokine productions. 
In agreement with the idea, the genetic deficiencies of SAP and FynT show a serious 
defect in Th2 cell responses (40-41). Furthermore, in the context of regulation of Th2 cell 
responses, the functional link between SLAM/SAP and FynT is strengthened by evidence 
from studying SAPR78A mice in which Arginine 78, a key residue for interaction between 
SAP and Fyn, is mutated to an Alanine in the germ line (41). In SAPR78A mice, SAP 
R78A is able to associated with SLAM in a manner that is similar to that seen in SAP, 
but the ability of SAP R78A to recruit FynT is abolished due to this key residue mutation. 
Not surprisingly, the ability of TCR stimulation to trigger Th2 cytokines in CD4+ T cells 
was markedly compromised in SAPR78A T cells. In addition, SAP-deficient and FynT-
deficient mice exhibit a much more severe defect in Th2 responses as compared with 
SLAM-, Ly108-, or Ly9-deficient mice, indicating that SLAM family members have 
overlapping functions in regulating Th2 cytokine production during T cell 
activation (Chapter 7) (34, 42, 43).  
 
      It has been well established that the genetic difference of mouse strains contributes to 
predisposition to the way in which immune responses are mounted. Th2-dominant 
responses are readily induced in the BALB/c mouse strain, whereas Th1-dominant 
responses are usually observed in C57BL/6 mice (45-47).  Since SLAM-, Ly108-, and 
Ly-9-deficient mouse strains are generated from 129 ES cells and backcrossed to 
C57BL/6 mice, there is the possibility that the defect in Th2 responses in SLAM-, Ly108-, 
and Ly9-deficicnt mice is due to mixed 129-C57BL/6 background. In our studies, 
however, the SLAM-deficient mouse strain was extensively backcrossed to C57BL/6 or 
BALB/c wild type. In both cases the resulting SLAM-deficient C57BL/6 and BALB/c 
mouse strains exhibited the same defect in Th2 responses in comparison to their 
littermates. Therefore, the possibility of the background-induced Th2 deficits can be 
excluded from the SLAM-deficient mice that we have generated. 
 
 
SAP independent signaling via SLAM-SLAM interaction 
 displayed susceptibility to infection with L. major in marked contrast to resistant wild-
type mice. This impaired ability to clear the parasite was confirmed by increased parasite 
titers in infected SLAM-deficient mice compared with wild-type mice (Chapter 7) (35). 
The inability of SLAM-deficient C57BL/6 to heal the L. major lesions is consistent with 
defective IL-12, TNF-�, and nitric oxide (NO) production by SLAM-deficient 
macrophages. The physiologic significance of IL-12 as an immunoregulatory protein has 
been amply demonstrated by its unique reversal of BALB/c susceptibility to progressive 
infection with L. major ( 57-58), because IL-12  not only initiates the development of a 
Th1 response, but also maintains a Th1 response once it has been established (59).  
Production of nitric oxide is involved in mediating parasite stasis or destruction by 
murine macrophages. Inhibition of nitric oxide production renders macrophages unable to 
restrict L. major replication in vitro (60, 61), and administration of nitric oxide inhibitors 
to otherwise resistant mice abrogates the capacity to control infection (62, 63). 
Furthermore, TNF-� enables activation of macrophages to a parasiticidal state, at least in 
part, by enhancing nitric oxide release (64, 65). Strikingly, SLAM-deficient BALB/c 
mice exhibited no alteration in their susceptibility to infection compared to wild-type 
control mice. In spite of the reduced in vitro IL-4 production by SLAM
-/- 
T cells, IL-4 
production by SLAM-deficient NKT cells is compatible to that of wild-type mice, which 
may lead to development of Th2 response to the parasite early in infection. Since the 
defect in IL-12, TNF-� and nitric oxide production was observed in macrophages from 
SLAM-deficient BALB/c mice, the deficit in SLAM
-/-
 macrophages should contribute to 
the sustained responses. By contrast, deficiency of SAP renders SAP-deficient BALB/c 
mice resistant to L. major infection because of the low level of IL-4 secretion and the 
functional macrophage. Thus, our data support a requirement for SLAM signaling in 
macrophages to provide the necessary factors such as cytokines to initiate killing of the 
parasites by infected macrophages. 
 
       Using a murine experimental model of asthma, we have also demonstrated that 
SLAM-deficient mice in the BALB/c background, primed with the model allergen 
ovalbumin and challenged through the airways with aerosolized antigen, are severely 
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impaired in their ability to generate both a Th2 response characterized by high levels of 
IL-4, IL-5, IL-13 and IgE and Th1 response (Chapter 8) (73). Moreover, SLAM-
deficient mice failed to develop airway hyperresponsiveness (AHR), tissue eosinophilia, 
and mucus metaplasia (Chapter 8) (73). IL-4, IL-5 and IL-13 produced by Th2 cells 
have been postulated to have central roles in the initiation and maintenance of allergic 
inflammation (66). In line with those findings, the defect in the Th2 response may 
contribute to the lack of the cardinal features of asthma in SLAM-deficient mice. 
However, in contrast to what is found in SLAM-deficient mice, Ovalbumin-sensitized 
SAP-deficient mice develop the airway inflammation and AHR of allergic asthma despite 
secreting low levels of Th2 cytokines (Wang et al unpublished data), which indicates that 
Th2 cytokines are not sufficient to induce allergic asthma. Therefore, alterations in 
factors controlling expansion of the opposing Th1 pathway may also play an important 
role. In this regard, IL-12 secreted by macrophages and other APCs is the primary 
determinant of T cell differentiation to a Th1 pattern (67), as indicated by the evidence 
that the blockade of endogenous production of IL-12 in naturally resistant murine 
stains (C3H/HeJ) renders them susceptible to the development of allergen-induced AHR 
and eosinophilic inflammation (68). Given that impairment of IL-12 and TNF-� 
production by SLAM-deficient macrophages exists, we speculate that the defect of 
SLAM
-/-
 macrophages may also be involved in the absence of allergen-induced AHR. 
Taken together, these results demonstrate that SLAM signaling regulates allergic 
responses by a SAP-independent mechanism. 
 
FUTURE DIRECTION: where to go next? 
 
     The thymus is indispensable for T cell development. As thymocytes mature, they 
move from the outer cortex to the medulla, where they undergo a series of differentiation, 
expansion and selection events. Eventually, CD4
-
CD8
-
 double negative thymocytes can 
undergo either apoptosis or further differentiation to CD4+ or CD8+ single positive T 
cells, depending on the nature of the interaction with intrathymic selecting ligand. 
Although there is growing evidence that growth factors and cytokines as well as direct 
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 cell-cell contact may play a role in this process, a full understanding of how thymus 
microenvironment effects the development of lymphocyte in lymphostromal interaction 
is still lacking. 
     The stoichiometry of the TCR has yet to be determined. The present consensus on the 
composition of the TCR/CD3 complex is that it comprises the TCR��, CD3��, CD3�� 
and CD3�� dimers. The minimal stoichoimetry possible is therefore ��������. There are 
two major competing models concerning the stoichoimetry: monovalent TCR/CD3 
complexes vs multivalent TCR/CD3 complex. The controversy over the TCR/CD3 
stoichiometry can be explained by the effects of different detergents on the integrity of 
the receptor. Thus, a final conclusion will be made by combining advanced biochemical 
methods using different detergents in combination with non-invasive techniques.  
In addition to elucidating the structural organization of the TCR with the associated 
CD3 signaling molecules, many major challenges  remain in T-cell biology, including 1) 
defining how signaling specificity is directed by TCRs and pre-TCRs during T cell 
selection; 2) understading how ��/��-TCR lineage fate is ultimately decided in immature 
thymocytes and what role TCR signaling plays in this decision; 3) determining if 
different thymocyte subsets use distinct sets of signaling transduction molecules and if 
these relate to different stages of development  or functional roles during the immune 
responses; and 4) clarifying how the signal transduction events through TCR-CD3 
complex is networked with signal transduction through all of the auxiliary activation 
structures and adhesion molecules.  
During the past decade, the studies using transgenic and gene knockout mice have 
provided us with increasing knowledge of the signaling mechanisms involved in T cell 
development and activation. These studies underscore the essential roles played by gene 
knockout technology in contemporary biology, specifically, in dissecting the precise 
physiological roles of various genes in key signaling molecules in T cell differentiation 
and function. However, other barriers remain because the same signaling molecules may 
be important at different checkpoints and therefore the outcomes of the targeted genes 
generally reflect only the roles they play at one time point during T cell differentiation 
and activation. Moreover, if certain molecule functions as inhibitor in one signaling 
pathway and, as activator in other signaling pathway, it is impossible to give whole 
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 picture of function for this gene. In future studies of T cell development and activation, 
therefore, tissue-specific conditional knockout, knockin or transgenic technology can be 
used as alternative, in which the gene of interest can be labeled to clarify its expression 
pattern, replaced with a related gene to study the effect of subtle variations between 
genes, or altered to mimic the mutations that lead to a gain or change of functions. 
Undoubtedly, future knockout and knockin mice will prove useful for identifying novel 
mechanisms for T cell development and function. 
 
 
     The accumulated data have indicated that an important role is played by SLAM and 
SAP families in multiple cell types that participate in the immune response. There are 
still many open questions concerning the function of SAP, EAT-2, and SLAM receptors 
and their role in the pathogenesis of XLP. Why XLP patients properly control most other 
viral infections but are susceptible to the EBV? What are the molecular and cellular 
underpinnings that render XLP patients prone to lymphomas? In addition to these 
unanswered issues a better definition of the signaling pathways in which SAP participates 
is necessary. SAP involvement in regulation of T-cell proliferation, cytokine production, 
differentiation and apoptosis awaits a better definition. Understanding of the molecular 
mechanisms responsible for impaired Th2 differentiation in the absence of SAP and 
SLAM family members therefore is also required.  
       Little is also known about the function of most of the SLAM receptors and related 
SAP-dependent and independent down-stream signaling events. The characterization of 
SLAM receptor knockout mice should help to clarify their role in antiviral responses and 
other immune functions. Primary data from our laboratory show that SLAM family 
members, although redundant, might play a selective role in the regulation of 
immunoglobulin production and B cell responses. A precise dissection of the functions of 
the members of the SLAM family will be required to further understand their role in 
innate and acquired immune defenses. Moreover, SLAM receptors might play an 
inhibitory role in immune responses as they contain ITIM-like SH2-docking motifs.  
      Fine mapping of the Sle1 locus determined that 3 loci within this congenic interval, 
termed Sle1a, Sle1b, and Sle1c, could independently cause a loss of tolerance to 
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 chromatin, a necessary step for full disease induction. The Sle1b region includes the 
SLAM-family locus and, interestingly, the Sle1a region contains the two genes, which 
encode the SLAM-family-receptor specific adapters EAT-2A and EAT-2B. Therefore, 
SLAM genes and EAT2 might be involved in the predisposition toward lupus and 
autoimmunity. In the future mice lacking multiple SLAM family gene or SLAM family 
locus would be generated to examine whether seven SLAM-family genes affect pathways 
that contribute to tolerance to chromatin, 
      NKT cells constitute a lymphocyte subpopulation that is abundant in the thymus, 
spleen, liver and bone marrow. NKT cells express surface markers that are characteristic 
of both natural killer cells and conventional T cells. It has been proposed that NKT cells 
might be important for the initiation and the regulation of immune responses by 
interplaying with innate and adaptive immune responses. In the absence of SAP, the 
development of NKT cells is severely impaired both in mice and in humans (74-75). Mice 
deficient in SLAM and Ly108 also display a defect in NKT cells, and not in NK cells 
(76). The effect of SAP-deficiency on NKT cell development is dramatic, whereas the 
reduction of NKT cell in SLAM or Ly108 mutant mice or even SLAM/Ly108 double 
mutant chimeras is not complete, suggesting other SLAM family members are involved 
in NKT cell development. Therefore, the generation of real SLAM/Ly108 double, 
SLAM/CD84/Ly108 triple or whole SLAM family knockout mice will reveal a possible 
role of SLAM family members in NKT cell functions. Such experiments are under way 
in our laboratory. 
     Two molecules, SLAM and CD46 have been identified as receptors for measles virus. 
Overwhelming data now indicate that SLAM acts as the principal cellular receptor for 
measles virus in vivo. Interesting questions would rise: does measles virus infection 
affect SLAM signaling? How do measles virus encoded proteins interact with SLAM? 
The 3D structures of measles virus H protein and SLAM, separately or combined, should 
be determined. These 3D structures will provide the necessary framework for the design 
of small therapeutic molecules which interfere in virus-receptor interaction. 
      Finally, as EAT-2 seems to regulate SLAM receptor signaling in APCs and NK cells, 
the generation of animal models in which the EAT-2A, EAT2B, EAT2A/B genes are 
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 either deleted or over-expressed might unravel important contributions of their products 
in the immune response mediated by APC and NK cells.  
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                                  SUMMARY 

Interplay of the T cell receptor/CD3 complex and the 
co-stimulatory molecule SLAM in immune responses 
SUMMARY
      The immune system is our defense against the outside world. It is formed by a highly 
complex interplay of different cell types and molecules that as a whole enable the body to 
fight constant external threats. Two main arms with extensive interaction define the 
system: the innate and the adaptive immune response. T cells are responsible for the cell-
mediated immune responses in adaptive immunity. T cells recognize antigen in the 
context of MHC molecules presented by professional APCs. Antigen specificity is 
defined by the T cell receptor. The T cell receptor is a multimeric complex composed of 
the antigen specific subunits, TCR-? and ? (or the related TCR-? and -?) and six 
noncovalently associated signaling subunits, CD3-??, CD3-?? and CD3-??. All of the 
TCR subunits are the products of distinct genes that are assembled in a highly 
orchestrated fashion.
     T cell development can be categorized through the phenotype of their surface markers 
CD25, CD44, TCR, CD4 and CD8, which are sequentially expressed. These markers 
indicate the progress from the double negative (DN, CD4-CD8-) stages DN1 to DN4, 
then become double positive (DP, CD4+CD8+) and select finally a single positive fate 
(SP, CD4+ or CD8+) before emigrating from the thymus. A feature common to all of the 
TCR invariant signaling subunits is the presence of one or more copies of conserved 
amino acid sequence motif termed immune receptor tyrosine-based activation motif 
(ITAM). In the ITAM two tyrosine residues are surrounded by a series of semi conserved 
amino acids and are separated by 6-8 amino acids (YxxLx6-8L). The phosphorylation of 
both tyrosine residues located within the ITAMs upon stimulation of the TCR initiates 
the well characterized signaling cascade in T cells. CD3-?, -? and ñ ? each contain one 
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ITAM, and CD3-? homodimer contains 6 of the 10 ITAMs present in the TCR/CD3 
complex. For this reason, it is widely believed that the CD3-? chain is the most important 
signaling component of the TCR/CD3 complex. 
      Based on these findings, we went to dissect the individual roles of CD3 components 
in vivo by generating mutant mice that either lack specific CD3 subunits entirely or 
express human CD3 transgenes in the CD3-deficient mice models. Since CD3-? and 
CD3-? genes are located only 1.4 Kb in mouse from one another in the mouse, which are 
organized in a head-to-head configuration, we take the advantage of deleting the first 
exons of both the CD3-? and CD3-? genes by the same targeting construct (Chapter 2).
The absence of CD3-? and CD3-? resulted in severe defect in the T cell development. 
Total cellularity of the thymi of CD3-??-deficient mice was 2-5% of that in wild-type 
mice. TCR-?? T cell development is blocked at the same DN 3 (CD4-CD8-CD44-CD25+)
check point as in Rag-deficient mice. Despite normal development and germline 
rearrangement of TCR-?, TCR-? and -? loci, the lack of CD3-?? in thymocytes prohibited 
surface expression of the pre-TCR and early ?? TCR complex. In contrast to the single 
deficienct CD3-? or CD3-? mice, CD3-??-deficient mice exhibit a complete block in ?? T 
cell development. Thus, these studies indicated that CD3-? and CD3-? pay a critical, yet 
partially overlapping, role in the development both ?? and ?? T cell lineages. 
      It appears that CD3-? chain plays a differential biological role in T cell development 
between human and mouse as CD3-?-deficient murine models fail to recapitulate human 
CD3-? immunodeficiency. Early blockage of T cell development was observed in CD3-?-
deficient mice, whereas humans lacking CD3-? exhibits a mild ?? T lymphopenia, which 
suggests that highly homologous CD3-? and CD3-? genes might replace each other in the 
human TCR/CD3 complex.  To prove the hypothesis, the CD3-??-deficient mice were 
crossbred with human CD3-? transgenic mice (Chapter 3). Unexpectedly, the resulting 
mutant mouse strain, ??- x h?Tg, shows a phenotype similar to that of CD3-?-deficient
patients. The expression of human CD3-? chain efficiently supports pre-TCR-mediated 
progression from the DN to the CD4+CD8+ double-positive stages. However, ??TCR-
mediated positive and negative selection was less efficient in ??- x h?Tg mice than in 
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wild-type mice. The further studies exhibit the impairments in TCR-initiated signal 
strength in regulating positive or negative selection in ??- x h?Tg thymocytes. In addition, 
direct support for a unique role for human CD3-? gene in ??- x h?Tg mice has been 
provided by the observation that the development and function of CD3-??-deficient T 
cells were not restored when the CD3-??-deficient mice were reconstituted with a mouse 
CD3-? transgene.  These findings, therefore, demonstrate that CD3-? and CD3-? play a 
different role in human and mice in pre-TCR and TCR function during T-cell 
development. 
       The CD3-? subunit is required for early T cell development, as its targeted deletion 
arrests development at the DN 3 stage. T cell development in the CD3-?-deficient mice 
was blocked prior to the completion of TCR-? selection, leaving thymocytes unable to 
express the pre-TCR on the cell surface. Since the CD3? subunit associated with the 
CD3-? and ñ ? during TCR assembly, it is not surprising that assembly and surface 
expression of the entire TCR complex would be disrupted by elimination of CD3-?.
However, our CD3-?-deficient mice display a complex disruption of CD3-? and CD3-?
expression, which makes it difficult to evaluate a role of CD3-? gene alone in T cell 
development (Chapter 4 and Chapter 5). On the other hand, the unexpected disruption 
of CD3-? and CD3-? raises question as to whether CD3-? gene regulates CD3-? and 
CD3-? expression or insertion of PGK-Neo cassette in targeted locus affects the 
expression of CD3-? gene and CD3-? gene. For this reason, we introduced a full length 
human CD3-? gene into the CD3-?-deficient mice. The reconstitution of CD3-?null mice 
(CD3?-/-x hTg? ) with the human CD3-? transgene did not restore CD3-? and CD3-?
expression (Chapter 5). The thymic phenotype of CD3?-/-x hTg? mice still resembles 
very much that of CD3-?-deficient mice. However, an impressive finding is that a very 
small population of prothymocytes expressing CD3-? and CD3-? from CD3?-/-x hTg?
mice is able to overcome first checkpoint (transition from CD44-CD25+ to CD44-CD25-)
and progress to CD4+CD8+ or SP thymocytes, which eventually lead to a significant T 
cell population in the periphery. Taken together, our studies demonstrate that CD3-? does 
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not regulate CD3-? and CD3-? expression and the severe suppression of CD3-? and CD3-
? expression in CD3-?-deficient mice is most likely due to PGK-Neo affection. 
      It is clear that CD3-?, -?, -?, and ñ ? chains, as invariant subunits of pre-TCR-?? and 
TCRs, are crucial for assembly of TCR/CD3 complex, but how the integration of the 
signals from  four individual CD3 proteins affect  pre-T cell development remains to be 
elucidated. Because the insertion of PGK-Neo cassette in CD3-? locus  abolished CD3-?
expression and almost completely suppressed CD3-? expression in CD3-?-deficient mice 
(Chapter 5), the breeding of this mouse strain with CD3-?-deficient mice generated 
CD3-????-deficient mouse strain (Chapter 4). In de facto CD3-????-deficient mice, 
thymopoiesis were arrested at the CD44-CD25+DN stage as observed in RAG-deficeint 
mice. The fact that thymocytes found in the CD3-????-deficient mice are capable of 
reaching a stage during which TCR-? gene rearrangements normally happen led us to 
determine the impact of the CD3-???? mutation on the occurrence of TCR-? gene 
rearrangement. Using a DNA-PCR assay, we showed that the absence of de facto CD3 
polypeptides had no measureable effect on the extent of both D? to J? and V? to D?J?
rearrangement. Thus, these studies demonstrate that CD3 complex collectively is required 
for the transition from DN2 (CD44+CD25+) to DN3 (CD44-CD25+) in T cell 
development, but they appear to be dispensable for earlier thymocyte development prior 
to DN2 thymocytes. 
      T cell immune responses are initiated at peripheral tissues where immunogenic 
peptides bound to MHC molecules are presented on the surface of professional APC as 
antigen. The MHC molecule hereby gets into close contact with the T cell receptor (TCR). 
This interaction (signal 1) leads to T cell activation by the initiation of a multistep 
intracellular signaling pathway. In addition to the signal delivered by the TCR-
MHC:peptide, a second signal (signal 2) provided by costimulatory  molecules is 
required for full T cell activation. The first signal provides antigen specificity and is 
necessary but not sufficient to induce complete T cell activation. For complete and 
sustained activation the costimulatory signal is required. The second signal is antigen 
independent and can be generated by a number of distinct molecular interactions that 
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occur at the APC-T cell interface. There is now a large of number of T cell costimulatory 
molecules, with distinct and overlapping function. One of the current challenges in this 
area is to understand the functions of each of these T cell costimulatory pathways. 
Costimulation is provide by three major families: the B7:CD28 superfamily, a 
TNF:TNFR subfamily that lack death domains, and the CD2 superfamily, as well as 
some integrins.  
      Costimulatory receptors of the SLAM family belong to the CD2 subset of the Ig 
superfamily, which function in the immune synapse between T cells and antigen-
presenting cells. The nine members of the SLAM family (SLAM, CD48, CD229, CD244, 
CD84. Ly108/NTB-A, CD319, SLAM8, and SLAM9) have been identified in 
hematopoietic cells. The cytoplasmic tails of six of these receptors carry one or more 
copies of a unique intracellular tyrosine-based switch motif (ITSM), which has a high 
affinity for the single SH2-domain signaling molecules SLAM-associated protein (SAP) 
and EAT-2 (EWS/FLI activated transcript-2). The notion that SLAM-family receptors 
operate as co-stimulatory molecules was initially based upon the function in T cell 
activation ascribed to the cell-surface receptor SLAM and its association with the adaptor 
SAP. SAP/EAT2-dependent and ñ independent recruitment of intracellular molecules 
leads to the inhibitory and stimulatory signals, which ensure upon engagement of these 
receptors. Integration of signaling networks determine the outcome of several effector 
functions depending on the cell type and state of activation. In this thesis, our studies 
have focused on SLAM (CD150) that is a prototypic molecule in the SLAM family. 
      The SLAM-family genes are located on chromosome 1 in human and mice; seven of 
the genes are located in a contiguous ~400kb fragment in both mouse and human 
chromosome 1. In Chapter 6, we characterized the mouse and human SLAM genes, each 
of which comprises seven exons spanning approximately 32 Kb. Mouse SLAM are 
expressed in thymoytes, memory CD4+ and CD8+ T cells. High levels of SLAM were 
found in Th1 cells and only small amounts of SLAM are detected in Th2 cells. Whereas 
expression of mouse SLAM is the highest on double positive (CD4+CD8+) thymocytes, 
single positive T cells express low levels of the receptor. Like in the human, mouse 
SLAM is rapidly up-regulated upon activation of peripheral T cells (Chapter 6).
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      SLAM demonstrates homotypic binding and functions as costimulatory molecule.  
Initial studies showed that treatment of anti-SLAM mAb enhanced IFN-? production by 
human T cells and redirected Th2 cells to a Th0/Th1 phenotype, but did not affect Th2 
cytokine secretion, suggesting an important role of SLAM in the Th1 cell differentiation. 
The striking finding that SAP with high affinity binds to the first phosphorylated or 
nonphosphorylated ITSM of the cytoplasmic tail of SLAM implies that SAP is involved 
in the SLAM-mediated signaling. However, the observation that SAP-deficient mice 
exhibit the severe defect in the Th2 cytokine production raises the possibility that SLAM 
positively regulates Th2 differentiation instead of Th1 differentiation. Consistent with 
this idea, the analysis of SLAM-deficient mice reveals that the levels of Th2 cytokine 
expression (IL-4 and IL-13) are low or barely detectable in response to triggering of the 
T-cell receptor (Chapter 7). This defect in IL-4 production is also evident from 
stimulation studies of antigen-specific TCR-transgenic T cells with APCs and peptides. 
In contrast to the effect of anti-mSLAM mAb on the induction of IFN-?, the deficiency in 
SLAM only marginally affects the capacity of polarized Th1 cells to enhance IFN-?
production. Therefore, the evidence that SAP recruits FynT to SLAM and the individual 
mutation of SLAM, SAP or FynT leads to the defect in the Th2 cytokines supports that 
SLAM/SAP/FynT signaling pathway plays a critical  role in controlling Th2 
differentiation.
      Clearly, as SLAM is widely expressed on hematopoietic cells in human and mouse, it 
is most likely that its immune regulation is not just limited to T cells. As expected, severe 
impairment in the production of IL-12, TNF-? and nitric oxide was observed in SLAM-
deficient macrophages in response to LPS (Chapter 7). To confirm if SLAM deficiency 
results in the alteration in T cell differentiation and macrophage function in vivo, SLAM-
deficient mice were infected with Leishmania major (L. major). This is one of well-
established models to study the differential development of CD4+ T helper cell subsets 
(Th1 and Th2) and macrophage functions. We compared L. major infection in mice 
lacking SLAM on the C57BL/6 and BALB/C backgrounds. SLAM-/-C57BL/6 mice 
displayed susceptibility to infection with L. major in marked contrast to resistant wild-
type mice. This impaired ability to clear the parasites was confirmed by increased 
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parasite titers in infected SLAM-deficient mice compared with wild-type mice (Chapter
7). The inability of SLAM-deficient C57BL/6 to heal the L. major lesions is consistent 
with defective IL-12, TNF-?, and nitric oxide (NO) production by SLAM-deficient 
macrophages. 
      T-helper type 2 (Th2)-derived cytokines such as IL-4, IL-5, IL-9 and IL-13 play an 
important role in the synthesis of IgE and in the promotion of allergic eosinophilic 
inflammation and airway wall remodeling. Based on the deviation of CD4+ SLAM-
deficient T cell response, I determined the importance of SLAM in allergic inflammation 
in a murine model (Chapter 8). The SLAM-deficient mice and their BALB/c wild-type 
counterparts were sensitized and repeatedly exposed to ovalbumin (OVA) aerosol. After 
three challenges with the OVA antigen, the mice were assessed for airway 
hyperresponsiveness (AHR) and inflammation. It was found that SLAM-deficient mice 
had significantly decreased AHR in OVA-immunized mice. Allergen-induced Th2 and 
Th1 cytokines were decreased in SLAM-deficient mice. These results suggest that the 
deficiency in SLAM strongly attenuates antigen-induced airway inflammation and hyper-
responsiveness in mice. 
     The results contained within this thesis have contributed to an increasing 
understanding of the role of the CD3 components in the TCR/CD3 complex in early T 
cell development as well as further defining the critical role of SLAM in T cell activation 
and macrophage function. We hope that our work will contribute to development of 
specific therapies for diseases such as XLP, measles virus infection and SLE, in which 
SAP/EAT-dependent or ñ independent SLAM signaling may involve. 
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Samenvatting

Samenspel tussen het T cel receptor/CD3 complex en de 
co-stimulator SLAM voor immuunreacties. 
Samenvatting
 Het immuunsysteem beschermt ons tegen de buitenwereld. Het bestaat uit een complexe 
samenhang van cellen en eiwitten die gezamenlijk het lichaam beschermen tegen 
lichaamsvreemde dreigingen. Twee belangrijke en sterk verweven onderdelen van het 
immuunsysteem worden gevormd door de zogenaamde aangeboren en adaptieve 
immuunrespons. Binnen de adaptieve immuunrespons vormen T cellen een belangrijke 
functie. Deze cellen herkennen specifieke antigenen wanneer die door MHC moleculen 
op antigeen presenterende cellen (APC) worden aangeboden. De specificiteit van T cellen 
wordt bepaald door hun T cel receptor (TCR), die bestaat uit verschillende onderdelen: de 
variabele TCR-? en -? (of TCR-? en -?) ketens die het antigeen herkennen, en de 
constante niet-covalent gebonden signaaleiwitten CD3-??, CD3-?? en CD3-??. Al deze 
TCR onderdelen worden gecodeerd door verschillende genen en worden op specifieke 
wijze geassembleerd. 
 De ontwikkeling van T cellen kan worden opgedeeld in stadia die herkend worden door 
de opeenvolgende expressie van een aantal oppervlakte-eiwitten: CD25, CD44, TCR, 
CD4 en CD8. Zij markeren allereerst de dubbel negatieve (DN, CD4-CD8-) stadia DN1 
tot DN4, gevolgd door een dubbel positief (DP, CD4+CD8+) stadium, om tenslotte te 
eindigen als danwel CD4 of CD8 enkel positieve T cellen die vervolgens uit de thymus 
het lichaam ingaan. Een eigenschap van de constante TCR onderdelen CD3-??, CD3-??
en CD3-?? is dat zij alle een of meerdere copieen van een geconserveerd aminozuur 
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motief in zich dragen dat immuunreceptor tyrosine-gebaseerd activatie motief (ITAM) 
wordt genoemd. In dit ITAM motief worden twee tyrosine aminozuren omringd door 
semi-geconserveerde aminozuren die 6-8 posities van elkaar verwijderd zijn (YxxLx6-
8L). Wanneer de TCR wordt gestimuleerd leidt dat to fosforylering van deze tyrosine 
residuen in het ITAM motief, wat vervolgens een cascade van signalen in de T cel 
teweegbrengt. CD3-?, -? and ñ ? hebben ieder een ITAM motief, terwijl de CD3-?
homodimeer 6 van de 10 ITAMs in het hele TCR/CD3 complex heeft. Hierom wordt 
CD3-? als het belangrijkste signalerende onderdeel van het TCR/CD3 complex 
beschouwd.
Met deze kennis zijn we begonnen om de eigenschappen van de verscshillende CD3 
componenten in vivo te ontrafelen. Hiertoe hebben we muizen gemaakt die de CD3 
componenten missen en transgene muizen waarin de muizen CD3 eiwitten zijn 
vervangen door de betreffende humane CD3 ketens. Omdat de CD3-? en CD3-? genen op 
slechts 1.4Kb van elkaar liggen in het muizengenoom konden we beide genen samen 
verwijderen met slechts È È n gen deletie construct (Hoofdstuk 2). De afwezigheid van 
zowel CD3-? als CD3-? leidde tot ingrijpende defecten in T cel ontwikkeling. The 
thymus van deze muizen bevat slechts 2-5% van het aantal cellen dat wordt gevonden in 
normale muizen, en TCR-?? T cellen kunnen zich niet verder ontwikkelen dan het DN3
(CD4-CD8-CD44-CD25+) stadium waar ook RAG-deficiente muizen niet voorbij komen. 
Ondanks de normale ontwikkeling en herschikking van de TCR-?, -? and -? loci kan het 
pre-TCR en ?? TCR complex niet aan de oppervlakte van thymocyten komen vanwege 
het ontbreken van CD3-?? in deze cellen. In tegenstelling tot muizen die alleen CD3-? of 
CD3-? missen hebben onze CD3-?? deficiente muizen geen enkele TCR-?? T cellen. Het 
lijkt er dus op dat CD3-? en CD3-? essentiele functies hebben voor zowel TCR-?? als 
TCR-?? T cel ontwikkeling die slechts gedeeltelijk door elklaar gecompenseerd kunnen 
worden.
Er lijkt een verschil te bestaan tussen mens en muis in de biologische functie van CD3-?
voor T cel ontwikkeling: CD3-? deficiente muizen hebben een ander fenotype dan 
mensen die een mutatie in dit gen dragen. In de muis wordt een vroege blokkade in T cel 
ontwikkeling gevonden terwijl mensen slechts een milde lymfopenie voor ?? T cellen 
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hebben. Dit suggereert dat in het menselijke TCR/CD3 complex er uitwisselbare functies 
bestaan voor CD3-? en -?. Om deze hypothese te testen hebben we in Hoofdstuk 3 onze 
CD3-?? muizen gekruisd met muizen die een humaan CD3-? transgen hebben. Deze ?? ?
h?Tg muizen hebben verassenderwijs hetzelfde fenotype als patienten met een mutatie in 
CD3-?. De expressie van humaan CD3-? is in staat om pre-TCR gedreven ontwikkeling 
van het DN naar het CD4+CD8+ DP stadium te bewerkstelligen. Edoch is de ??TCR
gedreven positieve en negatieve selectie minder efficient in deze ?? ? h?Tg muizen dan 
in normale muizen. Dit hebben we verder uitgewerkt in studies die de TCR-geinitieerde 
signalen in thymocyten van ?? ? h?Tg muizen onderzocht. Verder is duidelijk geworden 
dat humaan CD3-? een unieke rol vervult want zowel de ontwikkeling als functie van 
CD3-?? deficiente T cellen kon niet worden hersteld wanneer deze een muis CD3-?
transgen in zich droegen. Wij concluderen uit deze studies dat CD3-? en CD3-?
verschillende rollen vervullen in mens en muis voor de pre-TCR en TCR functie 
gedurende T cel ontwikkeling.  
Het CD3-? eiwit is ook essentieel voor T cel ontwikkeling want deletie van dit gen leidt 
tot een blokkade in T cel ontwikkeling in het DN3 stadium. Daar deze blokkade 
plaatsvindt voordat de TCR-? geselecteerd is zijn thymocyten in de CD3-? deficiente 
muis niet in staat een pre-TCR aan hun oppervlakte te brengen. Omdat CD3-? zich 
associeert met CD3-? en -? is het niet onverwacht dat de afwezigheid van CD3-? de 
expressie van het gehele TCR complex verhindert. Maar onze CD3-? muis heeft ook een 
complexe incomplete expressie van CD3-? en -?, wat analyse van de specifieke rol voor 
CD3-? compliceert (Hoofdstuk 4 en 5). Deze onverwachte veranderingen in CD3-? en -?
wekken de vraag op of ze een gevolg zijn van het gebrek aan CD3-? of een neveneffect 
van de insertie van de PKG-Neo cassette in een locus die de expressie van CD3-? en -?
reguleert. Om dit uit te zoeken hebben we het volle humane CD3-? transgen in de CD3-?
deficiente muis ingebracht. De reconstitutie van CD3-? deficiente muizen met het 
humane transgen (CD3?-/-? hTg? ) kon expressie van CD3-? en -? niet herstellen 
(Hoofdstuk 5). De thymocyten in deze CD3?-/-? hTg? muis lijken erg op thymocyten in 
de CD3-? deficiente muis. Een verschil tussen deze twee muis lijnen  is dat in CD3?-/-?
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hTg? muizen er een kleine groep prothymocyten, die CD3-? en -?  tot expressie brengen, 
in staat bleek het eerste stadium (van CD44-CD25+ naar CD44-CD25-) te passeren naar 
het CD4+CD8+ DP en het SP stadium, en uiteindelijk zelfs een significante populatie 
volwassen T cellen in de periferie kon genereren.  Deze resultaten leidden ons tot de 
conclusie dat CD3-? de expressie van CD3-? en -? niet reguleert en het gebrek van deze 
eiwitten in de CD3-? deficiente muis een bijwerking van de PKC-Neo cassette is.
Het is een feit dat CD3-?, -?, -?, en ñ ? ketens, de invariable onderdelen van de pre-TCR-
?? en TCR, essentieel zijn voor de assemblage van het TCR/CD3 complex maar hoe de 
signalen van deze vier ketens precies geintegreerd worden en de ontwikkeling van T 
cellen beinvloedt moet verder worden uitgezocht. Omdat de insertie van de PGK-Neo
cassette in de CD3-? deficiente muis tot complete suppressie van CD3-? en lage 
expressie van CD3-? leidde is het niet verrassend dat na kruising van de CD3-? en -?
deficiente muizen allevier de CD3 ketens niet tot expressie kwamen (Hoofdstuk 4). De 
thymus ontwikkeling in deze, de facto CD3-???? deficiente muis kwam tot stilstand in 
het CD44-CD25+DN stadium vergelijkbaar met de RAG deficiente muis. Omdat in dit 
stadium TCR-? genen-herschikking kan plaatsvinden wilden we dit proces onderzoeken 
in onze CD3-???? deficiente muizen. Met behulp van een DNA-PCR methode toonden 
we aan dat de afwezigheid van de CD3 ketens een meetbaar effect had op de D? naar J?
en de V? naar D?J? herschikking. Deze studies laten zien dat het CD3 complex vereist is 
voor de thymocyt ontwikkeling van DN2 (CD44+CD25+) naar DN3 (CD44-CD25+) maar 
niet vereist voor het stadium tot aan DN2.  
De immuunrespons door T cellen worden geinitieerd wanneer hen immunogene peptiden, 
gebonden aan MHC, worden gepresenteerd door professionele antigeen presenterende 
cellen (APC). Het MHC molecuul moet hiervoor in contact komen met de TCR. Dit 
contact (signaal 1) leidt tot T cel activatie via een stapswijze initiatie van intracellulaire 
signaaleiwitten. Naast signaal 1 via de TCR is voor activatie een tweede signaal nodig dat 
wordt gegeven door een co-stimulatoir molecuul. Signaal 1 geeft de activatie specificiteit 
maar is niet afdoende voor volledige T cel activatie, en een co-stimulatoir signaal is 
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nodig om T cellen compleet en duurzaam te activeren. Dit co-stimulatoire signaal is niet 
antigeen-specifiek en kan door verschillende signaalmoleculen op de APC worden 
gegeven. Er is een grote verscheidenheid aan signaalmoleculen die verschillende maar 
ook gemeenschappelijke eigenschappen bezitten. Het ontrafelen van de precieze functies 
van deze moleculen vormt een grote uitdaging. Er zijn drie families van co-stimulatoire 
eiwitten: de B7:CD28 superfamilie, de TNF:TNFR familieleden zonder doodsdomein, en 
de CD2 superfamilie. Verder hebben sommige integrines ook co-stimulatoire 
eigenschappen 
 De co-stimulatoire receptoren van de SLAM familie behoren tot de CD2 groep van de Ig 
superfamilie, en hebben een functie in de synapse die T cellen en APC kunnen vormen. 
Negen familieleden van SLAM zijn geidentificeerd op hemotopoietische cellen: SLAM, 
CD48, CD229, CD244, CD84, Ly108/NTB-A, CD319, SLAM8 en SLAM9. Het 
cytoplasmatische deel van 6 van deze receptoren bevatten een zogenaamd ë intracellular
tyrosine-based switch motif (ITSM), welk een hoge affiniteit heeft voor de signaal 
eiwitten SLAM-associated protein (SAP) en EWS/FLI activated transcript-2 (EAT2) die 
elk een enkel SH2 domein hebben. Het besef dat SLAM een co-stimuatoir eiwit was 
kwam aanvankelijk uit obersvaties dat SLAM T cellen kon activeren en zich assosieerde 
met SAP. SAP/EAT2 afhankelijke en onafhankelijke werving van intracellulaire 
moleculen leidt tot remmende en activerende signalen zodra deze familie van receptoren 
wordt geactiveerd. Vervolgens bepaalt de integratie van verschillende signaal netwerken 
welke effector functies worden uitgevoerd, wat afhankelijk is van het celtype en hun 
stadium van activatie. In dit proefschrift hebben we ons toegelegd op het bestuderen van 
SLAM, de prototypische receptor van deze familie 
De genen voor de SLAM familie liggen zowel in mens als muis op chromosoom 1, en 
zeven genen van deze familie liggen binnen een 400Kb gebied. In Hoofdstuk 6
beschrijven we de SLAM genen in mens en muis, die beide uit zeven exons bestaan 
uitgespreid over ongeveer 32Kb. In de muis komt SLAM tot expressie in thymocyten en 
zowel geheugen CD4+ als CD8+ T cellen. T helper 1 (Th1) cellen brengen veel SLAM tot 
expressie en Th2 cellen slechts weinig, CD4+CD8+ DP thymocyten veel en SP 
thymocyten weinig. SLAM wordt in muizen, net als in humane, T cellen snel 
opgereguleerd wanneer deze cellen geactiveerd worden.
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 SLAM bindt zichzelf, een zogenaamde homotypische binding, en is zoals vermeld een 
co-stimulatoire receptor. Vroege studies lieten zien dat een anti-SLAM antilichaam 
humane T cellen kon aanzetten tot IFN? productie en Th2 cellen naar een Th0/Th1 
fenotype kon terugbrengen. Anti-SLAM had geen effect op Th2 cytokine productie, wat 
tezamen een rol suggereerde voor Th1 differentiatie. Omdat SAP met hoge affiniteit 
bindt aan de eerste gefosforyleerde of ongefosforyleerde ITSM van het cytoplasmatische 
deel van SLAM lijkt SAP een rol te spelen in de signalerende rol van SLAM. Echter, 
SAP deficiente muizen hebben een defect in Th2 cytokine productie en dit lijkt aan te 
geven dat SLAM mogelijk een positief signaal geeft voor Th2 differentiatie in plaats van 
Th1 differentiatie. Hiermee in overeenstemming vonden wij dat T cellen van SLAM 
deficiente muizen  nauwelijks tot geen Th2 cytokinene (IL-4 en IL-13) kunnen 
produceren wanneer de TCR wordt geactiveerd (Hoofdstuk 7). Deze deficientie in IL-4 
productie kon worden bevestigd met antigeen-specifieke TCR transgene T cellen, APC 
en het betreffende peptide. En in tegenstelling to anti-SLAM antilichamen die IFN?
induceerden konden SLAM deficiente Th1 cellen nagenoeg evenveel IFN? produceren 
als normale T cellen.  Deze bevindingen, het feit dat SAP het eiwit FynT naar SLAM 
recruteert en de wetenschap dat mutaties in SLAM, SAP en FynT alle leiden tot 
defectieve Th2 cytokine productie onderbouwen onze stelling dat signalen via 
SLAM/SAP/FynT essentieel zijn voor Th2 differentiatie.
Daar SLAM op vele verschillende cellen van het hematopoietische systeem tot expressie 
komt lijkt het aannemelijk dat SLAM ook een rol speelt op andere cellen dan T cellen. 
Hiermee in overeenstemming vonden wij een vermindering in de productie van IL-12, 
TNF? en NO door SLAM deficiente macrofagen wanneer zij met LPS werden 
gestimuleerd (Hoofdstuk 7). Om te bevestigen dat de afwezigheid van SLAM ook een 
rol speelde in T cell differentiatie en macrofaag activatie in vivo hebben we SLAM 
deficiente muizen geinfecteerd met de parasiet Leishmania major (L.major). Deze 
infectie wordt algemeen geaccepteerd als een goed model voor Th1 en Th2 differentiatie 
en voor het functioneren van macrofagen. We vergeleken L.major infectie in SLAM 
deficiente muizen van de C57BL/6 en BALB/C lijnen. SLAM-/-C57BL/6 muizen waren 
ontvankelijk voor L.major infectie in tegenstelling tot normale C57BL/6 muizen die de 
infectie eenvoudig klaren. Deze ontvankelijkheid werd aangetoond door verhoogde 
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parasieten titers in de SLAM deficiente muizen in vergelijking met de normale muizen. 
Dit was in overeenstemming met het eerder vermelde defect in IL-12, TNF? en NO 
productie in SLAM deficiente macrofagen. 
Th2 cytokinen zoals IL-4, IL-5, IL-9 en IL-13 spelen een belangrijke rol in de productie 
van IgE en dragen bij aan allergische eosinofiele onstekingen en veranderingen in de 
luchwegen. Omdat SLAM deficiente CD4+ T cellen mogelijk een defect in Th2 
differentiatie dragen hebben we de rol van SLAM in een luchtweg allergie model 
bestudeerd (Hoofdstuk 8). SLAM deficiente muizen van de BALB/c lijn werden 
gesensitizeerd en vervolgens herhaaldelijk blootgesteld aan ovalbumine (OVA) via een 
vernevelaar. Na drie blootstellingen aan OVA werd de luchweg reactiviteit en onsteking 
gemeten. Wij vonden dat SLAM deficiente muizen significant minder luchtweg 
reactiviteit hadden dan gewone BALB/c muizen, en dat zowel Th1 als Th2 cytokinen 
verminderd waren. Deze resultaten toonden aan dat SLAM betrokken is bij antigeen-
gedreven luchtweg reactiviteit en ontsteking. 
De bevindingen in dit proefschrift hebben bijgedragen aan een beter begrip van de rol die 
verschillende CD3 onderdelen spelen bij vroege T cel ontwikkeling en de essentiele rol 
die SLAM speelt in de activatie van T cellen en macrofagen. Wij hopen dat ons werk zal 
bijdragen aan de ontwikkeling van therapieen voor ziekten die geassocieerd zijn met 
SAP/EAT2 afhankelijk en onafhankelijke SLAM signaaltransductie, zoals bijvoorbeeld 
de immuundeficientie XLP, mazelen infectie en lupus.
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